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clinical effectiveness and cost-effectiveness of
laparoscopic, laparoscopically assisted (hereafter
together described as laparoscopic surgery) and hand-
assisted laparoscopic surgery (HALS) in comparison
with open surgery for the treatment of colorectal
cancer. 
Data sources: Electronic databases were searched
from 2000 to May 2005. A review of economic
evaluations was undertaken by the National Institute
for Health and Clinical Excellence in 2001. This review
was updated from 2000 until July 2005. 
Review methods: Data from selected studies were
extracted and assessed. Dichotomous outcome data
from individual trials were combined using the relative
risk method and continuous outcomes were combined
using the Mantel–Haenszel weighted mean difference
method. Summaries of the results from individual
patient data (IPD) meta-analyses were also presented.
An economic evaluation was also carried out using a
Markov model incorporating the data from the
systematic review. The results were first presented as a
balance sheet for comparison of the surgical
techniques. It was then used to estimate cost-
effectiveness measured in terms of incremental cost
per life-year gained and incremental cost per quality-
adjusted life-year (QALY) for a time horizon up to 
25 years.
Results: Forty-six reports on 20 studies [19
randomised controlled trials (RCTs) and one IPD 
meta-analysis] were included in the review of clinical
effectiveness. The RCTs were of generally moderate
quality with the number of participants varying
between 16 and 1082, with 10 having less than 100
participants. The total numbers of trial participants who
underwent laparoscopic or open surgery were 2429
and 2139, respectively. A systematic review of four
papers suggested that laparoscopic surgery is more
costly than open surgery. However, the data they
provided on effectiveness was poorer than the
evidence from the review of effectiveness. The
estimates from the systematic review of clinical
effectiveness were incorporated into a Markov model
used to estimate cost-effectiveness for a time horizon
of up to 25 years. In terms of incremental cost per life-
year, laparoscopic surgery was found to be more costly
and no more effective than open surgery. With respect
to incremental cost per QALY, few data were available
to differentiate between laparoscopic and open
surgery. The results of the base-case analysis indicate
that there is an approximately 40% chance that
laparoscopic surgery is the more cost-effective
intervention at a threshold willingness to pay for a
QALY of £30,000. A second analysis assuming equal
mortality and disease-free survival found that there was
an approximately 50% likelihood at a similar threshold
value. Broadly similar results were found in the
sensitivity analyses. A threshold analysis was performed
to investigate the magnitude of QALY gain associated
with quicker recovery following laparoscopic surgery
required to provide an incremental cost per QALY of
£30,000. The implied number of additional QALYs
required would be 0.009–0.010 compared with open
surgery.
Conclusions: Laparoscopic resection is associated with
a quicker recovery (shorter time to return to usual
activities and length of hospitalisation) and no evidence
of a difference in mortality or disease-free survival up
to 3 years following surgery. However, operation times
are longer and a significant number of procedures
Health Technology Assessment 2006; Vol. 10: No. 45
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Abstract
Clinical effectiveness and cost-effectiveness of laparoscopic
surgery for colorectal cancer: systematic reviews and economic
evaluation
A Murray,1* T Lourenco,1 R de Verteuil,1,2 R Hernandez,2 C Fraser,1 A McKinley,3
Z Krukowski,3 L Vale1,2 and A Grant1
1 Health Services Research Unit, University of Aberdeen, UK
2 Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK
3 NHS Grampian, Aberdeen, UK
* Corresponding authorinitiated laparoscopically may need to be converted to
open surgery. The rate of conversion may be
dependent on experience in terms of both patient
selection and performing the technique. Laparoscopic
resection appears more costly to the health service
than open resection, with an estimated extra total cost
of between £250 and £300 per patient. In terms of
relative cost-effectiveness, laparoscopic resection is
associated with a modest additional cost, short-term
benefits associated with more rapid recovery and
similar long-term outcomes in terms of survival and
cure rates up to 3 years. Assuming equivalence of long-
term outcomes, a judgement is required as to whether
the benefits associated with earlier recovery are worth
this extra cost. The long-term follow-up of the RCT
cohorts would be very useful further research and
ideally these data should be incorporated into a wider
IPD meta-analysis. Data on the long-term complications
of surgery such as incisional hernias and differences in
outcomes such as persisting pain would also be
valuable. Once available, further data on both costs and
utilities should be included in an updated model. At this
point, further consideration should then be given as to
whether additional data should be collected within
ongoing trials. Few data were available to assess the
relative merits of HALS. Ideally, there should be more
data from methodologically sound RCTs. Further
research is needed on whether the balance of
advantages and disadvantages of laparoscopic surgery
varies within subgroups based on the different stages
and locations of disease. Research relating to the effect
of experience on performance is also required.
Abstract
ivList of abbreviations .................................. vii
Executive summary .................................... ix
1 Aim of the review ...................................... 1
2 Background ................................................ 3
Description of underlying health 
problem ...................................................... 3
Current service provision ........................... 5
Description of new intervention  ................ 6
3 Effectiveness ............................................... 9
Methods for reviewing effectiveness .......... 9
Results ........................................................ 10
Summary and conclusions of the evidence 
for and against the intervention ................ 24
4 Systematic review of economic 
evaluations ................................................. 27
Methods ...................................................... 27
Results ........................................................ 28
Comment on the submission by the 
Association of Laparoscopic Surgeons of 
Great Britain and Ireland (ALSGBI)  ......... 31
Summary of results and discussion ............ 32
Conclusions ................................................ 34
5 Economic evaluation .................................. 35
Introduction ............................................... 35
The balance sheet approach ...................... 35
Economic model  ........................................ 38
Summary of evidence on 
cost-effectiveness ........................................ 60
6 Implications for other parties .................... 61
Quality of life for the family and carers  .... 61
Financial impact for the patient and 
others .......................................................... 61
7 Implications for the NHS .......................... 63
Training ...................................................... 63
Fair access and equity issues  ...................... 63
Resource transfers between primary and
secondary care ............................................ 63
Availability of theatre space  ....................... 63
Budgetary impact on the NHS .................. 63
8 Discussion ................................................... 65
Main results ................................................ 65
Assumptions, limitations and 
uncertainties ............................................... 66
9 Conclusions ................................................ 69
Implications for the NHS  .......................... 69
Implications for patients and carers ............. 69
Implications for research  ........................... 69
Acknowledgements .................................... 71
References .................................................. 73
Appendix 1 Search strategies .................... 79
Appendix 2 Study eligibility form ............. 85
Appendix 3 Data extraction form ............. 87
Appendix 4 Quality assessment form –
systematic reviews ....................................... 95
Appendix 5 Quality assessment form – 
RCTs ........................................................... 97
Appendix 6 List of included studies  ......... 99
Appendix 7 Detailed quality assessment 
score for each of the included studies  ....... 103
Appendix 8 Characteristics of included 
studies ......................................................... 105
Appendix 9 Results of meta-analysis:
laparoscopic resection versus conventional
open resection ............................................ 119
Appendix 10 Summary of outcomes 
reported in converted patients  .................. 125
Appendix 11 Summary of included 
economic evaluations ................................. 127
Appendix 12 Estimation of parameter
estimates used in the economic model....... 139
Appendix 13 Markov model for the
management of colorectal cancer .............. 141
Health Technology Assessment reports
published to date ....................................... 143
Health Technology Assessment 
Programme  ................................................ 157
Contents
Health Technology Assessment 2006; Vol. 10: No. 45
vACPGBI Association of
Coloproctology of Great
Britain and Ireland
ALSGBI Association of Laparoscopic
Surgeons of Great Britain
and Ireland
BMI body mass index
CEAC cost-effectiveness
acceptability curve
CI confidence interval
CLASICC Conventional versus
Laparoscopic-Assisted
Surgery in Colorectal Cancer
COLOR COlon cancer Laparoscopic
or Open Resection Study
Group
COST Clinical Outcomes of
Surgical Therapy Study
Group
CT computed tomography
EORTC QLQ-3D European Organisation for
Research and Treatment of
Cancer Quality of Life Core
30 Questionnaire
HALS hand-assisted laparoscopic
surgery
HRG Health Care Resource
Group
ICER incremental cost-
effectiveness ratio
IPD individual patient data
IQR interquartile range
NICE National Institute for Health
and Clinical Excellence
QALY quality-adjusted life-year
RCT randomised controlled trial
RR relative risk
SD standard deviation
TNM tumour, lymphatic nodes
metastasis
WMD weighted mean difference
Health Technology Assessment 2006; Vol. 10: No. 45
vii
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
List of abbreviations
All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or 
it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case 
the abbreviation is defined in the figure legend or at the end of the table.Health Technology Assessment 2006; Vol. 10: No. 45
ix
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Previous guidance from the National Institute for
Health and Clinical Excellence (NICE) on the use
of laparoscopic surgery for colorectal cancer is that
open surgery is the preferred procedure and that
laparoscopic surgery should only be undertaken as
part of a randomised controlled trial (RCT). This
guidance was based on a technology assessment
review conducted in 2000. New evidence has since
become available, providing additional data on
both the short- and long-term outcomes of
surgery. 
Objective of the study
The aim of this study was to determine the 
clinical effectiveness and cost-effectiveness of
laparoscopic, laparoscopically assisted (hereafter
together described as laparoscopic surgery) and
hand-assisted laparoscopic surgery (HALS) in
comparison with open surgery for the treatment 
of colorectal cancer. Where evidence allowed,
possible differential effects were explored within a
number of subgroups. The subgroups relate to the
location of the cancer, the stage of the cancer and
age at diagnosis.
Description of proposed service
In laparoscopic surgery, ports are inserted through
which the laparoscopic instruments are
manipulated. In practical terms, a totally
laparoscopic procedure and a laparoscopically
assisted procedure are considered comparable
because of the size of incisions involved and
hereafter are jointly described as laparoscopic
surgery. In HALS, the surgeon inserts a hand into
the abdomen while pneumoperitoneum is
maintained. 
Epidemiology and background
Colorectal cancer is the second most common
malignancy in England and Wales. Approximately
36,000 new cases were diagnosed in 2002 and
17,000 people died from colorectal cancer in the
same year. About 80% of all patients diagnosed
with colorectal cancer (including some with
advanced disease) undergo surgery.  
Open resection is currently the standard method
for primary resection of tumours. However, there
is significant morbidity associated with this
procedure. Laparoscopic surgery is less invasive
and may lead to more rapid recovery. The
potential impact on cure rates is not clear. The
major concerns are that tumour recurrence might
occur at port sites and that clearance of the
tumour may be less complete than during open
surgery. However, it has also been suggested that
reduced tissues trauma may lower disruption to
the immune system and hence reduce the risk of
recurrence. Additionally, there are disadvantages
of laparoscopic surgery relating to the longer
operation length, the cost of materials and the
effect of surgeon experience on patient outcomes. 
This review assesses the clinical effectiveness and
cost-effectiveness of laparoscopic surgery and HALS
in comparison with open surgery for the treatment
of colorectal cancer. This was evaluated in terms of
short-term, long-term and recurrence outcomes.
The possible differential effects within predefined
subgroups relating to the location of the cancer, the
stage of the cancer and age at diagnosis were
explored, although limited data were available.
Methods
Effectiveness
Electronic searches were undertaken from 2000 to
May 2005 to identify published and unpublished
trials of laparoscopic compared with open surgery
for colorectal cancer. Systematic reviews and other
evidence-based reports were identified and their
lists of references searched. Selected conference
proceedings were searched. 
All RCTs and quasi-RCTs were eligible for
inclusion if they compared laparoscopic surgery or
HALS with open surgery for colorectal cancer. Also
eligible were individual patient data (IPD) meta-
analyses of such studies, where they provided
additional data.
Two reviewers independently extracted data and
assessed study quality. Dichotomous outcome data
from individual trials were combined using the
relative risk method and continuous outcomes
Executive summaryx
were combined using the Mantel–Haenszel
weighted mean difference method. Summaries of
the results from IPD meta-analyses were also
presented.
Cost-effectiveness
A review of economic evaluations was undertaken
by NICE in 2001. This review was updated from
2000 until July 2005. Quality assessment and data
abstraction were conducted according to the
guidelines for reviewers for the NHS Economic
Evaluation Database.
An economic evaluation was also carried out using
a Markov model incorporating the data from the
systematic review. This model was first used to
present a balance sheet for comparison of the
surgical techniques. It was then used to estimate
cost-effectiveness measured in terms of
incremental cost per life-year gained and
incremental cost per quality-adjusted life-year
(QALY) for a time horizon up to 25 years.
Results
Number and quality of studies
In total, 46 reports on 20 studies (19 RCTs and
one IPD meta-analysis) were included in the
review of clinical effectiveness. The RCTs were of
generally moderate quality with the number of
participants varying between 16 and 1082, with 10
having less than 100 participants. The total
numbers of trial participants who underwent
laparoscopic or open surgery were 2429 and 2139,
respectively.
Cost-effectiveness
A systematic review of four papers suggested that
laparoscopic surgery is more costly than open
surgery. However, the data they provided on
effectiveness was poorer than the evidence from
the review of effectiveness. One study compared
the two forms of surgery in the context of an
enhanced recovery programme. This study
reported no difference in effectiveness and similar
costs for both laparoscopic and open surgery. A
further small study was identified comparing
laparoscopic with HALS. This study also reported
similar estimates of effectiveness and cost.
The estimates from the systematic review of
clinical effectiveness were incorporated into a
Markov model used to estimate cost-effectiveness
for a time horizon of up to 25 years. In terms of
incremental cost per life-year, laparoscopic surgery
appeared more costly and no more effective than
open surgery. With respect to incremental cost 
per QALY, few data were available to differentiate
between laparoscopic and open surgery. The
results of the base-case analysis indicate that there
is an approximately 40% chance that laparoscopic
surgery is the more cost-effective intervention at a
threshold willingness to pay for a QALY of
£30,000. A second analysis assuming equal
mortality and disease-free survival found that
there was an approximately 50% likelihood at a
similar threshold value.
Sensitivity analyses
Broadly similar results were found in the sensitivity
analyses. A threshold analysis was performed to
investigate the magnitude of QALY gain associated
with quicker recovery following laparoscopic
surgery required to provide an incremental cost
per QALY of £30,000. The implied number of
additional QALYs required would be 0.009–0.010
compared with open surgery.
Limitations of the calculations
(assumptions made)
Much information available for some outcomes
was reported in a form that was unsuitable for
entry into the meta-analyses. The main limitations
related to the quantity and quality of the data
available. For example, the best data on mortality
and disease-free survival were only available for a
3-year follow-up.
The nature of the data available also had an
impact on the economic evaluation, which
extrapolated outcomes for up to 25 years. More
importantly, the data available to estimate costs
were limited and the data used to estimate 
QALYs were highly suspect. The UK-based
multicentre Conventional versus Laparoscopic-
Assisted Surgery in Colorectal Cancer (CLASICC)
trial is due to report its economic evaluation 
soon and a draft version of a cost analysis
conducted alongside the CLASICC trial was
incorporated within the economic model as
sensitivity analysis. The results of this analysis are
not contained in this report as the data were
supplied in confidence. Nevertheless, it is
expected that this study will provide additional
data on costs and will provide utility scores
relevant to the UK.
Conclusions
Summary of benefits
Laparoscopic resection is associated with a quicker
recovery (shorter time to return to usual activities
Executive summaryand length of hospitalisation) and no evidence of
a difference in mortality or disease-free survival up
to 3 years following surgery. However, operation
times are longer and a significant number of
procedures initiated laparoscopically may need to
be converted to open surgery. The rate of
conversion may be dependent on experience in
terms of both patient selection and performing
the technique. 
Costs
Laparoscopic resection appears more costly to the
health service than open resection, with an
estimated extra total cost of between £250 and
£300 per patient. 
Cost-effectiveness
In terms of relative cost-effectiveness, laparoscopic
resection is associated with a modest additional
cost, short-term benefits associated with more
rapid recovery and similar long-term outcomes in
terms of survival and cure rates up to 3 years.
Assuming equivalence of long-term outcomes, a
judgement is required as to whether the benefits
associated with earlier recovery are worth this
extra cost.
Other important issues regarding
implications
Should the use of laparoscopic surgery be
increased from its current level of 0.1% to 25% 
of total resections, then the extra cost to the 
NHS has been estimated at £2.1 million 
per year. 
The increased adoption of laparoscopic techniques
may allow patients to return to usual activities
faster. This may, for some people, reduce any loss
of income. However, current provision is very
limited and few patients have access to
laparoscopic surgery.
For the NHS, increased use of laparoscopic
surgery would lead to an increased requirement
for training, which may be costly. Owing to the
limited number of surgeons currently providing
laparoscopic surgery, it may take some time before
the provision of laparoscopic surgery can be
increased.
Both open and laparoscopic surgery may be
provided in the context of an enhanced recovery
programme. Such an approach may reduce length
of stay for both procedures but may not lead to
reduced total costs to the NHS.
Notes on the generalisability of the
findings
The 19 trials were conducted in a wide range of
settings but data relating to the subgroups were
limited. With respect to the data on costs, only two
UK studies were identified, one of which was a
preliminary analysis. Such cost data as were
available may not reflect practice within the UK.
Further data, when available from the CLASICC
trial, would improve the confidence with which the
findings can be generalised.
Need for further research
Although useful data on long-term outcomes were
available from the IPD meta-analysis identified as
part of the review, this study only reported data
from four RCTs for up to 3 years. The long-term
follow-up of the RCT cohorts would be very useful
and ideally these data should be incorporated into
a wider IPD meta-analysis. 
Few data were available on the long-term
complications of surgery such as incisional hernias.
Given the apparent similarity between the
procedures in survival and disease-free survival,
attention might be given to identifying differences
in outcomes such as persisting pain, that may
affect a patient’s quality of life.
Key limitations of the economic model were the
limited data on both costs and utilities. Once
available, such data should be included in an
updated model. At this point, further
consideration should then be given as to whether
additional data should be collected within ongoing
trials.
Few data were available to assess the relative
merits of HALS. Ideally, there should be more
data from methodologically sound RCTs.
Further research is needed on whether the balance
of advantages and disadvantages of laparoscopic
surgery varies within subgroups based on the
different stages and locations of disease.
Laparoscopic surgery for colorectal cancer is, like
other laparoscopic procedures, technically
challenging and performance is likely to improve
with experience. This issue is important in its
evaluation and further methodologically sound
research related to this is warranted in the context
of both trials and meta-analyses of trial data.
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revious guidance from the National Institute
for Health and Clinical Excellence (NICE) on
the use of laparoscopic surgery for colorectal
cancer was that open rather than laparoscopic
surgery was the preferred procedure and that
laparoscopic surgery should only be undertaken as
part of a randomised controlled trial (RCT).1 This
guidance was based on a technology assessment
review conducted in 2000.1 New data have become
available since then, particularly from three large
RCTs2–4 (each with around 800 participants) and
an unpublished individual patient data meta-
analysis of these three trials plus a fourth
moderate-sized trial (Bonjer J, QE II Health
Sciences Centre, Halifax, NS: personal
communication, 2005). This meta-analysis
included data describing 1536 participants with
follow-up for death and disease-free survival for
3 years after surgery.
This study takes into account these and other data
in an updated review. More specifically, the aim is
to determine the clinical effectiveness and cost-
effectiveness of laparoscopic, laparoscopically
assisted (hereafter together described as
laparoscopic surgery) and hand-assisted
laparoscopic surgery (HALS) in comparison with
open surgery for the treatment of colorectal
cancer. Where evidence allows, possible differential
effects will be explored within a number of
subgroups. The subgroups relate to the location of
the cancer, the stage of the cancer and age at
diagnosis.
Health Technology Assessment 2006; Vol. 10: No. 45
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Chapter 1
Aim of the reviewDescription of underlying health
problem
Introduction
The large intestine, commonly known as the large
bowel, can be divided into two main sections: the
colon and the rectum. The colon is about
1.5–1.8 m long and consists of four parts: the
ascending, transverse, descending and sigmoid
colon. The rectum is a straight, muscular tube,
which commences at the end of the sigmoid colon
and terminates at the anal canal.5
The aetiology of colorectal cancer is multifactorial,
including genetic and environmental factors.5
Colorectal cancer frequently results from
malignant change in an adenomatous polyp that
has developed in the lining of the large intestine.
Colorectal cancers are broadly divided into two
groups, depending on their location within the
large bowel. Colonic cancer consists of all tumours
occurring in the area from the large intestine
proximal to the rectum. Rectal cancer is defined as
a tumour within 15 cm of the anal verge.6,7
Colorectal cancer most commonly presents with
chronic symptoms such as rectal bleeding, a
change in bowel habit or iron deficiency anaemia.6
A proportion of patients present as emergencies
with bowel obstruction, perforation or bleeding.
Table 1 provides further details of the mode of
presentation.
Epidemiology
Colorectal cancer is the second most common
malignancy in England and Wales in terms both of
incidence and mortality.9 Approximately 36,000
new cases were diagnosed in 2002 and 17,000
people died from colorectal cancer in the same
year. Over the last three decades, colorectal cancer
mortality has fallen by over 25% whereas
incidence has increased slowly (Figure 1).
The overall incidence of colorectal cancer is
higher in men than in women (Figure 2). In the
UK, the male to female ratios for colonic and
rectal cancer are 11:10 and 7:4, respectively.11
This holds for all age groups. There is no
evidence that the pathogenesis of the disease
differs by gender.12
The mean age at diagnosis for colorectal cancer in
the UK is 65 years.13 As Figure 2 illustrates, the
incidence of colorectal cancer rises sharply with
age with approximately 41% of patients affected
being over 75 years of age and 57% of deaths
from colorectal cancer occurring in this age
group.14 Table 2 gives further details specific for
England, Scotland, Wales and Northern Ireland.
A small subgroup of colorectal cancer is caused by
inherited predisposition; however, it is estimated
that over 75% of cases arise ‘sporadically’
(Figure 3). Diet, including over-nutrition, high
meat and fat consumption, deficiencies in
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TABLE 1 Modes of presentation of patients with colorectal cancer8
Mode of presentationa Proportion of all patients 
with colorectal cancer (%)
Common modes of presentation of patients with established cancer
Rectal bleeding associated with a change in bowel habit 35
Abdominal or rectal mass 30
Iron deficiency anaemia below 100 g/l 30
Intestinal obstruction 20
Change in bowel habit as a single symptom 10
Uncommon symptomatic presentations of patients with cancer
Rectal bleeding with anal symptoms and without a change in bowel habit 3
Abdominal pain as a single symptom without an abdominal mass 3
a A patient can present with more than one symptom.Background
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FIGURE 1 Incidence and mortality rates over time in England and Wales, 1971–2001 (data specific to males only)10
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FIGURE 2 Frequency distribution of new cases by age group, England and Wales, 200110
TABLE 2 Death rates per 100,000 population for colorectal cancer in 2002 for England, Wales, Scotland and Northern Ireland15
Age (years)
35–44 45–54 55–64 65–74 75–84 85+
Colon cancer
England 1.4 5.8 20.0 56.1 119.4 200.9
Wales 2.2 7.5 21.9 65.1 114.0 191.3
Scotland 1.7 8.2 23.7 58.8 127.4 225.7
Northern Ireland 2.4 5.9 23.3 62.6 103.7 282.7
Rectal cancer
England 0.8 4.1 12.8 27.6 57.6 98.7
Wales 0.7 5.8 11.6 30.6 50.6 101.3
Scotland 1.3 6.7 14.6 43.2 72.1 111.4
Northern Ireland 0.9 4.4 11.3 16.3 56.6 92.0vegetables, key minerals and vitamins, is a major
risk factor.11
Five-year relative survival, following surgical
resection, is related to the stage of the tumour and
is approximately 85–95% in Dukes’ A cancer
(TNM Stage I) (tumour confined to mucosa and
submucosa of the bowel), 60–80% in Dukes’ B
cancer (TNM Stage II) (tumour penetrating
through muscle layer of the bowel), 30–60% in
Dukes’ C cancer (TNM Stage III) (metastasis to
regional lymph nodes)16 and 13% in Dukes’ D
cancer (TNM Stage IV) (distant metastasis)17
(TNM: classification of malignant tumours, where
T stands for tumour, N for lymphatic nodes and M
for metastasis).
Significance in terms of ill-health
Colorectal cancer is a major cause of morbidity
and mortality, particularly in the elderly. Patients
with colorectal cancer may suffer pain, bleeding,
frequent or irregular bowel movements, diarrhoea
and fatigue.18,19 Studies have reported a decrease
in quality-of-life scores during the first few months
after colorectal surgery, followed by improvements
3–6 months after surgery.20
Current service provision
In the UK, open surgical resection of all malignant
tissue is the recommended primary treatment for
colorectal cancer.1 Approximately 80% of all
patients diagnosed with colorectal cancer
(including some with advanced disease) undergo
surgery.21 Most surgical resections are performed
as elective procedures. However, up to 30% of
primary resections present as an emergency
(Table 3).13
Open surgical resection of primary colorectal
tumour is the most common procedure for
treating colorectal cancer. However, morbidity
rates associated with this can be high.
Laparoscopic surgery is less invasive and is
therefore likely to lead to more rapid recovery
from the operation. It has also been suggested
that the reduced trauma associated with
laparoscopic procedures might minimise any
disruption to the immune system caused by
surgery and hence reduce the risk of recurrence.22
However, there are concerns that tumour
recurrence might occur at port sites and the
potential impact on cure rates is not established.
Additionally, there are disadvantages relating to
the longer length of the operation, the cost of
materials and the effect of surgeon experience on
patient outcomes.
Some of the disadvantages associated with open
surgical resection include: incisional pain, intra-
and postoperative metabolic stress, tissue trauma
and postoperative ileus from manual intestinal
manipulation.23 It has been postulated that
laparoscopic surgery may reduce the impact of
these. If so, this might justify the apparent
increase in interest amongst surgeons to introduce
laparoscopic techniques to treat colorectal cancer.
The open surgical procedure (laparotomy)
requires a relatively long incision through the
abdominal wall.23 The surgical resection of the
cancer itself involves the removal of the bowel
containing the tumour, adequate disease-free
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FIGURE 3 Risk factors associated with new cases of colorectal cancer11longitudinal margins, any involved adjacent
organs, lymph nodes and associated vessels.12,23
For rectal cancers located in the lower two-thirds
of the rectum, a total mesorectal excision is
performed to reduce local recurrence.12 Upper-
third rectal tumours may be managed with a 5-cm
distal longitudinal margin. Whenever possible, this
is followed by anastomosis, suturing or stapling
the proximal colon to the rectum/anus.
According to the 2003–4 hospital episode
statistics, 31,356 primary resections were
performed in England using 473,530 bed days
with patients staying in hospital for a mean of
17 days. The majority of these were colonic
resections (61%). Within the six periods surveyed,
there was a relative decrease in the number of
primary resections performed (Table 3).13
Description of new intervention
Laparoscopic surgery
Minimally invasive approaches to treat colorectal
diseases were developed to take advantage of the
benefits observed in laparoscopic procedures
elsewhere in the gastrointestinal tract.24 In
laparoscopic surgery, ports are inserted through
which the laparoscopic surgical instruments are
manipulated. In practical terms, a totally
laparoscopic procedure and a laparoscopically
assisted procedure are considered comparable
because of the size of incisions involved. Hand-
assisted laparoscopic surgery (HALS) is a different
concept and is discussed below. 
Adoption has been relatively slow since the first
entirely laparoscopic colorectal resection was
performed in July 1991.24 Difficulties include
working in multiple sites within the peritoneal
cavity, inadequate instrumentation, evolving
surgical techniques and the necessity to remove a
large specimen.25 Taken against a background of
fears about adequacy of tumour clearance, these
have combined to inhibit widespread adoption.
Laparoscopically assisted surgery
In laparoscopically assisted surgery, the bowel is
mobilised laparoscopically and extracted through
an enlarged laparoscopic port site with excision
and/or anastomosis performed externally. As
noted earlier, throughout the remainder of this
report laparoscopic and laparoscopically assisted
surgery are collectively called laparoscopic surgery.
Hand-assisted laparoscopic surgery
(HALS)
In HALS, the surgeon inserts a hand into the
abdomen while pneumoperitoneum is maintained.
Some surgeons find this easier than laparoscopic
surgery, particularly in the transitional phase
between conventional and laparoscopic surgery.
Advantages claimed for placing the hand in the
abdomen include tactile feedback, the ability to
palpate, blunt dissection, organ retraction, control
of bleeding and rapid organ removal.26–28
Identification of subgroups of patients
Resection can be performed in patients of all ages
and both genders, with any stage of cancer and
location. However, stay in the intensive care unit
and postoperative hospitalisation have been
reported to be significantly longer in patients
older than 70 years.29 In addition, surgical
procedures for advanced colorectal cancer are
most commonly used to relieve obstructing lesions
and pelvic symptoms.30 The laparoscopic
treatment of rectal cancer is more difficult than for
colonic cancers.31 Currently, laparoscopic
procedures are unlikely to be used in emergency
situations and the study has not considered a
subgroup analysis for the comparison of
alternative forms of resection in patients
presenting as emergencies.
Background
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TABLE 3 Details of primary colorectal resections, England, 1998–200413
Year No. of  Emergency Male (%) Average age  Aged over  Mean stay 
resections (%) (years) 75 years (%) (days)a
2003–04 31,356 28.0 50.9 65.5 33 17.1
2002–03 31,705 28.6 51.4 65.5 33 17.3
2001–02 31,331 29.7 50.9 65.5 33 17.7
2000–01 31,796 27.7 50.0 66 33 17.4
1999–2000 32,725 29.0 50.0 65.5 32 17.1
1998–99 32,580 24.8 50.0 66 33 17.0
a Over this period, the median length of hospital stay has remained at 13 and 14 days for colon and rectal cancer,
respectively.Criteria for treatment
Laparoscopic treatment is contraindicated in
patients who have significant bowel dilatation or
who are intolerant of a pneumoperitoneum.32
Furthermore, conversion from laparoscopic to
open surgery may negate any advantage of an
initial laparoscopic approach. Consequently,
patients at high risk of conversion from
laparoscopic to open surgery should be identified
preoperatively and receive open surgery. Factors
that may be relevant include body habitus,
extensive peritoneal adhesions and local spread of
the tumour.
Personnel involved
The number of staff employed in laparoscopic
operations is usually similar to that involved in
open resections. The operating time for
laparoscopic resection is believed to be longer.
Laparoscopic resection is a technically more
difficult procedure and there is a long learning
curve,30 in which a relatively large number of cases
(30–50) are required for the surgeon to obtain
proficiency.29
Setting
The mean length of hospital stay for patients
undergoing open resections in the UK as judged
from routinely collected hospital episode statistics
is approximately 17 days.13 The time from
hospital admission to discharge has been
suggested to be lower for patients undergoing
laparoscopic surgery.33–35
To a large extent, length of hospital stay after
surgery is dependent on local surgical policy.
However, it is also influenced by prolonged pain,
nausea and vomiting, persistence of ileus, fatigue,
mechanical factors (such as the presence of
drains), stress-induced organ dysfunction and
postoperative complications.36,37 It has been
claimed that an ‘enhanced recovery programme’
specially designed to address these factors can
lead to a marked decrease in length of stay36–39
with no increased morbidity, deterioration in
quality of life or increased cost.40 An enhanced
recovery programme is characterised by a highly
scripted pre- and postoperative care plan
regulating the introduction of analgesia, diet and
ambulation.36 It has been suggested that the
length of hospital stay of patients undergoing an
open resection followed by an enhanced recovery
programme could match that seen after
laparoscopic resection. 
Irrespective of type of approach to surgery, it is
widely recommended that colorectal cancer
patients should be nursed in an environment that
promotes independence and mobilisation, with
patients out of bed for 2 hours on the day of
surgery and for 6 hours each day from then on.37
Equipment required
All laparoscopic techniques incur additional
material costs compared with an open operation
because of the requirement for an endoscopy
system. This includes items such as ports, staplers,
diathermy and ultrasonic instruments. These
additional costs are strongly influenced by the
amount of disposable equipment used.
Degree of diffusion 
The current NICE guidance on the use of
laparoscopic surgery for colorectal cancer1 states
that:
“1. For colorectal cancer, open rather than
laparoscopic resection should be the preferred
surgical procedure.
2. Laparoscopic surgery should only be
undertaken for colorectal cancer as part of a
randomised clinical trial.”
Reflecting this, laparoscopic colorectal surgery has
not been adopted widely. From 1998 to 2001 there
were no changes in the percentage of colorectal
cancer cases treated with laparoscopic surgery in
the UK (around 0.1%).41
A survey42 performed among existing members of
the Association of Coloproctology of Great Britain
and Ireland (ACPGBI) has identified that only 45
surgeons currently perform laparoscopic colorectal
resections. 
Expected costs
The current use of laparoscopic colorectal surgery
is low but there is the potential for its use to
increase dramatically. The expected costs of
adopting laparoscopic surgery based on different
degrees of diffusion are illustrated in Table 4. The
total direct costs to the NHS are based on mean
costs of £6117 and £5852 for laparoscopic and
open surgery, respectively (the methods used to
estimate these costs are described in Chapter 5).
The number of resections per year is based on the
data for 2003–4 reported in Table 3.
These projections suggest that if the use of
laparoscopic resection increased to a relatively
modest 1%, then the total cost to the NHS in
England would increase by approximately
£75,000. However, these estimates are subject to
considerable uncertainty. First, the costs of both
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precisely. Second, the calculations have assumed a
fixed operation cost and therefore have not
considered whether the unit cost of laparoscopic
resection would change as diffusion increases.
Finally, these figures do not reflect the cost of
training the increased numbers of surgeons
required to perform the additional operations.
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TABLE 4 Cost of surgery for colorectal cancer
Proportion of total resections that  NHS cost  Additional cost above the cost of 
are laparoscopic (%) (£ million) current provision (£000)
0.1 183.5 0
1.0 183.6 74.8
5.0 183.9 407.2
10.0 184.3 822.6
15.0 184.7 1238.1
20.0 185.2 1653.6
25.0 185.6 2069.0T
he Health Technology Assessment (HTA)
report submitted to NICE in July 2000, when
laparoscopic surgery for the treatment of
colorectal cancer was first appraised, summarised
the evidence on clinical effectiveness available at
that time.1 Not all studies included in that report
met the inclusion criteria for this update and it
became apparent that some RCTs reported before
2000 had not been included in the original review.
Evidence for assessing the clinical effectiveness
considered in this report therefore comprises the
eligible trials from the original report in addition
to RCTs and individual patient data meta-analyses
identified from literature searching performed for
this review, plus additional pre-2000 RCTs
included in systematic reviews identified from the
literature search. 
Methods for reviewing
effectiveness
Search strategy
Electronic searches were undertaken to identify
published and unpublished reports of RCTs 
and systematic reviews evaluating the effectiveness
of laparoscopic surgery and HALs for colorectal
cancer. Searches were restricted to the years 
2000 onwards without language restriction and
included abstracts from recent conference
proceedings.
The main databases searched were MEDLINE
(2000–May Week 1, 2005), EMBASE
(2000–Week 19, 2005), BIOSIS (2000–May 2005),
Science Citation Index (2000–27 May 2005),
MEDLINE Extra (11 May 2005), Cochrane
Controlled Trials Register (The Cochrane Library,
Issue 2, 2005), Cochrane Database of Systematic
Reviews (The Cochrane Library, Issue 2, 2005),
Database of Abstracts of Reviews of Effectiveness
(May 2005), HTA Database (May 2005), Health
Management Information Consortium (2000–May
2005) and Journals@Ovid Full Text (2000–July
2005 for selected surgical journals). In addition,
recent conference proceedings and reference lists
of all included studies were scanned to identify
additional potentially relevant studies. Full details
of the search strategies used are documented in
Appendix 1.
All titles and abstracts identified in these ways
were assessed to identify potentially eligible
studies. Two reviewers independently assessed
them for inclusion, using a study eligibility form
developed for this purpose (Appendix 2). Any
disagreements were resolved by consensus or
arbitration. Systematic reviews were used to
identify pre-2000 RCTs but were not included in
this review. Lead authors of all included RCTs
were contacted directly to identify further studies
and unpublished data.
Inclusion and exclusion criteria
Types of studies
We included individual RCTs and individual patient
data meta-analyses of RCTs of laparoscopic surgery,
laparoscopic-assisted surgery and HALS compared
with open surgery for colorectal cancer. UK
registries, providing data for a minimum of 3 years’
follow-up for any of the surgical techniques, either
alone or in comparison with each other, were also
included. Studies were eligible irrespective of the
language in which they were reported. Initially, we
had intended to include cohort studies with a
minimum follow-up of 3 years, but in the event we
decided that this was not necessary as the length of
follow-up available from RCTs (and particularly an
individual patient data meta-analysis of RCTs) was
considered sufficient to provide long-term data that
were more robust than data from non-randomised
cohort studies.
Types of participants
Studies of adults with colorectal cancer who have
undergone surgery were included. Patients
undergoing palliative treatment (non-curative
surgery) were excluded. In addition, the following
subgroups were considered: location of cancer;
stage of cancer; and mean age at diagnosis. Other
subgroups, such as gender or grade of cancer,
might have been considered. In the former case it
was not expected that gender would greatly
influence the results and in the latter case it was
not expected that there would be any data. 
Types of outcomes
The following measures of outcomes were sought:
Short-term outcomes:
● duration of operation
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Effectiveness● anastomotic leakage
● abdominal wound breakdown
● lymph node retrieval
● number of ports used for laparoscopic 
resection
● ‘opposite’ method initiated
● completeness of resection, margins of tumour
clearance
● conversion
● seroma
● blood loss
● wound infection
● urinary tract infection
● vascular injury
● visceral injury
● 30-day mortality
● length of stay
● postoperative pain
● time to return to usual activities.
Long-term outcomes:
● overall survival
● recurrence
● disease-free survival
● incisional hernia
● health-related quality of life
● port site hernia.
Other outcomes such as postoperative bowel
recovery were also considered. However, they were
not included as outcomes as they were felt to be
surrogates for length of stay and postoperative
recovery.
Data extraction strategy
The titles and abstracts of all papers identified 
by the search strategy were screened. Full text
copies of all potentially relevant studies were
obtained and two reviewers independently
assessed them for inclusion. Reviewers were not
blinded to the names of studies’ authors,
institutions or sources of the reports. Any
disagreements were resolved by consensus or
arbitration.
A data extraction form was developed to record
details of trial methods, participants,
interventions, patient characteristics and outcomes
(Appendix 3). Two reviewers independently
extracted data from the included studies. Any
differences that could not be resolved through
discussion were referred to an arbiter. With respect
to outcomes data, the authors’ definitions of
outcomes were used. Such definitions may vary
between included studies but would be consistent
within studies and hence would still be useful
when estimating relative effect sizes.
Quality assessment strategy
Two reviewers, working independently, assessed
the methodological quality of the included studies.
Again, any disagreements were resolved by
consensus or arbitration. The methodological
quality of the meta-analysis was assessed by a
previously validated nine-item checklist
(Appendix 4) developed by Oxman and
colleagues.43,44 Primary RCTs were assessed using
the Delphi criteria list45 (Appendix 5).
Data synthesis
For trials with multiple publications, only the most
up-to-date data for each outcome were included.
Dichotomous outcome data were combined using
the Mantel–Haenszel relative risk (RR) method.
This statistic was used as it was more appropriate
for use in the economic model developed in
Chapter 5. Continuous outcomes were combined
using the inverse variance weighted mean
difference (WMD) method; 95% confidence
intervals (CIs) and p-values were calculated for the
estimates of RR and WMD. All results are reported
using a fixed-effects model. 2 tests and I-squared
statistics were used to explore statistical
heterogeneity across studies and, when present,
random effects methods were applied. Other
possible reasons for heterogeneity were explored
using sensitivity analyses. The meta-analyses were
conducted using the standard Cochrane software
RevMan 4.2.
Owing to the lack of uniformity of the data
presented in many studies, a qualitative review
looking for consistency between studies was also
performed. This was supplemented, where
appropriate, by the investigation of the consistency
in the direction of the results using the Sign test.46
Opposite method initiated was defined as a
laparoscopic operation initiated when an open
resection was allocated, or vice versa. Duration of
operation was defined as time from first incision
to last suture or, where this was not available, time
in theatre or duration of anaesthesia. Length of
hospital stay was defined as time from admission
to discharge. A conversion was defined as a
procedure initiated as laparoscopic but converted
to an open procedure.
Results
Quantity and quality of research available
Number of studies identified
The results of the searches are summarised in
Table 5. The numbers retrieved from the 
Effectiveness
10searches in SCI, BIOSIS, Journals@Ovid Full 
Text and CENTRAL include only the additional
reports found after excluding those identified
from the MEDLINE/EMBASE multifile 
search.
A total of 982 reports were identified from the
various searches, of which 167 (157 full-text
papers and 10 abstracts) were selected for full
assessment. Table 6 details the numbers of these
that were included and excluded.
Number and type of studies included
Thirty-three papers (31 full-text papers and two
abstracts) met the inclusion criteria for the review.
In addition, 11 pre-2000 reports were included,
five from the original review and six that were not
included but were identified from other systematic
reviews. A further two reports, both unpublished,
were obtained from their authors (Bonjer J, QE II
Health Sciences Centre, Halifax, NS: personal
communication, 2005).40
Hence, in total, 46 reports describing 20 studies
(19 RCTs and one individual patient data 
meta-analysis) were included in the review of
clinical effectiveness. The sources of the most
recent report of studies (primary reports), and
additional reports relating to these studies
(secondary reports), are summarised in Table 7.
The list of included studies (Bonjer J, QE II
Health Sciences Centre, Halifax, NS: personal
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TABLE 5 Search results
Database No. retrieved
MEDLINE/EMBASE/MEDLINE Extra multifile search (after deduplication in Ovid) 167
Science Citation Index 14
BIOSIS 3
CENTRAL 70
Journals@Ovid Full Text 35
Health Management Information Consortium 34
Cochrane Database of Systematic Reviews 24
Database of Abstracts of Reviews of Effectiveness 30
HTA database 12
National Research Registry 1
Current Controlled Trials 1
Clinical Trials 10
Selected from conference abstracts 581
Total retrieved 982
TABLE 6 Papers selected for full assessment
Assessment No. of papers
Included in review 33
Retained for background information 28
Excluded – did not meet inclusion criteria 77
Excluded – not relevant to review 22
Unobtainable papers 4
Systematic reviews 3
Total 167
TABLE 7 Included reports
Source Primary  reports Secondary  reports
Identified from searches (2000–5) 13 20
Pre-2000 (original review) 3 2
Pre-2000 (not in original review) 2 4
Unpublished 2 0
Total 20 26communication, 2005)2–4,22,40,47–60 and associated
references61–86 are listed in Appendix 6.
Number and type of studies excluded, with
reasons for specific exclusions
A total of 77 reports (72 full-text papers and five
abstracts) were obtained but subsequently excluded
because they failed to meet one or more of the
inclusion criterion. Of these, 59 were not RCTs or
individual patient data meta-analyses. Of the 18
remaining studies, three had no usable results,87–89
two were reports of the current status of an
ongoing trial,90,91 two were comparisons of types
of follow-up,92,93 one compared medial-to-lateral
versus lateral-to-medial laparoscopic dissection94
and in 10 the authors did not report outcomes
separately for participants with cancer.95–104
Study quality, characteristics and evidence rating
A summary of the quality assessment of the 19
full-text RCTs is presented in Table 8 and the
detailed quality assessment score for each of the
included studies is reported in Appendix 7. An
adequate method of random sequence generation
(computer generated or random numbers table)
was performed in all but one60 of the studies.
Suboptimal approaches to concealment of
randomisation (serially numbered sealed
envelopes) were used in five studies.22,48,52,58,59
The intervention groups were dissimilar at
baseline in five studies in respect of the most
important prognostic indicators.50–52,57,59
Eligibility criteria were clearly specified in all 19
studies. 
In the majority, it was unclear whether studies
blinded the outcome assessor and patients. In
addition, the 19 studies did not blind the care
provider (but it is questionable if this is possible
given the nature of the treatments compared).
Point estimates and measures of variability were
presented for the primary outcome measures in all
but one study.47 However, only seven presented an
appropriate measure of variability [standard
deviations (SDs), interquartile ranges or 95%
CIs).3,22,40,53,56,59,60 Seven studies included an
intention-to-treat analysis2–4,40,56,58,59 and it was
unclear whether five other studies included an
intention-to-treat analysis.22,47,52,55,60
The quality assessment scores of the individual
patient data meta-analyses are tabulated in
Appendix 7 (Bonjer J, QE II Health Sciences
Centre, Halifax, NS: personal communication,
2005). [Academic-in-confidence information
removed.] 
Characteristics of included studies
Appendix 8 provides details of the characteristics
of the RCTs, which are summarised in Table 9.
Within the 19 eligible RCTs, there were 19
relevant comparisons, none of which involved a
comparison with HALS. Four studies took place in
the USA,2,48,51,52 two in Germany,55,56 two in Hong
Kong,50,53 two in the UK,3,40 one each in Brazil,47
China,60 Denmark,57 Italy,59 Japan,49 Spain22 and
Singapore58 and one was a multi-centre European
study.4 Across the studies with this information,
recruitment dates ranged from January 1993 to
March 2004. Two studies failed to provide
information on recruitment dates.50,57,104
In the included RCTs, the number of participants
randomised to laparoscopic or open resections
ranged from 1650 to 1082.4 Three trials had more
than 750 participants,2–4 six more than 100 and
10 fewer than 100. The total number of
participants allocated to laparoscopic surgery was
2429 and to open resection 2139.
All but one study gave details of the numbers of
men and women in each trial group with
colorectal cancer.59 Across studies, the percentage
of males was higher than the percentage of
Effectiveness
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TABLE 8 Summary of the quality assessment of the included RCTs
Criteria Yes No Unclear
1. Was a method of randomisation performed?  18 0 1
2. Was the treatment allocation concealed? 6 5 8
3. Were the groups similar at baseline regarding the most important prognostic indicators? 14 5 0
4. Were the eligibility criteria specified? 19 0 0
5. Was the outcome assessor blinded? 1 2 16
6. Was the care provider blinded? 0 19 0
7. Was the patient blinded? 0 3 16
8. Were point estimates and measures of variability presented for the primary outcome measures? 18 1 0
9. Did the analysis include an intention-to-treat analysis? 7 7 5females, with the exception of two studies.51,52 In
total, there were at least 1257 men and 1162
women allocated to laparoscopic resection and at
least 1103 men and 967 women to open resection.
The total number of males and females does not
match the total number of participants receiving
laparoscopic or open resection as some trials
report the gender of all eligible participants rather
than the gender of the actual number of
participants who received the operation.
When data allowed, the patient population was
split by the anatomical site of cancer, the stage of
cancer and participant’s age. Generally, studies
provided only the mean or median age and range
of ages, the number of participants with cancer in
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TABLE 9 Summary of the baseline characteristics
Study ID Comparators No. of participants Age (years)a Male/female Colon/rectum
Araujo, 200347 Laparoscopic 13 59 9/4 0/13
Open 15 56 10/5 0/15
CLASICC, 20053 Laparoscopic 526 69 296/230 273/253
Open 268 69 145/123 140/128
COLOR, 20054 Laparoscopic 536 71b 326/301 536/0
Open 546 71b 336/285 546/0
COST, 20042 Laparoscopic 435 70b 223/212 435/0
Open 428 69b 208/220 428/0
Curet, 200048 Laparoscopic 25 66 15/10 25/0
Open 18 69 14/4 18/0
Hasegawa, 200349 Laparoscopic 24 61 14/10 22/2
Open 26 61 18/8 24/2
Hewitt, 199850 Laparoscopic 8 54b 4/4 8/0
Open 8 70b 3/5 8/0
Kaiser, 200451 Laparoscopic 28 59 12/16 28/0
Open 20 60 9/11 20/0
Kim, 199852 Laparoscopic 19 70b 8/11 19/0
Open 19 65b 10/8 18/0
King, 200640 Laparoscopic 41 72 23/18 27/14
Open 19 70 8/11 14/5
Lacy, 200222 Lap-assisted 111 68 56/55 111/0
Open 108 71 50/58 108/0
Leung, 200453 Laparoscopic 203 67 104/99 0/203
Open 200 66 114/86 0/200
Milsom, 199854 Laparoscopic 55 69b 26/29 48/7c
Open 54 69b 36/18 50/4c
Neudecker, 200355 Laparoscopic 14 62b 7/7 14/0
Open 16 64b 10/6 16/0
Schwenk, 1998a56 Laparoscopic 30 64 14/16 23/7
Open 30 65 16/14 23/7
Stage, 199757 Laparoscopic 15 72b 8/7 15/0
Open 14 73b 5/9 14/0
Tang, 200158 Laparoscopic 118 64b 61/57 118/0
Open 118 62b 70/48 118/0
Vignali, 200459 Laparoscopic 146 NR NR 98/48
Open 143 NR NR 94/49
Zhou, 200460 Laparoscopic 82 45 46/36 0/82
Open 89 44 43/46 0/89
NR, not reported.
a Age is given as mean, unless otherwise stated.
b Median.
c Some colon patients were actually upper rectum.a specific location and its stage, for each
participant group as a whole, and did not report
outcomes within each participant group separately.
However, 10 studies provide outcome information
in relation to patients who had colon resections
and three studies provide information in relation
to patients who underwent a rectal resection.3,47,60
All 19 studies gave details of participants’ ages.
One study, however, gave only the mean age of the
participant group as a whole (patients with benign
colorectal disease and colorectal cancer) and
therefore the ages of participants with colorectal
cancer could not be distinguished.59 Across
studies, the mean or median ages of participants
allocated to laparoscopic surgery ranged from 4540
to 72.3 years60 compared with 4440 to 70.4 years
for patients allocated to open resection.60
Across the studies, the total number of
participants having a colon resection was much
higher than those having a rectal resection. The
total number of participants who had a colon
resection laparoscopically was 1800 compared with
629 rectum resections, and 1638 participants
received an open colon resection compared with
499 open rectum resections. 
In general, studies reported the participants’ stage
of cancer using either Dukes’ or TNM
classification (see Appendix 8 for further details).
One study failed to report the stage of cancer at
which participants were enrolled55 and in one
study the stage was not clearly reported.3 Where
specified, the majority of participants receiving
either laparoscopic or conventional open
interventions had either Dukes’ B (TNM Stage II)
or Dukes’ C (TNM Stage III) cancer. 
The individual patient data meta-analysis
(Bonjer J, QE II Health Sciences Centre, Halifax,
NS: personal communication, 2005) included
patients from four of the above trials:
Conventional versus Laparoscopic-Assisted
Surgery in Colorectal Cancer (CLASICC), the
COlon cancer Laparoscopic or Open Resection
Study Group (COLOR), the Clinical Outcomes of
Surgical Therapy Study Group (COST) and Lacy
and colleagues.2–4,22 [Academic-in-confidence
information removed.] 
Description of surgery received
‘Opposite’ method initiated
The ‘opposite’ method to the one to which the
patient was randomised was initiated in 
46/1173 (3.9%) of those randomised to
laparoscopic resections (Table 10). Rates varied
between the trials that reported this information.
[Academic-in-confidence information removed.] 
Number of ports
Seven studies provided information on the
number of port-sites used for laparoscopic
resection.47–50,57,58,77 The number varied between
three and five across the studies. 
Conversion
In total, 12 studies reported conversions from
laparoscopic to open surgery. Rates varied between
trials from 0 to 46%. Overall, 417 (21%)
laparoscopic procedures were converted to an
open surgery amongst 1972 allocated to
laparoscopic resection (Table 11). [Academic-in-
confidence information removed.] 
Surgeon prior experience
Ten of the RCTs reported that surgeons
performing the procedures were experienced in
laparoscopic colorectal surgery.2–4,22,48,50,51,53,57,59
However, only three trials2–4 reported a minimum
level of experience required to enter the trial. In
these trials, surgeons were required to have
undertaken at least 20 laparoscopic colorectal
operations before participating in the trial. 
Effectiveness
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TABLE 10 ‘Opposite’ method initiated
Study ID Laparoscopic Open
Nn % Nn%
CLASICC, 20053 526 23 4.3 268 4 1.5
COLOR, 20054 536 11 2.0 – –
Lacy, 200222 111 12 11 – –
Bonjer, 2005 (unpublished)a [Academic-in-confidence information removed] 
a Individual patient data meta-analysis including patients from COLOR, COST, CLASICC and Lacy trials.Assessment of effectiveness
Table 12 gives a summary of the outcomes reported
in the included studies. None provided information
for the following four outcomes: seroma, visceral
and vascular injury and long-term pain. The
remaining outcomes are discussed in the
subsequent section. The results of the meta-analyses
performed for this review are given in Appendix 9.
Duration of operation
Of the 19 eligible studies, 16 (n = 4125) provided
information on the duration of operation
(Table 13). In all but one study,47 the duration of
operation was longer in the laparoscopic group
(Sign test, p < 0.001) and this was statistically
significant (p < 0.05) in 12 studies. Only three
studies22,53,56 presented data in a form sufficiently
similar to allow quantitative synthesis (Appendix
9, comparison 01:01). The WMD was 40 minutes
(95% CI 32 to 48, p < 0.001) for laparoscopic
versus open surgery. This result is consistent
with the data from those trials that provided data
not amenable to meta-analysis (medians and
ranges, e.g. the difference in medians in the UK-
based CLASICC trial was 45 minutes) (Table 13).
There was evidence of statistical heterogeneity
between the three trials in the meta-analysis, but
the direction of effect was consistent across the
studies even though the size of effect estimates
varied. Using a random effects model did not
change this pattern. The cause of the
heterogeneity is unclear, but in the study by 
Leung and colleagues53 all participants suffered
from rectal or sigmoid cancers, in that by Lacy
and colleagues22 all participants had colon cancer
and in that by Schwenk and colleagues56 both
groups were included. Furthermore, the study by
Leung and colleagues53 had many more
participants with TNM Stage IV than the other
two studies.
Blood loss
Blood loss data were not reported in a form
sufficiently similar to allow for a quantitative
synthesis (Table 14). Nine studies4,22,40,48,49,51,53,57,60
provided information on the quantity of blood lost
for patients undergoing laparoscopic or open
interventions. Eight studies favoured the
laparoscopic group4,22,40,48,49,53,57,60 and six of the
nine studies reported a statistically significant
difference. Based on the Sign test, there was a
statistically significant difference between the two
interventions (p = 0.039). The largest trial that
provided data reported a median difference in
blood loss of 75 ml.4 The other trials are broadly
consistent with this.
Anastomotic leakage
A total of 55 (3%) leakages were reported amongst
1640 allocated laparoscopic resections versus 34
(2.5%) amongst 1373 allocated open resections
(Appendix 9, comparison 01:02: RR 1.13, 95% CI
0.74 to 1.73, p = 0.58). The direction and size of
effect varied across the eight studies. These results
were particularly influenced by the COLOR and
CLASICC trials.3,4 The difference remained
statistically non-significant when colon and rectum
patients were considered separately (Appendix 9,
comparison 01:20).
Abdominal wound breakdown
Of the 19 included studies, three reported
abdominal wound breakdown.4,40,47 In two studies,
the proportion of patients who had an abdominal
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TABLE 11 Conversions
Study ID No. of conversions  No. of allocated to laparoscopy %
Araujo, 200347 01 3 0
CLASICC, 20053 143 526 27
COLOR, 20054 91 536 17
COST, 20042 90 435 21
Curet, 200048 72 5 2 8
Hasegawa, 200349 52 9 1 7
Kaiser, 200451 13 28 46
King, 200640 34 1 7
Leung, 200453 47 203 23
Stage, 199757 31 8 1 6
Tang, 200158 15 118 13
Bonjer, 2005 (unpublished)a [Academic-in-confidence information removed] 
a Individual patient data meta-analysis including patients from COLOR, COST, CLASICC and Lacy trials.Effectiveness
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T
ABLE 12
Summary of outcomes reported in the included studies
Short-term outcomes
Long-term outcomes
Study
ID
Araujo, 2003
47
✓✓
✓
✓
✓
✓
✓
CLA
SICC, 2005
3
✓✓
✓
✓✓
✓✓
✓
✓
✓
✓
COL
OR, 2005
4
✓✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
COST
, 2004
2
✓✓
✓
✓
✓
✓
✓
✓
✓
✓
Winslow
, 2002
83
a
✓✓
✓
W
eeks, 2002
82
a
✓✓
Curet, 2000
48
✓✓
✓
✓
✓
✓
✓
✓
✓
✓
Hasegawa, 2003
49
✓✓
✓
✓
✓
✓
✓
✓
✓
✓
Hewitt, 1998
50
✓✓
✓
✓
K
aiser
, 2004
51
✓✓
✓
✓
✓
✓
✓
✓
✓
✓
Kim, 1998
52
✓
King, 2006
40
✓✓
✓
✓
✓
✓
✓
✓
✓
✓
Lacy
, 2002
22
✓✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
Leung, 2004
53
✓✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
Milsom, 1998
54
✓✓
✓
Neudecker
, 2003
55
✓
Schwenk, 1998a
56
✓✓
Schwenk, 1998b
77
a
✓✓
✓
Schwenk, 1998c
78
a
✓
Stage, 1997
57
✓✓
✓
✓
✓
✓
✓
✓
✓
T
ang, 2001
58
✓✓
✓
✓✓
Vignali, 2004
59
✓
Zhou, 2004
60
✓✓
✓
✓
✓
✓
✓
✓
a
Additional reports of the same study
.
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nwound breakdown appeared to be higher in the
open group;4,40 however, the CIs were wide
enough for clinically important differences
between laparoscopic and open resection to exist
(Appendix 9, comparison 01:03: RR 0.63, 95% CI
0.26 to 1.52, p = 0.30).
Lymph node retrieval
Twelve studies provided information on the mean
or median number of lymph nodes retrieved
(Table 15). Seven studies3,47,49,51,53,54,57 showed
more lymph nodes retrieved in the open 
group than in the laparoscopic group, two48,59
showed more in the laparoscopic group and in
three studies there were no differences (Sign 
test, p = 0.289). Meta-analysis of the three
trials22,53,59 reporting data suitable for synthesis
showed no statistically significant difference
between groups (Appendix 9, comparison 01:04:
WMD –0.41, 95% CI –1.42 to 0.59, p = 0.42). The
mean number of lymph nodes retrieved reported
in the individual patient data meta-analysis
(Bonjer J, QE II Health Sciences Centre, Halifax,
NS: personal communication, 2005) [Academic-
in-confidence information removed].
Completeness of resection
Complete surgical resection of colorectal cancer is
an absolute requirement, albeit no guarantee of
cure. The adequacy of resection can be assessed by
Health Technology Assessment 2006; Vol. 10: No. 45
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TABLE 13 Duration of operation
Study ID Laparoscopic Open p-Value Comments
n Duration (minutes) n Duration (minutes)
Araujo, 200347 13 228 15 284 0.04 Mean
CLASICC, 20053 526 180 (135–220) 268 135 (100–180) Median (IQR)
COLOR, 20054 536 145 (45–420) 546 115 (40–355) <0.001 Median (range)
COST, 20042 435 150 (35–450) 428 95 (27–435) <0.001 Median (range)
Curet, 200048 18 210 (128–275) 18 138 (95–240) <0.05 Unknown
Hasegawa, 200349 24 275 (184–410) 26 188 (127–272) <0.001 Mean (range)
Hewitt, 199850 8 165 (130–300) 8 107.5 (90–150) 0.02 Median (range)
Kaiser, 200451 28 125 (70–270) 20 65 (45–125) <0.05 Mean (range) 
King, 200640 41 187 (168–207) 19 140 (121–163) 0.001 Geometric mean (95% CI)
Lacy, 200222 111 142 (52) 108 118 (45) 0.001 Mean (SD)
Leung, 200453 203 190 (55) 200 144 (58) <0.001 Mean (SD)
Neudecker, 200355 14 205 (120–260) 16 165 (100–285) <0.05 Median (range)
Schwenk, 1998a56,104 30 219 (64) 30 146 (41) <0.01 Mean (SD)
Stage, 199757 15 150 (60–275) 14 95 (40–195) 0.05 Median (range)
Tang, 200158 118 88 (15–220) 118 70 (20–195) Median (range)
Zhou, 200460 82 120 (110–220) 89 106 (80–230) 0.051 Mean (range)
IQR, interquartile range.
TABLE 14 Blood loss
Study ID Laparoscopic Open p-Value Comments
n Blood loss (ml)a n Blood loss (ml)a
COLOR, 20054 536 100 (0–2700) 546 175 (0–2000) <0.0001 Median (range)
Curet, 200048 18 284 (100–700) 18 407 (100–1000) <0.05 Unknown
Hasegawa, 200349 24 58 (1–350) 26 137 (32–355) 0.0034 Mean (range)
Kaiser, 200451 28 146.4 (100–1000) 20 100 (100–800) Mean (range)
King, 200640 41 11 (27%) 19 18 (95%) <0.001 Number with blood loss
>100 ml
Lacy, 200222 111 105 (99) 108 193 (212) 0.001 Mean (SD)
Leung, 200453 203 169 (0–3000) 200 238 (0–5836) 0.06 Mean (range)
Stage, 199757 15 275 (50–2100) 14 300 (50–2150) Median (range)
Zhou, 200460 82 20 (5–120) 89 92 (50–200) 0.025 Mean (range)
aExcept for King, 200640 (see ‘Comments’ column).proximal, distal and circumferential disease-free
margins during histological examination. In rectal
cancer, the distal and circumferential margins are
particularly important. 
Table 16 gives the results of studies reporting
completeness of resection in terms of proximal,
distal and circumferential resection margins.
Further data were reported in two RCTs4,54,60 and
in one meta-analysis (Bonjer J, QE II Health
Sciences Centre, Halifax, NS: personal
communication, 2005) using other definitions,
which were not always well described (Table 17).
Furthermore, whereas the CLASICC trial included
rectal cancers, most trials were limited to colonic
cancer. There appears to be no statistical
difference in this outcome between laparoscopic
and open surgery; however, meta-analysis of four
studies3,4,54,60 reporting sufficiently comparable
data showed a slightly better rate for open
resections but the difference was again not
statistically significant (Appendix 9, comparison
01:05: RR 1.15, 95% CI 0.74 to 1.77, p = 0.53).
Wound infection
Meta-analysis of data from the nine
trials3,4,22,40,48,49,53,58,83 that reported wound
infections showed no statistically significant
difference between the laparoscopic group and
open group, although 95% CI was wide
(Appendix 9, comparison 01:06: 96/1620 versus
86/1348, RR 0.86, 95% CI 0.64 to 1.14, p = 0.29).
Effectiveness
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TABLE 15 Lymph node retrieval (number)
Study ID Laparoscopic Open p-Value Comments
n Number n Number
Araujo, 200347 13 5.5 15 11.9 0.04 Mean
CLASICC, 20053 526 12 (8–17) 268 13.5 (8–19) Median (IQR)
COLOR, 20054 536 10 (0–41) 546 10 (0–42) 0.35 Median (range)
COST, 20042 435 12 428 12 Median
Curet, 200048 18 11 (2–23) 18 10 (1–21) Unknown
Hasegawa, 200349 24 23 (7–50) 26 26 (15–56) 0.25 Mean (range)
Kaiser, 200451 28 13.3 (1–32) 20 14 (3–27) Mean (range)
Lacy, 200222 111 11.1 (7.9) 108 11.1 (7.4) Mean (SD)
Leung, 200453 203 11.1 (7.9) 200 12.1 (7.1) 0.18 Mean (SD)
Milsom, 199854 42 19 (5–59) 38 25 (4–74) Median (range)
Stage, 199757 15 7 (3–14) 14 8 (4–15) Median (range)
Vignali, 200459 144 15.2 (8.6) 145 15.0 (7.7) 0.9 Mean (SD)
Bonjer, 2005  [Academic-in-confidence information removed] Mean
(unpublished)a
a Individual patient data meta-analysis including patients from COLOR, COST, CLASICC and Lacy trials.
TABLE 16 Resection margins
Study ID Laparoscopic Open p-Value Comments
n Value n Value
Proximal resection margins
COLOR, 20054 526 0 538 1 1.0 No. of positive resection margins
COST, 20042 435 13 (2–78) 428 12 (3-50) 0.38 Median (range) (cm)
Distal resection margins
COLOR, 20054 526 1 538 1 1.0 No. of positive resection margins
COST, 20042 435 10 (2–40) 428 11 (1–42) 0.09 Median (range) (cm)
Leung, 200453 203 4.5 (3.0) 200 4.5 (2.7) 0.97 Mean (SD) (cm)
Circumferential resection margins
CLASICC, 20053 439 46 (10.5%) 228 20 (8.8%) 0.45 No. of positive resection margins
Colon 246 16 (0.4%) 131 6 (4.6%) 0.8
Rectum 193 30 (0.5%) 97 14 (14.4%)
COLOR, 20054 526 9 (1.7%) 538 8 (1.5%) 1.0 No. of positive resection marginsUrinary tract infection
Six studies reported urinary tract infections. There
was no statistically significant difference in the
proportion of patients having a urinary tract
infection in the laparoscopic group compared with
the open group, but again the 95% CI was wide
and did not rule out clinically important
differences (Appendix 9, comparison 01:07:
25/1050 versus 21/1029, RR 1.15, 95% CI 0.66 to
1.98, p = 0.62). The direction of effect favoured
laparoscopic surgery in two studies4,58 but the
difference was not statistically significant.
30-day mortality
Seven RCTs2–4,22,40,48,53 and one meta-analysis
(Bonjer J, QE II Health Sciences Centre, Halifax,
NS: personal communication, 2005) provided
information on operative and 30-day mortality.
[Academic-in-confidence information removed.]
Data were also available from the seven individual
RCTs. Three studies reported operative
mortality,22,48,53 two reported 30-day mortality,2,40
one reported the number of people that died in
hospital3 and one reported 28-day mortality4 (the
last was treated as 30-day mortality for meta-
analysis purposes). In terms of operative mortality,
the overall direction of effect favours laparoscopic
surgery; however, the difference was not
statistically significant and the 95% CI was wide
(6/339 versus 7/326: RR 0.84, 95% CI 0.29 to 2.47,
p = 0.75). Also, 30-day mortality was non-
significantly less in the laparoscopic group than in
the open group (8/1011 versus 15/992: RR 0.57,
95% CI 0.25 to 1.29, p = 0.18).
Length of hospital stay
All 14 studies that provided information on length
of hospital stay reported lower mean or median
stay in the laparoscopic group and this was
statistically significant in 11 studies (Table 18). The
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TABLE 17 Other data on resection margins
Study ID Laparoscopic Open p-Value Comments
Nn % Nn%
Milsom 199854 42 0 0 38 0 0 Positive surgical margins
Zhou 200460 82 0 0 89 0 0 Cancer cell found in the cut margins
Bonjer, 2005  [Academic-in-confidence information removed]
(unpublished)a
a Individual patient data meta-analysis including patients from COLOR, COST, CLASICC and Lacy trials.
TABLE 18 Length of hospital stay
Study ID Laparoscopic Open p p-Value Comments
n Stay (days) n Stay (days)
Araujo, 200347 13 10.5 15 NR 0.42 Mean
CLASICC, 20053 526 9 (7–14) 268 11 (8–15) Median (IQR)
Colon 273 9 (7–12) 140 9 (8–13) Median (IQR)
Rectum 253 11 (9–15) 128 13 (9–18) Median (IQR)
COLOR, 20054 536 8.2 (6.6) 546 9.3 (7.3) <0.0001 Mean (SD)
COST, 20042 435 5 (4–6) 428 6 (5–7) <0.001 Median (IQR)
Curet, 200048 18 5.2 18 7.3 <0.05 Unknown
Hasegawa, 200349 24 7.1 (4–15) 26 12.7 (6–57) 0.0164 Mean (range)
Hewitt, 199850 8 6 (5–7) 8 7 (4–9) Median (range)
Kaiser, 200451 28 5.9 (3–13) 20 6 (5–9) <0.05 Mean (range)
King, 200640 40 5.2 (4.2–6.5) 18 7.4 (6.0–9.2) 0.018 Geometric mean (95% CI)
Lacy, 200222 111 5.2 (2.1) 108 7.9 (9.3) 0.005 Mean (SD)
Leung, 200453 203 8.2 (2–99) 200 8.7 (3–39) <0.001 Mean (range)
Schwenk, 1998b77
(Schwenk 1998a56) 30 10.1 (3.0) 30 11.6 (2.0) <0.05 Mean (SD)
Stage, 199757 15 5 (3–12) 14 8 (5–30) 0.01 Median (range)
Zhou, 200460 (rectum) 82 8.1 (3.1) 89 13.3 (3.4) 0.001 Mean (SD)
NR, not reported except as longer than laparoscopic group.direction of apparent effect towards laparoscopic
surgery is supported by the Sign test (p < 0.001).
Four RCTs reported data suitable for quantitative
synthesis.4,22,60,77 Across them, the average length
of stay was significantly shorter in the laparoscopic
group than in the open group (Appendix 9,
comparison 01:09: WMD –2.58, 95% CI –3.12 to
–2.03, p < 0.001)). This result was consistent with
the data from those trials that reported data not
amenable to meta-analysis (Table 18). Nonetheless,
there was a marked heterogeneity observed in the
meta-analysis of this outcome, but there was
consistency in the direction of effect, reflecting
variation in the size of estimated effect across
studies. Using the random effects method, the
WMD was –2.63 days (95% CI –4.82 to –0.44,
p = 0.02). The main source of heterogeneity
appeared to be from the study by Zhou and
colleagues,60 where the average age of 
participants was lower than in the rest of the
studies included in this review. Additionally, all
participants in the Zhou study had rectal cancer.
When data from Zhou and colleagues were
excluded from the analysis, the trend towards
laparoscopic surgery was maintained but the WMD
was decreased (WMD –1.40, 95% CI –2.10 to
–0.70, p < 0.0001). It should be noted that
Schwenk and colleagues77 kept their patients in
hospital for at least 7 days regardless of the type of
surgery.
Postoperative pain 
Five studies included a measure of postoperative
pain (Table 19).3,53,57,77,82 Between the first day and
2 weeks postoperation, four studies favoured the
laparoscopic group3,53,57,77 and one did not show
Effectiveness
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TABLE 19 Postoperative pain – pain scores
Study ID Measure Laparoscopic Open p-Value Comments
n Pain score n Pain score
CLASICC, 20053 EORTC QLQ-C30  526 40 268 35 NS Estimated from graph
(pain) at 2 weeks 
postoperation
EORTC QLQ-C30  526 21 268 19 NS Estimated from graph 
(pain) at 3 months  (back to baseline)
postoperation
Leung, 200453 VAS at 1 day  203 4.6 (2.4) 200 5.4 (2.3) 0.003 Mean (SD)
postoperation
Schwenk, 1998b77 VAS at rest at 1 day  30 17.5 (0–50) 30 26 (0–50) 0.2 Median (range)
(Schwenk, 1998a56)postoperation
Cumulative VAS  30 161 (17–729) 30 252 (123–441) 0.07 Median (range)
score during rest for 
first week 
postoperation
Stage, 199757 VAS at rest at 1 day 15 15 14 16 NS Estimated from graph
postoperation
VAS at rest at 5 days  15 0 14 5 NS Estimated from graph
postoperation
VAS at rest 30 days  15 0 14 0 NS Estimated from graph
postoperation
Weeks, 200282 Pain distress at  203 2 (1–3) 198 2 (1–3) NS Median (IQR)
(COST, 2004) 2 days postoperation
Pain distress at  201 1 (1–2) 194 1 (1–2) NS Median (IQR)
2 weeks 
postoperation
Pain distress at  199 1 (1–1) 180 1 (1–2) NS Median (IQR)
2 months 
postoperation
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Core 30 Questionnaire
(100: better); VAS, visual analogue score (0: better); NS, not significant.any differences between the two interventions82
(Sign test, p = 0.125). Three studies measured pain
at 1–3 months postoperatively but this did not
differ significantly between the two
interventions.3,57,82 Data were not presented in a
form sufficiently similar to allow quantitative
synthesis. Results in terms of analgesic requirements
consistently favoured the laparoscopic group (Table
20). In four studies, patients in the laparoscopic
group required fewer days of postoperative
analgesia than in the open group,2,49,51,60 and this
was statistically significant in three. A further study
recorded that the number of participants in the
laparoscopic group requiring opioid supplements
was less than that required in the open group [9/41
(22%) versus 14/19 (74%)].40 In another study,
patients in the laparoscopic group required 35 mg
less morphine in the first 48 hours as compared
with the open group50 (Sign test, p = 0.031).
Time to return to usual activities
Only one study reported data on time to return to
usual activities.53 This study was based in Hong
Kong and compared laparoscopic (n = 203) with
open surgery (n = 200) in patients with
rectosigmoid cancer. The authors report that the
average time to resume household activities in the
laparoscopic group (mean 32 days, range
4–365 days) was lower than that in the open group
(mean 44 days, range 7–198 days, p = 0.002). 
Health-related quality of life
Four studies, using a variety of instruments,
reported the quality of life of people undergoing
laparoscopic or open resections (Table 21).3,40,56,82
In three studies, the quality of life was assessed
using the European Organisation for Research and
Treatment of Cancer Quality of Life Core 30
Questionnaire (EORTC QLQ-C30).3,40,78 In one
study, quality of life was measured using two
distinct instruments: Quality of Life Index and the
Global Rating Scale.82
Three studies reported higher quality of life
following laparoscopic surgery and in one the
quality of life scores were similar in both the
laparoscopic and open groups;40 however, this was
a randomised study embedded within an
enhanced recovery programme (Sign test,
p = 0.125). One study reports that patients
assigned to laparoscopic surgery who were
converted to open showed poorer quality of life at
baseline and at every follow-up assessment than
patients who underwent laparoscopic resection.82
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TABLE 20 Postoperative pain – analgesic requirement
Study ID Measure Laparoscopic Open p-Value Comments
n Value n Value
COST, 20042 Duration of  435 3 (2–4) 428 4 (3–5) <0.001 Median (IQR)
parenteral narcotics 
(days)
Duration of oral  435 1 (1–2) 428 2 (1–3) 0.02
analgesics (days)
Hasegawa, 200349 Analgesic  24 1.7 (0–4) 26 3.4 (0–17) 0.0022 Mean (range)
requirement 
(postoperative 
days)
Hewitt, 199850 Analgesic  8 27 (0–60) 8 62 (28–88) 0.04 Median (range)
requirement 
(mg of morphine 
in first 48 hours)
Kaiser, 200451 Use of analgesics  15 2 (0–3) 20 4 (2–7) <0.05 Mean (range)
(days) 
King, 200640 Epidural insufficiency  41 9 (22%) 19 14 (74%) <0.001
requiring opioid 
supplements
Zhou, 200460 Parenteral analgesics  82 3.9 (0.9) 89 4.1 (1.1) 0.225 Mean (SD)
(days)Overall survival
Seven RCTs2,3,22,48,51,53,60 (Guillou PJ, University of
Leeds: personal communication, 2005) and one
individual patient data meta-analysis (Bonjer J,
QE II Health Sciences Centre, Halifax, NS:
personal communication, 2005) provided
information on overall survival for patients
undergoing laparoscopic or open resection.
Length of follow-up of the RCTs ranged from one
to 108 months. Bonjer and colleagues reported a
‘time to event’ meta-analysis based on individual
patient data of four big trials: COST, CLASICC,
COLOR and the study conducted by Lacy and
colleagues22 (Bonjer J, QE II Health Sciences
Centre, Halifax, NS: personal communication,
2005). Figure 2 of their study is reproduced here
as Figure 4 [Academic-in-confidence information
removed]. Bonjer and colleagues did not include
all the RCTs; the data from six of the individual
RCTs were included in a meta-analysis to
determine whether the results of these studies
were consistent with those from Bonjer and
colleagues. The results of this analysis showed no
difference between groups (Appendix 9,
comparison 01:10: RR 1.03, 95% CI 0.98 to 1.09,
p = 0.28). The direction of effect was not
consistent across the studies. Four studies slightly
favoured laparoscopic resection2,22,48,53 and one
slightly favoured open resection.51 The results of
this meta-analysis should be treated with caution
as the length of follow-up of the RCTs varied and
only the proportion of deaths, not time to death,
was utilised. The remaining RCT was a 3-year
follow-up of the CLASICC trial. Only preliminary
unpublished data from this trial were obtained; as
these data were supplied as academic-in-
confidence, they have not been included in this
report (Guillou PJ, University of Leeds: personal
communication, 2005).
Disease-free survival
Five RCTs2,22,51,53 (Guillou PJ, University of Leeds:
personal communication, 2005) and one meta-
analysis (Bonjer J, QE II Health Sciences Centre,
Halifax, NS: personal communication, 2005)
provided information on disease-free survival.
[Academic-in-confidence information removed.]
Further data were available from the CLASICC
trial; however these data were preliminary and
unpublished. As these data were supplied as
academic-in-confidence, they have not been
included in this report (Guillou PJ, University of
Leeds, personal communication, 2005). A meta-
analysis of the data provided by the remaining
four RCTs showed no difference in disease-free
survival (Appendix 9, comparison 01:11: RR 1.01,
95% CI 0.95 to 1.07, p = 0.83).
Recurrence
Seven RCTs2,22,47,48,51,53,57 and one meta-analysis
(Bonjer J, QE II Health Sciences Centre, Halifax,
NS: personal communication, 2005) provided
information on recurrence. Considering 1528
patients over the six trials, cancer recurrences
appeared less frequently in the laparoscopic group
than in the open resection group. Two studies
favoured the open group51,53 and another three
favoured the laparoscopic group,2,22,48 but none of
the differences were statistically significant
(Appendix 9, comparison 01:12: 135/789 versus
144/765, RR 0.92, 95% CI 0.74 to 1.14, p = 0.44).
The results of this meta-analysis should be treated
with caution as the follow-ups of the RCTs ranged
from 3 to 108 months. [Academic-in-confidence
information removed.]
In terms of wound recurrence alone, there were
only three reported cases of wound recurrences
across the four studies2,51–53 that reported this
outcome: two cases of wound recurrence in the
laparoscopic group and one in the open group2
(Table 22). Eight studies provided information on
Effectiveness
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TABLE 21 Quality of life
Study ID Measure Laparoscopic Open Comments
CLASICC, 20053 EORTC QLQ-C30 55 52 Estimated from graph at 2 weeks 
King, 200640 EORTC QLQ-C30 NR NR Scores were similar at 2 weeks
Schwenk, 1998c78 EORTC QLQ-C30 NR NR Scores favours laparoscopic at 1 and 4 weeks 
(Schwenk, 1998a56)( p = 0.05)
Weeks, 200282 QLI 1 (0–2) 1 (0–2)
(COST, 2004) Global QoL 80 (70–90) 75 (60–90) Median (IQR) at 2 weeks
Global QoL, Global quality of life (0, death; 100, excellent health); QLI, quality of life index (0, normal functioning; 
1, moderately impaired functioning; 2, severely impaired functioning).
FIGURE 4 [Academic-in-confidence information
removed]port-site recurrence.22,49,51–54,57,60 Of 483 patients,
three were found to have a port-site recurrence
(Table 23).22,60
Incidence of incisional hernia
Only two studies provided information on this
outcome.53,83 The average follow-up in one was
2.5 years83 and in the other 4.2 years.53 Incisional
hernias were reported in 17 out of 249 (7%) in the
laparoscopic group and 13 out of 243 (5%) in the
open group, one of which was a port-site hernia,
but this difference was not statistically significant
(Appendix 9, comparison 01:14).
Important subgroup differences for
laparoscopic versus open techniques
Patients undergoing conversions
Three studies reported separate outcome data for
patients undergoing conversions.3,48,51 Appendix
10 gives a summary of outcomes reported for
converted patients. The pattern observed in
conversion patients for duration of operation,
urinary tract and wound infection and overall
survival was similar to that observed for both
laparoscopic and open resection groups.
Converted patients, however, displayed higher
blood loss and longer length of hospital stay. In
addition, although lymph node retrieval was
higher, tumour recurrence appeared to be greater
than that observed for the other two groups
successfully managed according to their allocation.
Data for converted patients were limited and
therefore these results should be interpreted with
caution.
Effect of surgeon experience
Three trials reported the effect of surgeon
experience on outcomes.2–4 The COST trial found
no experience-based trends for conversion, length
of stay or quality of life measures.2,82 However, the
CLASICC trial reported a decline in number of
conversions by year of recruitment from 38% in
the first year to 16% in the sixth year.3 The
COLOR trial also found that the duration of
surgery for laparoscopic procedures reduced with
increasing numbers of patients per centre
(p = 0.03), although number of lymph nodes
harvested and length of hospital stay did not
differ significantly.4
Location of cancer
Subgroup analysis showed no evidence that the
treatment effect size for anastomotic leakages was
different for colon compared with rectal cancer.
However, the evidence is limited as only two RCTs
reported anastomotic leakages in rectal patients3,60
(Appendix 9, colon, comparison 01:15:01: RR
1.27, 95% CI 0.70 to 2.31, p = 0.44; rectum,
comparison 01:15:02: RR 1.25, 95% CI 0.63 to
2.46, p = 0.52).
Stage of cancer
Two RCTs provided subgroup analysis by stage of
cancer for overall survival.2,53 In both of these
trials there was no significant difference in overall
survival of patients undergoing laparoscopic
resection compared with open resection for 
cancer Stages I, II or III (p > 0.05). The meta-
analysis of individual patient data compared
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TABLE 22 Wound recurrence
Study ID Follow-up (months) Laparoscopic Open p-Value
COST, 20042 Median 4.4 years 2/435 (0.5%) 1/428 (0.2%) 0.50
Kaiser, 200451 Median 35 (range 3–69) 0/28 0/20
Kim, 199852 (Range 1–12) 0/19 0/19
Leung, 200453 Laparoscopic, median 52.7 (IQR 38.9);  0/167 0/170
open median 49.2 (IQR 35.4)
TABLE 23 Port-site recurrence
Study ID Follow-up (months) Laparoscopic
Hasegawa, 200349 Median 20 (range 6–34) 0/24
Kaiser, 200451 Median 35 (range 3–69) 0/28
Kim, 199852 Range 1–12 0/19
Lacy, 200222 Median 43 (range 27–85) 1/106
Leung, 200453 Laparoscopic, median 52.7 (IQR 38.9); open, median 49.2 (IQR 35.4) 0/167
Milsom, 199854 Laparoscopic, median 18 (range 1.5–46); open, median 20.4 (range 3–48) 0/42
Stage, 199757 Median 14 (range 7–19) 0/15
Zhou, 200460 Range 1–16 2/82Effectiveness
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overall and disease-free survival for patients
undergoing laparoscopic with open resection by
stage of cancer (Bonjer J, QE II Health Sciences
Centre, Halifax, NS: personal communication,
2005). [Academic-in-confidence information
removed.]
Age
No separate data were provided in the included
studies to compare older and younger patients.
Summary and conclusions of the
evidence for and against the
intervention
This update considered data from over 4500
randomised participants across 18 RCTs of
generally good quality. The data indicate that after
laparoscopic resection, length of hospital stay is
shorter, blood loss and postoperative pain are less
and return to usual activities is likely to be faster
than after open resection. The duration of
operation for laparoscopic resection is longer.
Lymph node retrieval, completeness of resection
and quality of life do not appear to differ 
between the two approaches, although clinically
important differences could not be ruled out. 
The occurrence of complications such as
anastomotic leakage, abdominal wound
breakdown, incisional hernia, wound and urinary
tract infections are similar, again with wide 95%
CIs. Operative and 30-day mortality were also
statistically similar in both groups. [Academic-in-
confidence information removed.] There was also
no evidence of a difference in the number of
recurrences (including wound recurrences).
Furthermore, after laparoscopic resection, port-site
recurrences were found in less than 1% of patients.
In this review, the results for duration of operation
and length of stay displayed significant
heterogeneity. Consistency in the direction of
effect was, however, observed in the two outcomes.
Much of the variation might be due to differences
in the characteristics of participants, particularly
differences on patients’ age and location and stage
of cancer. In part this may have been due to the
differences in the specific aims and objectives of
the trials, which led to important differences in
inclusion criteria. Other likely sources of
heterogeneity include differences in the way in
which those outcomes were defined, in the
operator experience and in the length of 
follow-up.
A low conversion rate is a key issue in laparoscopic
resection as it is associated with better short-term
outcomes. In this review, we identified that
converted patients have higher blood loss and
longer length of hospital stay. Furthermore, there
is evidence from the CLASICC trial that
conversion rates fall with experience. There is
FIGURE 5 [Academic-in-confidence information
removed]
TABLE 24 Summary of the clinical effect size from meta-analysis
Outcome No. of trials Effect size 95% CI p-Value
Duration of operation 3 39.65b 31.64 to 47.67 <0.001
Lymph node retrieval  3 –0.41b –1.42 to 0.59 0.42
Length of hospital stay  4 –2.58b –3.12 to –2.03 <0.001
Completeness of resection 4 1.15 0.74 to 1.77 0.53
Anastomotic leakage  8 1.13c 0.74 to 1.73 0.58
Abdominal wound breakdown  3 0.63c 0.26 to 1.52 0.30
Positive resection margins 4 1.15c 0.74 to 1.77 0.53
Wound infection  9 0.86c 0.64 to 1.14 0.29
Urinary tract infection  7 1.15c 0.66 to 1.98 0.62
30-day mortality  3 0.57c 0.25 to 1.29 0.18
Operative mortality 4 0.84c 0.29 to 2.47 0.75
Overall survival  7 1.03c 0.98 to 1.09 0.28
Disease-free survival 5 1.01c 0.95 to 1.07 0.83
Recurrencea 7 0.92c 0.74 to 1.14 0.44
Recurrence – wound 4 1.97c 0.18 to 21.62 0.58
Hernia 2 1.49c 0.76 to 2.9 0.29
a Total number of recurrences when reported as it is by the author.
b Weighted mean difference.
c Relative risk.good evidence that laparoscopic resection is
associated with short-term benefits in terms of a
more rapid recovery.
Clinical effect size
A summary of the clinical effect sizes for all
outcomes derived from the meta-analyses where
data were available is given in Table 24. A summary
of clinical effect for other outcomes is given in
Table 25.
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TABLE 25 Summary of clinical effect size for other outcomes
Outcome No. of trials Effect
Duration of operation  15 15 (12)a studies report shorter duration of operation in the open
group; range of differences: 14–87 minutes
Blood loss 9 8 (7)a studies report less blood loss in the laparoscopic group; range of
differences: 25–123 ml
1 favours open; difference: 46.4 ml
Lymph node retrieval  11 No significant differences reported
Positive resection margins 6 No significant differences reported
Length of hospital stay 13 13 (11)a studies report shorter length of hospital stay in the
laparoscopic group; range of differences: 0.1–5.6 days
Postoperative pain:
Pain scores 5 4 (1)a studies report less pain in the laparoscopic group
Analgesic requirement 6 6 (5)a studies report less analgesic requirement in the laparoscopic
group
Time to return to usual activities 1 1 (1)a study reports less time away from usual activities in the
laparoscopic group
Health related quality of life 4 3 favour laparoscopic group
a (n) Studies that reported statistically significant results at the 0.05 level.Methods
Search strategies
Studies that reported both costs and outcomes of
laparoscopic and/or HALS techniques compared
with open surgery for the treatment of colorectal
cancer were sought from the systematic review of
the literature. No language restrictions were
imposed but as this review is an update of an earlier
review conducted in 2000, the searching was limited
to studies published between 2000 and 2005.
Databases searched were MEDLINE (2000–May
Week 2, 2005), EMBASE (2000–Week 21, 2005),
MEDLINE Extra (23 May 2005), Science Citation
Index (2000–27 May 2005), NHS Economic
Evaluation Database (May 2005), HTA Database
(May 2005), Health Management Information
Consortium (2000–May 2005) and Journals@Ovid
Full Text (2000–July 2005 for selected surgical
journals). In addition, recent conference
proceedings and reference lists of all included
studies were scanned to identify additional
potentially relevant studies. Other sources of
information consulted included references in
relevant articles, selected experts in the field and
references of consultees’ submissions. Full details
of the search strategies used are documented in
Appendix 1.
Inclusion and exclusion criteria
To be included, studies had to compare, in terms
of both costs and outcomes, strategies involving
laparoscopic and/or HALS compared with open
surgery for treatment of colorectal cancer. Studies
were included even if they made no formal
attempt to relate cost to outcome data in a cost-
effectiveness or cost–utility analysis. One reviewer
assessed all abstracts for relevance and full papers
were obtained for those that appeared potentially
relevant.
Data extraction strategy
The following data were extracted for each
included primary study using the framework
provided for abstracts prepared for the NHS
Economic Evaluation Database:105
1. Study identification information
(a) author and year
(b) the interventions studied
(c) the type of economic evaluation
(d) the country of origin and currency
reported.
2. The intervention, study design and main outcomes
(a) fuller description of treatment
(b) numbers receiving or randomised to each
intervention
(c) outcomes studied.
3. Sources of data
(a) effectiveness data
(b) mortality and co-morbidity (if measured)
(c) cost data 
(d) quality of life (if measured).
4. Methods and study perspective
5. Results
(a) costs 
(b) benefits
(c) incremental cost-effectiveness ratio (ICER)
(d) sensitivity analyses.
6. Additional comments relating to the design and
reporting of the economic evaluation
For reviews of economic evaluations, data were
extracted on the nature of the review
methodology used, the inclusion criteria for
studies, the number of studies identified, the
method of quality assessment for individual
economic evaluations and the conclusions
drawn on the relative efficiency of the
alternative methods.
Quality assessment strategy
One economist assessed included studies using the
NHS Economic Evaluation Database guidelines for
reviewers.105 The systematic review provided by
the Association of Laparoscopic Surgeons of Great
Britain and Ireland (ALSGBI) was assessed using
the following criteria adapted from Oxman and
colleagues44,106 and Mulrow and Cook107 used in a
recent study of the quality of systematic reviews of
economic evaluations.108
The following questions were addressed for the
quality assessment of reviews: 
1. Is it unlikely that important relevant studies
were missed?
2. Were the inclusion criteria used to select
articles appropriate?
3. Was the assessment of studies reproducible?
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Chapter 4
Systematic review of economic evaluations4. Were the design and/or methods and/or topic
of included studies broadly comparable?
5. How reproducible are the overall results?
6. Will the results help resource allocation in
healthcare?
Each stem (1–6) was answered by one of the
following: ‘Impossible to judge’, ‘No’, ‘Partly’,
‘Yes’.
Data synthesis
No attempt was made to synthesise quantitatively
the primary studies that were identified. Data from
all included studies were instead summarised and
appraised in order to identify common results,
variations and weaknesses between studies. If a
study did not report ICERs but provided sufficient
data, then, where possible, the data were
reanalysed to provide estimates of ICERs. The
data were then interpreted alongside the results of
the systematic review of effectiveness so that
conclusions could be drawn on the relative
efficiency of the different surgical strategies. 
The results of the systematic review of economic
evaluations reported in this chapter were
compared with those drawn from the consultee
submissions and similarities and differences
highlighted.
Where relevant data were available from studies
which were unpublished but for which the authors
were seeking publication, these data have been
treated as academic-in-confidence and not
reported.
Results
Number of studies identified
The results of the literature searches are presented
in Table 26. The number of reports retrieved from
the searches in the Science Citation Index and
Journals@Ovid Full Text are the totals after
deduplication against the results of the
MEDLINE/EMBASE multifile search.
Of the studies selected for assessment, three
studies53,66,109 met the inclusion criteria. Two
additional unpublished papers were obtained from
experts in the field40 (Franks PJ, Thames Valley
University: personal communication, 2005). A
further study that compared laparoscopic against
HALS and, as a consequence, did not meet the
inclusion criteria, was also identified. However, a
summary of this study is provided as part of the
section ‘Summary of results and discussion’
(p. 34).104
Study identification and key elements
Two studies compared laparoscopic colon resection
with open colon resection in the treatment of
colon cancer,66,109 but one of them focused on
right hemicolectomy;109 a further study compared
laparoscopic-assisted with conventional open
resection for rectosigmoid carcinoma,53 and two
compared laparoscopic with open resection for
colorectal cancer40 (Franks PJ, Thames Valley
University: personal communication, 2005). One
of these was in the context of an enhanced
recovery programme.40
Four studies were classified as cost–consequence
analyses, that is, costs were compared with various
different measures of effectiveness. Two were
based on single-centre RCTs40,53 and one was
based on data from 10 Swedish centres.66 The
fourth study was based on a single-centre cohort-
matched study conducted in China (Table 27).109
Two studies considered costs from a societal
perspective40,66 whereas the others adopted a
hospital perspective (Table 27).53,109 The fifth study
was described as a cost analysis (data supplied as
academic-in-confidence has not been presented in
this report) (Franks PJ, Thames Valley University:
personal communication, 2005).
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TABLE 26 Results of searching for studies on cost-effectiveness
Database Hits screened Selected for full assessment
MEDLINE/EMBASE/MEDLINE Extra multifile search  256 28
(after deduplication in Ovid)
Science Citation Index 63 5
NHS Economic Evaluation Database 5 0
HTA Database 30 3
Heath Management Information Consortium 35 2
Selected from conference abstracts 3 3
Total 392 41The study by Franks and colleagues represented a
preliminary analysis conducted on a subset of
patients from the CLASICC trial who had agreed
to be included in the economic evaluation. The
dates for data collection were not reported. The
Swedish study collected data from January 1999 to
May 2002,66 the study by King and colleagues
from January 2002 to March 2004,40 the study by
Leung and colleagues, conducted in Hong Kong,
from September 1993 to October 200253 and the
Chinese study from September 2002 to February
2003.109 In all five studies, costs were estimated
prospectively from the same sample as that used
for collecting the effectiveness data40,53,66,109
(Franks PJ, Thames Valley University: personal
communication, 2005).40,53,66,109
Patient group, study sample and study
design
The sample sizes in four of the five studies were
modest (Table 27). In the cohort-matched study,
patients with colon cancer underwent laparoscopic
right hemicolectomy surgery and were matched
with patients who received open right
hemicolectomy surgery.109 Patients for the open
surgery group in this study were matched for
gender, age, Dukes’ staging, tumour site, previous
abdominal operation and extent of resection and
randomly selected from 87 patients who
underwent open surgery during the same period. 
The analysis in all studies was conducted on an
intention-to-treat basis; however, the follow-up
period varied considerably between studies
(Table 27). The outcome measures also varied
between studies (Table 28).
Methods of economic analysis
The four trial-based papers40,53,66 (Franks PJ,
Thames Valley University: personal communication,
2005) presented details on which items were
included in the cost calculations, whereas no details
were reported in the Chinese study.109 Relatively
good details of unit costs were presented in the
Swedish and UK studies40,66 (Franks PJ, Thames
Valley University: personal communication, 2005),
whereas no unit costs were reported in the other
two studies.53,109 Discounting was performed only in
the Swedish study whereas it was actually relevant in
all studies with a follow-up greater than 12 months.
Indirect costs were calculated in three of the studies
using the human capital approach (time off paid
work)40,60 (Franks PJ, Thames Valley University:
personal communication, 2005). Three papers did
not use any summary measure of health
benefits40,53,109 and left the results disaggregated.
One study focused on costs alone (Franks PJ,
Thames Valley University: personal communication,
2005). In the study by Janson and colleagues, the
mean cost for reoperated patients for each arm of
the trial was presented (although it is not reported
in this chapter).66
One-way sensitivity analysis was performed in
three studies. Changes in perioperative,
equipment, recovery, intensive care unit and
hospital costs were considered in the study by
Franks and colleagues (Franks PJ, Thames Valley
University: personal communication, 2005). They
also considered a subgroup analysis by location of
cancer (colon or rectum). Cost per minute for the
operating room, anaesthesia and recovery room
time were explored in the Swedish study66 while
duration of in-patient stay and the consumption of
community resources after discharge were
explored in the study by King and colleagues.40
Results
The results of the included studies are
summarised in Table 29. The results of the study
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TABLE 27 Characteristics of the included studies
Study ID Design Sample Follow-up Perspective
(months)
Franks, 2005,  Multicentre RCT  Laparoscopic: 452 3 Stated as hospital (NHS) but 
(unpublished) (UK) (CLASICC) Open: 230 societal
Janson, 200466 (Sweden) Single-centre from a  Laparoscopic: 98 36 Societal
multicentre RCT Open: 112
King, 200640 (UK) Single-centre RCT Laparoscopic: 43 3 Societal
Open: 19
Leung, 200453 Single-centre RCT Laparoscopic: 203 52.7 (mean)  Hospital
(Hong Kong) Open: 200 49.2 (mean)
Zheng, 2005109 (China) Single-centre cohort- Laparoscopic: 30 27 (mean) Hospital
matched Open: 34 26 (mean)by Franks and colleagues were provided as
academic-in-confidence and have been removed
from this report.
In the study by Janson and colleagues, total costs,
including productivity loss, were not significantly
different between the laparoscopic and open
groups. However, total costs, excluding productivity
losses (that is, cost to the healthcare system), were
significantly higher for the laparoscopic group
than the open group (€9474 versus €7235;
p = 0.018), as were the costs related to the first
admission and the costs of primary surgery.66
In King and colleagues’ study, the results reflected
the increased duration of laparoscopic procedures
and also the increased use of disposable equipment
in theatre. However, in their analysis, King and
colleagues found that these costs were more than
offset by lower postoperative costs such as
reoperations and productivity cost savings resulting
from the earlier return to usual activities.40
Similarly, the health service costs in the study by
Leung and colleagues were also higher for
laparoscopic than for open surgery and this
difference, as with the other two RCT-based
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TABLE 28 Outcome measures used in the included studies
Study ID End-points
Franks, 2005  None specified
(unpublished) (UK)
Janson, 200466 (Sweden) Complication rate (e.g. anastomotic leak, bowel perforation, wound rupture, ileus,
postoperative bleeding, incarcerated abdominal hernia, endoscopic dilation, closure loop
ileostomy)
Reoperations
Mortality
3-year survival 
King, 200640 (UK) Requirement of opioid analgesia
Anti-emetic administration
Major morbidity (e.g. haemorrhage, anastomatic leak, wound dehiscence and sepsis requiring
at least high-dependency support)
Hospital stay 
Length of stay for readmissions
Mortality
Leung, 200453 (Hong Kong) Duration of operation
Blood loss
Anastomotic leakage
Lymph node retrieval
Completeness of resection/margins of tumour clearance
Conversion
Wound infection
Urinary tract infection
30-day mortality
Postoperative pain
Survival
Disease-free survival
Recurrence
Zheng, 2005109 (China) Operation time
Blood loss
Specimen length 
Lymph node yield
Pathological staging (Dukes’ staging)
Analgesic requirements
Time to flatus passage
Time to resume normal diet 
Duration of hospitalisation
Morbidity
Local recurrence rate 
Metachronous metastasis rate
Mortality
Cumulative survival probabilityanalyses, was statistically significant (p < 0.001).53
However, no significant difference was observed in
the total cost of operation and drugs between the
two groups in the Chinese study [CNY1000 (~£67);
www.bloomberg.com, accessed 24 August 2005].109
Overall, the magnitude of the mean additional cost
of laparoscopic compared with open surgery varied
considerably between studies. For example, the
relative cost of laparoscopic surgery compared with
open surgery varied between 95%40 and 130%.53
The data on the relative effectiveness of
laparoscopic compared with open surgery for the
RCTs are reported in detail in Chapter 3. For
details on Zheng and colleagues’109 study, see
Appendix 11. Only one measure of effectiveness
was common across all four studies: complications.
Table 30 reports the number of complications (see
Table 28 for types of complications) in each study.
Only two studies reported p-values for the
difference between the number of complications in
the laparoscopic and open groups,40,109 and in
these the difference was not statistically significant.
Using the data presented in Tables 29 and 30, the
incremental cost per complication avoided can be
calculated (Table 31).
Based on mean data for costs and complications
open surgery is dominant (i.e. less costly and more
effective) in one study66 whereas in another
laparoscopic surgery is dominant.40 For the two
studies laparoscopic surgery could avoid a
complication at a cost of US$76,87253 and
CNY 10,008109 (approximately £42,000 and £780,
respectively).
One study conducted a subgroup analysis by
location of disease (colon or rectum) (Franks PJ,
Thames Valley University: personal
communication, 2005). The results of this analysis
were supplied on an academic-in-confidence basis
and are not presented in this report.
Comment on the submission by
the Association of Laparoscopic
Surgeons of Great Britain and
Ireland (ALSGBI)
The cost-effectiveness review submitted by the
ALSGBI included three RCT-based analyses53,62,66
and four non-RCT-based analyses.35,109–111 Two of
the former53,66 and one of the latter109 were
included in this review. All studies included in the
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TABLE 29 Cost data reported in the included studiesa
Study ID Laparoscopic Open Difference (%) p-Value
Janson, 200466 (Sweden) Total costb €11,660 €9,814 €1,846 p = 0.104
(18.8)
Perspective: societal Total costs, excluding productivity lossesb €9,474 €7,235 €2,239 p = 0.018
(30.9)
First admissionb €6,931 €5,375 €1,556 p = 0.015
(28.9)
Primary surgeryb €3,493 €2,322 €1,171 p = 0.001
(50.4)
King, 200640 (UK) Total cost £6,433 £6,790 –£357 95% CI:
(–5.3) –2167 to 
2992
Perspective: societal Total costs – indirect costs £5,985 £6,068 –83 NA
(–1.4%)
Theatre costs £2,885 £1,964 £921 95% CI: 
(46.9) 1251 to 
586
Leung, 200453 (Hong Kong) Direct costsc US$9,297 US$7,148 US$2,149 p < 0.001
Perspective: hospital (30.1)
Zheng, 2005109 (China) Total cost of operation and drugsd CNY 11,499 CNY 10,228 CNY 1,271 p = 0.131
Perspective: hospital (SD: 2,619) (SD: 2,373) (12.4)
NA, not available.
a The results from Franks and colleagues have been removed from this table as they were supplied as academic-in-confidence.
b €1 ≈ £0.67.
c US$1 ≈ £0.55.
d CNY = Chinese yuan (renminbi); CNY 1 ≈ £0.067.ALSGBI review compared laparoscopic with open
surgery for colorectal diseases and were broadly
comparable. The principle difference was that the
ALSGBI review included studies which involved
outcomes not presented in a disaggregate form for
colorectal cancer and non-colorectal cancer
patients. Furthermore, the ALSGBI review did not
report the search strategies used. However, it
seems unlikely that any important relevant studies
had been missed. 
The ALSGBI review concluded: “the operative
costs for laparoscopic resection of colorectal cancer
are higher because of longer operating time and
the use of more expensive devices. However, these
costs are offset by shorter hospital stay, less use of
analgesia, less use of blood products and less
complications in short and long term”. The first
part of this statement agrees with the findings of
the review reported in this chapter; however, the
data available from the review presented in this
chapter do not suggest that the additional
operative costs are offset by cost savings resulting
from fewer complications and shorter length of
stay.
Summary of results and discussion 
In the previous review conducted for NICE on this
subject, eight studies were identified.21 This review
reported that: “No consistent patterns were found,
with most studies showing no significant difference
in cost between the two procedures. It is clear that
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TABLE 30 Number of complications reported in the included studiesa
Study ID Laparoscopic Open Difference (%) p-value
Janson, 200466 (Sweden) Total complications 33 (33%) 26 (23.2%) 7 NR
(9.8)
First admission 21 (21%) 18 (16.1%) 3 NR
(4.9)
After discharge  12 (12%) 8 (7.1%) 4 NR
(4.9)
King, 200640 (UK) Major morbidity 6 (15%) 5 (26%) 1 Odds 
(–11) ratio: 0.40 
(0.10 to 1.66)
p = 0.208
Leung, 200453 (Hong Kong) Complications of surgery 40 (7%) 45 (2%) –5 NR
(–2.8)
Zheng, 2005109 (China) Major complications 5 (16.7%) 10 (29.4%) –5 p = 0.23
(–12.7)
NR, not reported.
a The results from Franks and colleagues have been removed from this table as they were supplied as academic-in-
confidence.
TABLE 31 Incremental cost per complication avoideda
Study ID Incremental cost Difference in complications (%) ICER
Janson, 200466 (Sweden) €1,846 –10% Open dominates
Perspective: societal 
Janson, 200466 (Sweden)  €2,239 –10% Open dominates
Perspective: Health Service
King, 200640 (UK) 
Perspective: societal –£357 11% Laparoscopic dominates
King, 200640 (UK) 
Perspective: NHS  –£83 11% Laparoscopic dominates
Leung, 200453 (Hong Kong) US$2,149 3% US$76,872
Zheng, 2005109 (China) CNY 1,271 13% CNY 10,008
a The results from Franks and colleagues have been removed from this table as they were supplied as academic-in-
confidence.length of stay is consistently (although not always
significantly) shorter in the case of laparoscopic
surgery, and so the differences in cost are mainly a
question of relative cost of hospital days and hours
in theatre used in the papers”.
The four RCT-based analyses identified by this
updated review appear to have statistically
significant longer operating times for laparoscopic
surgery. This is consistent with the data in the
review of effectiveness reported in Chapter 3.
However, the study by Zheng and colleagues
reported no statistically significant difference.109
With respect to length of hospital stay, this
appeared to be longer in the open groups, again,
a result consistent with the review of effectiveness
reported in Chapter 3. Overall, in terms of these
findings, the results of the review presented in this
chapter are consistent with the findings of
Vardulaki and colleagues.17
The five articles included in this review concluded
that operation costs for the laparoscopic
procedure were statistically significantly higher
than those for open surgery. The mean total cost
of laparoscopic surgery appeared to be greater
than that for open surgery in all studies except
that of King and colleagues.40 However, there was
no evidence of a statistically significant total cost
difference between laparoscopic and open surgery.
The submission by Ethicon Endo-Surgery was a
brief presentation of some of the key issues in the
consideration of laparoscopic surgery (submission
to NICE by Ethicon Endo-Surgery, July 2005). It
did not contain a systematic review or an
economic model. The submission concluded that
the long-term clinical outcomes are equivalent.
The evidence reported in Chapter 3 suggests that
this conclusion may be warranted for a 3-year
follow-up for survival and disease-free survival.
The results presented in this chapter and
Chapter 3 also tend to support Ethicon Endo-
Surgery’s conclusion of shorter recovery following
laparoscopic resection and that enhanced recovery
programme may help to lower total costs. The
submission also contended that the conversion
rate is potentially a key driver of total cost of
laparoscopic surgery. The evidence supporting this
claim is indirect. It is likely that the total cost of
laparoscopic surgery is increased as conversions
increase although, as reported in Chapter 3, the
evidence for comparing converted, non-converted
laparoscopic and open patients is limited. It is less
clear how reducing the risk of conversion would
affect the difference in cost when laparoscopic and
open surgery are compared for similar patients,
although Ethicon Endo-Surgery contend that the
costs of laparoscopic surgery may be lower when
there are lower rates of conversion.
Data reporting a detailed subgroup analysis by
location of disease supplied by Franks and
colleagues were provided as academic-in-
confidence and have not been included in this
report.
The incremental cost per complication avoided,
shown in the previous section, should be
interpreted extremely cautiously. For example, all
the studies had relatively small sample sizes and
the differences in number of complications (used
as effectiveness measure in these calculations)
between laparoscopic and open groups were not
statistically significant. With respect to the
estimates of complications, the estimates of the
individual studies are likely to be less reliable than
estimates derived from the review of effectiveness.
Data from the review of effectiveness provide no
evidence of a difference in complication rates.
Data from Franks and colleagues supplied as
academic-in-confidence have not been presented
in this report. In addition, the data from Zheng
and colleagues were for a relatively small, non-
randomised study which might be subjected to
selection bias.109
The measure of total cost used differed
substantially between studies. For example, Franks
and colleagues (Franks PJ, Thames Valley
University: personal communication, 2005),
Janson and colleagues66 and King and
colleagues40 considered indirect costs whereas the
other two studies considered only direct costs from
surgery and hospital stay.53,109 The costing
methodology was also poorly described in these
last two studies. For example, Zheng and
colleagues reported only final cost figures and no
details on the way in which calculations were
performed.109
The extent to which the costs from the three non-
UK studies would be applicable to the UK is
unclear. One UK study had a very small sample
size, and it was based on a single centre.40 Further
data relevant to the UK were also provided by the
study by Franks and colleagues, but these data
were supplied as academic-in-confidence and are
not presented in this report. The study by Janson
and colleagues66 was larger and the relative
difference in cost between the two interventions
(see Table 29) may help inform decision-makers in
the UK. However, the relatively short follow-up in
both studies indicates that a modelling exercise
Health Technology Assessment 2006; Vol. 10: No. 45
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information for decision-making.
In addition to the studies comparing laparoscopic
with open surgery, a further study was identified
comparing conventional laparoscopic surgery with
HALS.104 This study was a prospective RCT
conducted in Barcelona, Spain. A total of 54
patients were enrolled in the study, 27 to
laparoscopic and 27 to HALS. The groups were
well matched in terms of age, sex, body mass
index (BMI), location of disease, percentage of
malignant diagnoses and type of surgical
procedure. Twenty-two individuals in each group
were cancer patients.
The study found no evidence of a statistically
significant difference in terms of operation time or
conversion rates (Table 32). The authors also did
not find any statistically significant differences in
terms of bowel sounds, refeeding, overall
morbidity rates, reoperation and hospital length
of stay. Total costs, calculated by adding the cost of
using the operating room (no disposable materials
plus salaries) to the cost of disposable instruments,
were also not statistically different. The authors
concluded, “Although it is a more aggressive
procedure, HALS preserves the feature of a
minimally invasive approach, maintains all the
oncological features of conventional laparoscopic
surgery, and does not increase the cost”.
Conclusions
This chapter has presented the overall evidence
available on cost-effectiveness analyses of
laparoscopic surgery for colorectal cancer
compared with open surgery, based on a
systematic review of the literature and on the
revision of the review submitted by the ALSGBI.
Laparoscopic surgery was generally more costly
than open surgery as the former seems to involve
longer operation times and higher equipment
costs, although the evidence is mixed. With
respect to effectiveness, the data used by the
individual studies are likely to be imprecise and
unreliable when compared with the data available
from a systematic review of effectiveness (Chapter
3). Hence, the evidence provided by the included
economic evaluations using longer term outcomes
such as survival is likely to be imprecise and
unreliable.
There is a suggestion that the short-term benefits
of laparoscopic surgery in terms of a shorter
recovery may make laparoscopic surgery appear
less costly. However, the measurement and
inclusion of such costs (indirect costs) in an
economic evaluation is contentious.
No data were identified that compared HALS with
open surgery. Evidence comparing laparoscopic
with hand-assisted laparoscopic surgery is very
limited and provides no evidence for a difference
in either costs or effects.
Systematic review of economic evaluations
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TABLE 32 Summary of results from Taragona and colleagues104
Intervention Operation time (minutes): mean (range) Conversionsa Operation costa
Laparoscopic (n = 27) 135 (109–240) 6 €1959±593
HALS (n =27) 120 (70–300) 2 €2035±512
a No statistically significant differences.Introduction
In this chapter, the data available on the costs and
effects will be used to provide information on the
relative cost-effectiveness of laparoscopic
compared with open resection for colorectal
cancer. This has been facilitated using two
approaches. The first compares laparoscopic with
open resection using a balance sheet approach
and the second more formally synthesises the
available data in an economic model. With the
balance sheet, the differences between
interventions, in terms of costs and natural and
clinical measures of effectiveness, are presented.
Such an approach served to highlight the choices
and trade-offs between the two forms of resection. 
Nonetheless, any decision based on the balance
sheet approach is made using an implicit (rather
than an explicit) synthesis of the available data. In
the economic model, the disparate effects of
surgery for colorectal cancer are considered.
However, the results of this model are tentative
because, as described below, the model is
constrained by the paucity of data available for
some model parameters.
The balance sheet approach
A balance sheet is a method of presenting a
cost–consequence analysis that can be used to
identify who bears the costs and who reaps the
benefits from any change in the way surgery is
performed. Costs and benefits are measured in
units that seem appropriate for each patient
parameter. 
Methods
Estimates of the relative effects of laparoscopic
compared with open resection are taken directly
from Chapter 3. These data have been used to
describe differences in both the short- and the
long-term health effects of the different forms of
resection. Data on the costs of resection were
derived using data reported in a paper by King
and colleagues40 (this paper is summarised and
critiqued in Chapter 4) and data from the
systematic review of effectiveness (reported in
Chapter 3).
The study by King and colleagues40 defined the
cost of resection in terms of five components
relevant to the perspective of the NHS (theatre
costs; hospitalisation costs; postoperative costs;
chemotherapy and radiotherapy costs; and follow-
up costs at 3 months). For each component, and
also for the total cost, an estimate was provided of
the mean value for both laparoscopic and open
resection. In addition, an estimate of the mean
difference between the two forms of resection and
the statistical imprecision surrounding these mean
differences was also provided. Using the methods
described below, the data from King and
colleagues were used in the re-estimation of costs
for laparoscopic and open resection. 
Theatre costs
The length of time in surgery for both
laparoscopic and open resection reported by King
and colleagues40 was broadly consistent with the
findings of the systematic review of effectiveness.
Therefore, the data reported for theatre costs in
this study were used. This makes the assumption
that the use of disposable equipment for
laparoscopic resection observed by King and
colleagues is typical of practice within the UK.
This study did not report information on the
statistical precision surrounding estimates of
theatre cost for each intervention. However they
did report an estimate of the variability of the
mean difference in theatre costs. It was assumed
that the theatre costs of both procedures were
subject to this imprecision. Consequently, it was
apportioned on a pro rata basis to each
intervention and assumed to be evenly distributed
around the mean value using a triangular
distribution. The values used to estimate this
distribution are reported in Table 33.
Hospitalisation costs
The study by King and colleagues40 involved a
comparison of the two forms of resection in the
context of an accelerated discharge scheme. It is
likely that the lengths of stay observed in this
study may not be representative of practice within
the UK. Therefore, the length of stay for open
resection was based on the mean length of stay for
Health Care Resource Group (HRG) 07
(15.2 days) from the Hospital Episode Statistics112
for 2004, the most frequently recorded HRG for
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Chapter 5
Economic evaluationcolorectal cancer resection (the other HRGs have a
similar length of stay). A distribution for this
parameter was constructed using the median length
of stay, the only other available evidence, and the
mean length of stay for this HRG. Using these two
pieces of data, the use of alternative distributions
was investigated. A Weibull distribution was chosen
as it provided a plausible lower estimate of length
of stay and also allowed the possibility of a
substantially greater length of stay. The length of
stay for laparoscopic resection was derived by
adding the estimate for the weighted mean
difference in length of stay from the length of stay
for open resection. The length of stay data for both
operations were then combined with information
on the cost per day for a surgical high-dependency
unit (assumed 1-day stay for both procedures) and a
surgical ward (the remainder of the stay). Both ward
costs were taken from King and colleagues.40
Postoperative costs
The postoperative costs estimated by King and
colleagues40 included the use of medications in
addition to surgery for complications. The estimate
for laparoscopic resection was very much less than
that for open resection. This appeared to be due to
the higher rates of complications seen in the open
arm of the study. The evidence from the review of
effectiveness presented in Chapter 3 showed no
statistically significant difference in postoperative
complications. Therefore, it has been assumed that
the cost of open resection for this element is the
same as that of laparoscopic resection.
Chemotherapy and follow-up costs
The final two elements of total cost estimated by
King and colleagues40 were the costs of
chemotherapy and radiotherapy and follow-up costs
up to 3 months from the initial operation. Follow-up
costs were collected via patient-completed
questionnaires after 2 weeks and 3 months of follow-
up. These questionnaires requested information on
the number of inpatient days, outpatient visits, GP
visits, use of district (community) and stoma nursing
services. It is unclear whether the statistically non-
significant differences observed for this or any of
the other cost components are real or are a
consequence of the imprecision caused by the small
sample size. The distributions around these
chemotherapy and follow-up costs were estimated
using the same methods as described earlier for
theatre costs. The data used to derive these
distributions are also described in Table 33.
Estimation of total costs
Table 34 summarises the estimates of the costs of
laparoscopic and open resection obtained using
the methods described above. Monte Carlo
simulation employing 10,000 iterations was then
performed to generate a distribution for the
incremental cost of laparoscopic compared with
open resection. This was conducted using the
Microsoft Excel add-on Crystal Ball. 
It should be noted that these estimated costs do
not reflect any interactions between components
of total cost. For example, the follow-up costs and
the hospital costs estimated by King and
colleagues40 may be correlated. This is because
hospital costs are influenced by the number and
type of complications. These complications would
also be expected to influence follow-up costs.
One of the key determinants of the difference in
cost between laparoscopic and open surgery was
the difference in length of stay. To consider the
importance of this, a threshold analysis was
conducted to consider what difference in length of
stay would lead to an equal cost (Figure 6).
The threshold analysis suggests that should
laparoscopic resection be associated with a length
of stay that is on average just over 4 days less than
open surgery, then the costs of the two surgeries
would be equivalent. A difference of this
magnitude was rarely observed in the studies
included in the review of effectiveness presented
in Chapter 3. The analysis also indicates that
should the difference in length of stay reduce, as
may occur in an enhanced recovery programme,
the incremental cost of laparoscopic compared
with open surgery increases (to over £500 when
the difference in length of stay was 1 day). 
Results
Table 35 presents the balance sheet for the
comparison of laparoscopic with open surgery for
colorectal cancer. 
As Table 35 illustrates, after laparoscopic resection,
length of hospital stay is shorter, blood loss and
persistent pain are less and return to usual
activities is likely to be faster than after open
resection (although data came from one RCT
conducted in Hong Kong53 and may not be
generalisable to the UK). The duration of
operation for laparoscopic resection is longer and
a significant number of patients are converted
from laparoscopic to open resection. Findings
relating to overall and disease-free survival suggest
similar rates of these outcomes when comparing
laparoscopic with open resection for a 3-year
follow-up. With respect to cost, although
differences are non-significant, it is likely that
Economic evaluation
36laparoscopic resection is associated with a modest
incremental cost compared with open surgery. For
other outcomes, even though there are trends
favouring one method of resection over another,
the 95% CI are sufficiently wide that clinically and
economically important differences cannot be
ruled out.
Overall, it would seem likely that laparoscopic
resection is associated with a modest additional
cost (approximately £260), short-term benefits
associated with more rapid recovery, and similar
long-term outcomes in terms of survival and cure
rates up to 3 years. A judgement is required as to
whether the findings with respect to survival and
Health Technology Assessment 2006; Vol. 10: No. 45
37
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
TABLE 33 Data used to estimate cost estimates for each element of total cost
Parameter Value Distribution Data used to define the distribution
Estimation of theatre costs
Laparoscopic resection £2885 Triangular Derived using data below
Open resection £1964 Triangular Derived using data below
Ratio of laparoscopic to combined cost of 
open and laparoscopic resection 0.595 NA NA
Range of 95% CI around mean difference 
in cost £664.6 NA NA
Estimation of hospital costs
Length of stay (open) 15.2 days Weibull Median stay 11 days
WMD laparoscopic vs open –2.6 days Normal 95% CI –3.1 to –2 days
Cost per day (HDU) £530 NA NA
Cost per day (surgical ward) £162 NA NA
Chemotherapy and radiotherapy cost
Laparoscopic resection £175.5 Triangular Derived using data below
Open resection £176.5 Triangular Derived using data below
Ratio of laparoscopic to combined cost of  0.499 NA NA
open and laparoscopic resection
Range of 95% CI around mean difference  £265 NA NA
in cost
Follow-up cost
Laparoscopic resection £359.6 Triangular Derived using data below
Open resection £593.6 Triangular Derived using data below
Ratio of laparoscopic to combined cost of  0.377 NA NA
open and laparoscopic resection
Range of 95% CI around mean difference in cost £234 NA NA
HDU, high-dependency unit; NA, not applicable.
TABLE 34 Estimates of costs of laparoscopic and open resection
Components of cost Type of resection Difference (£)
Laparoscopic (£) Open (£)
Theatre cost 2885 1964 921
Hospital cost 2409 2830 –421
Post-operative cost 287 287 0
Chemotherapy and radiotherapy 176 177 –1
Follow-up costs at 3 months 360 594 –234
Total cost 6117 5852 265
95% CI –3829 to 4405a
a 95% CI is based on the 2.5 and 97.5 percentile points from the range of values produced by the Monte Carlo simulation.disease-free survival will persist in the longer term.
If survival and disease-free survival do remain
similar, then a further judgement is required as to
whether the benefits associated with earlier
recovery are worth this extra cost.
Economic model
The economic evaluation was conducted using a
Markov model (constructed in TreeAge Pro 2005).
The model estimates the long-term costs and
benefits of a cohort of typical patients for the
different surgical procedures (Figure 7). The model
follows a cohort of patients from their initial
operation through their convalescence (operation
state) to their return to usual activities (defined in
the model as a ‘disease-free’ state). The patients
may remain in this state until they die or they
suffer a recurrence or metastasis and therefore
have a reoperation or some other form of patient
management. Conceptually the patients could
move between states within the model until they
all eventually die. For the purposes of the analysis,
however, the cohort of patients has been modelled
for a maximum of 25 years (which represents the
maximum survival for the majority of the patients)
following the initial operation. All costs are
presented in UK pounds sterling for 2004 and
costs and benefits are discounted at 6 and 1.5%,
respectively.
Following their initial surgery, patients could move
into one of the following states:
● Disease-free.
● Recurrence of the disease where it may be
possible to have a second operation or some
form of non-operative management.
● Disease-free (after a recurrence), where a
patient following a successful second operation
remains until they have a second
recurrence/metastasis or die.
● Non-operable recurrence resulting in 
non-curative management of the disease.
● Death.
A cost per patient for each health state in the
Markov model was calculated using the methods
outlined below. The main cost components in the
model are the initial operative procedure and the
costs of any subsequent reoperation or
management. It has been assumed that if a
recurrence occurred and a reoperation was
indicated, the patient would be operated on using
an open procedure regardless of the surgical
procedure they originally received. Death is the
only state within the model that a patient cannot
leave (i.e. it is an absorbing state). As all general
surgical procedures carry some risk of
complications, the costs of postoperative
complications have been included but will not be
explicitly modelled as their effect would
principally have been captured through increased
operating times and longer hospitalisation.
However, the risk of an emergency reoperation
within the first few weeks after surgery has been
explicitly modelled, due to the additional
operation costs incurred. Similarly, where the cost
of managing other complications would not be
captured through increased operating time and
length of stay, estimates of the management cost
Economic evaluation
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TABLE 35 Balance sheet comparing laparoscopic with open resection
Favours laparoscopic resection Favours open resection Trials contributing data
Proportion of laparoscopic procedures  12
converted (21%)
Shorter operation time (40 minutes less,  16 (3 in MA)
95% CI 32 to 48)
Shorter hospital stay (WMD 2.6 less,  14
95% CI 3.1 to 2.0)
Less blood loss (about 75 ml per operation) 9 (4 in MA)
Less time away from usual activities  1
(32 vs 44 days)
Less postoperative pain and analgesia  5 and 6
(1 day less on average)
No statistically significant difference in:
Cost (mean difference £265, 95% CI –3829 to 4405)a
Anastomotic leakage (RR 1.13, 95% CI 0.74 to 1.73) 8
Abdominal wound breakdown (RR 0.63, 95% CI 0.26 to 1.52) 3
Wound infection (RR 0.89, 95% CI 0.67 to 1.10) 9
Urinary tract infection (RR 1.15, 0.66 to 1.98) 6
30-day mortality (RR 0.57, 0.25 to 1.29) 7
Incisional hernia (RR 1.49, 95% CI to 0.76 to 2.9) 2
Disease-free survival (RR 1.01, 0.95 to 1.07) 5 plus 1 MA
Overall survival (RR 1.03, 95% CI 0.98 to 1.09) 7 plus 1 MA
Health-related quality of life (Sign test, p = 0.125) 4
MA, patients’ data meta-analysis by Bonjer and colleagues (Bonjer J, QE II Health Sciences Centre, Halifax, NS: personal
communication, 2005).
a Laparoscopic surgery is probably more costly but results are imprecise. Ranges are the 2.5 and 97.5 percentile points from
the range of values produced by the Monte Carlo simulation.
Operation Disease free (1)
Recurrence and reoperation
Disease free (2)
Death
Non-operable 
recurrence
FIGURE 7 Markov model for the comparison of alternative methods of resectionand probability of occurrence have been factored
into the cost of a state.
The cycle length (the minimum period between
transitions) of the model has been set at 6 months,
as this would be the first instance that a recurrence
or metastasis might be detected. Thus, the model
will run for a maximum of 50 cycles. An outline of
the model is described in Appendix 13.
Estimation of model parameters
Baseline parameters
Where quantitative synthesis was possible, the
outputs of the systematic review of effectiveness
(Chapter 3) were presented as RRs for
dichotomous variables and WMDs for continuous
variables. For these data to be incorporated into
the model, they needed to be combined with
estimates of baseline rates for one of the
interventions. Furthermore, although it might be
argued that such relative effect sizes are
transferable between settings,113 it is important to
ensure that they are applied to baseline rates that
are applicable to the UK, so that the resultant
absolute differences between interventions are
more likely to be applicable to the UK. 
Estimation of the risk of death was based on the
survival curve for open resection provided by
Bonjer and colleagues, reproduced here as
Figure 4 (Bonjer J, QE II Health Sciences Centre,
Halifax, NS: personal communication, 2005).
These data provided estimates of survival up to 
3 years post-surgery. Overall survival for open
resection for each 6-month period up to
36 months was estimated from these curves. From
these data, a mortality rate for each 6-month cycle
length was calculated. As interpreting rates from
these curves is an imprecise method, and the
mortality rates for each 6-month period were
similar, a constant mortality rate was assumed
(Table 36).
The risk of recurrence of local or of metastatic
disease was based on data on disease-free survival
also provided by Bonjer and colleagues (Bonjer J,
QE II Health Sciences Centre, Halifax, NS:
personal communication, 2005). These data were
estimated using the same methods as described
for the risk of death described above. As with the
risk of death, a constant risk of recurrence was
assumed (Table 36).
The risk of death following the recurrence of non-
operative cancer was based on data derived from
Benoist and colleagues.114 This study is a case-
matched study set in France, which had the aim of
determining the best treatment strategy for
patients with asymptomatic colorectal cancer and
irresectable synchronous liver metastases. Patients
were recruited between 1997 and 2002 with 27
patients being treated with chemotherapy, without
an initial primary resection, compared with 32
patients who were initially treated by resection of
the primary tumour. The 27 chemotherapy
patients (intervention group) were matched by
age, sex, performance status, primary tumour
location, number of liver metastases, nature of
disease and the type of chemotherapy to the 32
patients who underwent resection of the primary
tumour (control group). The mean ages of the
chemotherapy and resection groups were 61 and
60 years, respectively. Although this study
currently provides the best available data for this
particular subset of patients, it should be noted
that the very small sample size may result in
imprecise estimates. The study setting might also
impact upon the generalisability of results for the
UK as this study, set in France, may have
treatment regimes that differ from standard
treatment in the UK.
For the purposes of the model, the risk of death
for patients with inoperable cancer was based on
the interpretation of the survival curve for the
‘chemotherapy group’ from the aforementioned
study.114 This population was deemed to have
similar characteristics to the patients undergoing
non-operative management of recurrent disease
within the model. The actuarial survival for the
time period of 24 months, divided into 6-month
periods, was estimated from this curve. A mortality
rate for each 6-month cycle length was calculated
and, from this, a constant mortality rate was
obtained. Based on these data, a mortality rate for
inoperable cancer with the value of 0.2 was
calculated and is shown in Table 36. In order to
reflect the statistical imprecision surrounding the
occurrence of an event, a beta distribution was
used. This distribution was used as it has been
argued that it provides realistic representations of
proportions.115 For TreeAge, the  parameter
required for this distribution is the number of
patients who experienced the event of interest and
the  parameter is the number of patients who did
not experience the event. 
Other baseline parameters required for the model
related to the risk of hernia, the risk of an
emergency reoperation for a postoperative
complication and the risk of a reoperation for
recurrent disease. The risk of hernia was identified
as a potentially important long-term complication
of both forms of resection. The severity and rates
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incision) were identified as review outcomes, as it
was believed that they may have differed between
laparoscopic and open resection. However, the
data available were sparse and no distinction has
been drawn between the two types of hernia. The
rate of hernia for open resection was derived from
the rates of hernia reported in the open arms of
those trials identified by the systematic review of
effectiveness. These data were supplemented by
rates of hernia reported in the non-randomised
studies included in the submission by the ALSGBI
(ALSGBI submission to NICE, 2005). From these
data, the risk of hernia per cycle was estimated for
each of the studies that provided data
(Appendix 12). The median estimate of the risk of
hernia per cycle was selected for use in the model
with a triangular distribution based on the
estimated 25 and 75 percentile from the identified
studies (Table 36).
The risk that a patient might require an
emergency operation for a complication of surgery
for colorectal cancer was allowed for within the
model. Although a variety of different
complications might result in the need for a
reoperation, it was believed, based on clinical
opinion, that the risk of reoperation for most of
these would be low. The risk of complications
requiring non-operative management was not
explicitly included in the model as the effect of
these would principally be captured through
longer operating times and length of stay. 
The one complication for which it was believed
that a greater proportion would require an
emergency operation was anastomotic leakage. In
the model, it has been assumed that the risk of an
emergency reoperation is equal to the risk of an
anastomotic leakage. The baseline risk of an
anastomotic leakage was based on the rates
reported in the open arms of those trials
identified by the systematic review of effectiveness
(Appendix 12). From these data, the median
observed risk of anastomotic leakage was selected
for use in the model with a triangular distribution
based on the interquartile range of rates from the
identified studies (Table 36).
Should the cancer recur, the patients might have a
reoperation. Data on this risk were not available
from any of the included studies. However, data
from NHS Grampian suggest that out of over 300
procedures per year, approximately 14–15 are for
recurrence or residual disease. Based on these
data, a beta distribution was used to allow for
greater uncertainty of the point estimate. This
distribution was calculated as outlined above for
the mortality rate for inoperable cancer. 
It should be noted that the baseline effects do not
change over time. 
Derivation of relative effect sizes
Data on the relative effect sizes were derived from
the systematic review of effectiveness and the
meta-analysis by Bonjer and colleagues (Bonjer J,
QE II Health Sciences Centre, Halifax, NS:
personal communication, 2005). The relative
effect size of death for laparoscopic compared with
open resection was derived from the estimate of 
3-year survival reported by Bonjer and colleagues.
[Academic-in-confidence information removed.]
These estimates of an absolute difference were
converted into a relative effect size for
laparoscopic surgery (Table 37). The 95% CIs
around the point estimate reported by Bonjer and
colleagues assumed a normal distribution. These
data were used to estimate a similar distribution
around the relative effect size.
The relative effect size for recurrence was also
based on data taken from Bonjer and colleagues.
[Academic-in-confidence information removed.]
The same methods used to estimate the relative
difference in mortality were used to estimate the
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TABLE 36 Baseline parameter values used in the model
Baseline parameters Value Distribution Values for distribution
Transition probabilities
Mortality 0.030 No  distribution
Recurrence 0.046 No  distribution
Mortality (non-curative cancer)  0.2 Beta  = 5.4,  = 21.6
Other probabilities
Emergency operation rate 0.019 Triangular IQR 0.008–0.034
Risk of hernia 0.003 Triangular IQR 0.002–0.012
Reoperation rate (after recurrence) 0.05 Beta  = 15,  = 285relative difference in recurrence and an associated
distribution (Table 37).
It was assumed that the RR of mortality faced by a
patient with non-curative cancer was one
(Table 37). This assumption was made, as it was
believed that once a recurrence occurred, the
prognosis would be the same regardless of the
initial method of resection.
Other relative effect sizes were also required for
the model. The first of these relates to the 
RR of an emergency operation. For the same
reason as described above, the RR for this
parameter was based on that for anastomotic
leakage. These data were derived from the
systematic review of effectiveness reported in
Chapter 3 (Table 37). The statistical imprecision
surrounding the point estimate was characterised
by log-normal distributions for RRs due to 
the methods used to derive these relative 
effects. 
Two other relative effect sizes required for the
model are the RR of hernia and the RR of a
reoperation after a recurrence. In both cases an RR
of one has been assumed. In the former case, the
evidence from the review of effectiveness is limited
but there is no statistically significant difference
between the rates of both types of hernia. In the
latter case, an RR of one has been assumed as it is
believed that the initial method of resection would
not affect the method of management subsequent
to a recurrence (Table 37).
Table 37 details the point estimates of the relative
effect sizes used in the model. Also included in the
table are the 95% CIs surrounding the point
estimates and distributions used. It should be
noted that a further assumption has been made
that the relative effects do not change over time. 
Resource use and costs
The main cost component included in the model
is the costs associated with the initial operation.
The method used to derive the cost for open
resection is described in the section ‘Methods’
(p. 37). A triangular distribution for the cost of
open resection was used to help evaluate the
uncertainty around this cost estimate. The cost of
laparoscopic resection was estimated by
multiplying the cost of open resection with an
estimate of the relative cost of laparoscopic
resection (i.e. the cost of open resection plus the
difference in cost between laparoscopic and open
resection; the product of this was then divided by
the cost of open surgery). A Monte Carlo
simulation using 10,000 iterations was conducted
using the Excel add-on Crystal Ball to create a log-
normal distribution around the relative difference
between laparoscopic and open resection. The
choice of a log-normal distribution was made
empirically as this distribution appeared to best fit
the data from the Monte Carlo simulation. 
The cost of surgical resection would be incurred in
the first cycle of the model. Other costs would also
be incurred in this cycle relating to the cost of
emergency surgery and the cost of an outpatient
visit and computed tomography (CT) scan at
6 months (other outpatient visits might be made
in the first cycle but these have been subsumed
into the cost of surgical resection). The cost of
emergency surgery was taken from the National
Reference Costs for HRG F42 (a general
abdominal, very major or major procedure).116
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TABLE 37 Relative effect sizes used in the modela
Parameter Point estimate Limits of 95% CI Distribution
Low High
Transition probabilities
Mortality 1.016 0.958 1.054 Normal
Recurrence 0.993 0.943 1.06 Normal
Mortality (non-curative cancer) 1 1
Other probabilities
Emergency operation rate 1.13 0.74 1.73 Log-normal
Risk of hernia 1 1 1
Reoperation rate (after recurrence) 1 1 1
a Absolute parameter values for each intervention were derived by applying the relative effect sizes to estimates of the
absolute rate for open resection (Table 36) with the relative rates reported in this table.A triangular distribution was defined for this 
cost based on the interquartile range of costs
reported for this HRG (Table 38). The cost of an
outpatient visit made at 6 months was based on
the unit cost reported by King and colleagues.40
The cost of a CT scan was taken from the National
Reference Costs and a distribution for this cost was
defined using the same method as used for
emergency surgery.
For patients who are disease free, regular review is
performed. Based on clinical guidelines,117 it was
assumed that patients would receive a CT scan
and outpatient visit at 12 and 24 months
postoperatively. Patients would also be reviewed
and undergo colonoscopy after 3 years and then
subsequent colonoscopy every 5 years, until aged
approximately 70 years. The cost of a colonoscopy
was taken from the National Reference Costs and
based on HRG F35 (an endoscopic or
intermediate procedure for the large intestine).
The distribution for this cost was defined using
the same method as used for emergency surgery.
As costs in this state are likely to be incurred
several times over the course of a patient’s life, a
table was constructed in TreeAge to allow these
costs to be taken account of at the given time
point at which they were incurred. The limitation
of using a table to define these costs, however, is
that the uncertainty surrounding these cost
estimates cannot be explored as distributions
could not be incorporated into the costs in the
table.
The cost of a hernia repair was likewise based on
the National Reference Costs. The cost used
related to HRG F72 (abdominal hernia procedures
at age less than 70 years) and a distribution for
this cost was defined using the same method used
for emergency surgery (Table 38).
The cost of care for patients who suffered 
some degree of recurrent cancer would, of 
course, be dependent upon the nature of the
disease. Should further surgery be indicated,
it has been assumed that it would cost the same 
as the initial open surgical resection as, based 
on expert opinion, it was deemed unlikely that 
any reoperation would be performed
laparoscopically. In addition to the cost of a
reoperation, patients might receive medications
for the control of symptoms if surgery was not
indicated. The cost for a typical regime of care for
a patient was defined following consultation with a
Macmillan Cancer Nurse (O’Dea F, Hospital
Specialist Palliative Care Team, Grampian
University Hospital NHS Trust: personal
communication, 2005) (Table 38). Details of the
basis of the cost estimated are provided in
Appendix 12.
Estimation of quality-adjusted life-years (QALYs)
No suitable utility data required to estimate
QALYs were identified in any of the economic
evaluations identified in Chapter 4. Potential
utility data were sought from a focused search of
the Harvard Cost Utility Database118 and a search
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TABLE 38 Cost parameters used within the model
Costs Value (£) Source Distribution, and values used to
define the distribution
Initial operation
Open 5852 Earliera Triangular with high and low based
on IQR. IQR £4968–6272
Relative cost of laparoscopic resection 1.05 Earliera Lognormal; SD 0.33
Emergency operation 1615 NRC. HRG F42 Triangular with high and low based
on IQR. IQR £1132–2322
Reoperation (as open) 5852 Earliera Triangular with high and low based
on IQR. IQR £4968–6272
Outpatient visit 99 King, 200640
CT scan 73 NRC, CT (other) Triangular with high and low based
on IQR. IQR £56–91
Colonoscopy  622 NRC HRG 35 Triangular with high and low based
on IQR. IQR £370–868. 
Surgery for hernia 1689 NRC HRG F72 Triangular with high and low based
on IQR. IQR £1306–2234.
Non-operative management following recurrence 1216 Expert advice
a See the section ‘Introduction’ (p. 35)for relevant studies conducted as part of the
search for economic evaluations (see Chapter 4 for
methods). However, despite this search, few usable
data were identified. The CLASICC Trial, which
has not yet fully reported, is using the EQ-5D
instrument collected at baseline, 2 weeks and 3, 6,
18 and 36 months postoperation. These data will
be collected from the first 500 patients
randomised to the trial (approximately 340
laparoscopic and 170 conventional patients). 
Until such data are obtained, reliable utilities 
data applicable to the UK will not be available. In
the interim, data were taken from one published
study which has used the EQ-5D questionnaire.119
This study was conducted in Norway and 
recruited 95 patients from 1993 to 1996. The 
aim of the study was to assess the cost-effectiveness
of adjuvant chemotherapy in the treatment of
Dukes’ B and C colorectal cancer after surgical
resection. The quality of life of the participants
was assessed using a questionnaire which included
the EQ-5D questionnaire, a simple quality of life
scale and the global quality of life measure of the
EORTC QLQ-C30. It reported a median quality of
life value of 0.83 (0–1 scale) in all patients and
measures. From these limited data, assuming that
the recovery from surgery was associated with a
value of 0.83, it has been assumed that by
definition the time spent free from disease is
associated with a value of one. The value
associated with the other states (except death) was
also 0.83. As such data are very limited, the
estimates of quality-adjusted life-years (QALYs)
should be treated with caution.
Assessment of cost-effectiveness
The base-case analysis was based on the costs and
outcomes faced by a cohort of 65-year-olds (the
mean age of patients receiving a surgical resection
of colorectal cancer in England and Wales). Within
the economic model, two different outcomes are
presented: the incremental cost per additional life-
year and the incremental cost per QALY. Data on
these two outcomes are presented in two ways.
First, mean costs, life-years or QALYs for the
alternative interventions are presented and
incremental cost per additional life year or QALYs
calculated where appropriate. The second way in
which the cost-effectiveness of the alternative
interventions is presented is in terms of cost-
effectiveness acceptability curves (CEACs).120
CEACs have been used to illustrate the uncertainty
caused by the statistical variability in the model’s
parameter estimates. These curves illustrate the
likelihood that a strategy is cost-effective at various
threshold values for society’s willingness to pay for
an additional life-year or QALY. 
Sensitivity analysis and subgroup
analysis
Sensitivity analysis focused on varying assumptions
or parameters in the base-case model.
Assumption of equal survival and disease-free
survival
[Academic-in-confidence information removed.]
One interpretation of all the evidence available on
overall survival and disease-free survival is that
there is no difference between laparoscopic and
open resection. In this analysis, it has been
assumed that the relative effect size for these two
parameters is one. There is, of course, some
uncertainty surrounding this and a similar
distribution to that used in the base-case analysis
has been used.
Use of pooled estimate for relative difference in
survival and disease-free survival from meta-
analysis conducted as part of review of
effectiveness
As part of the systematic review of effectiveness, a
pooled analysis of outcomes of interest was
conducted where data allowed it. Two such pooled
estimates were derived for overall survival and
disease-free survival. As such, it was therefore
possible to conduct a sensitivity analysis using
these estimates in place of those provided by
Bonjer and colleagues (Bonjer J, QE II Health
Sciences Centre, Halifax, NS: personal
communication, 2005). From the meta-analysis
conducted as part of the review of effectiveness,
the relative effective sizes in terms of mortality
and recurrence rates for laparoscopic compared
with open resection were 0.97 (SD 0.03) and 0.99
(SD 0.03), respectively. Given the nature of the
data, a normal distribution was assigned to the
parameters. 
Costs
Source of cost data
Data regarding the costs of procedures were made
available from other sources. This sensitivity
analysis explored the cost estimates for
laparoscopic and open surgical procedures for
colorectal cancer from an unpublished paper by
Franks and colleagues (Franks PJ, Thames Valley
University: personal communication, 2005). This
paper is a cost-analysis and reports cost data for a
subset of the patients entered into the CLASICC
trial; the paper is summarised and critiqued in
Chapter 4. The method used to derive the cost for
open resection was the same as the method used
to determine the costs for the base-case analysis
described in the section ‘Methods’ (p. 35). The
first sensitivity analysis, with regard to this cost
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Franks and colleagues. A second sensitivity
analysis was performed using the WMD in length
of stay reported in Chapter 3, which was applied
to the length of stay for open resection from
Franks and colleagues. The data used to conduct
this sensitivity analysis was supplied as academic-
in-confidence and has not been included in this
report.
Additional cost data
Currently, the cost data have not taken into
account the extra cost which preoperative
preparation for laparoscopic resection might incur
and essentially assume that the same approach is
used for both methods of resection. These costs
could include such aspects as the necessity for a
CT scanner for preoperative staging as opposed to
an ultrasound scanner. This sensitivity analysis
assessed the impact on cost of extra assessment
which may be required to determine suitable
laparoscopic candidates. All patients treated 
by laparoscopic resection are assumed to incur an
additional cost of a CT scan to allow for
preoperative staging and all patients whose
resection was undertaken via the open method are
assumed to incur the additional cost of an
ultrasound scan preoperatively. The cost of 
an ultrasound scan was taken from the National
Reference Costs. A triangular distribution was
defined for this cost based on the interquartile
range of costs reported for this HRG. The mean
cost was £32 with an interquartile range of
£26–39.
Changes to the reoperation rate for recurrent
disease
An estimate of the number of reoperations that
might take place given recurrent disease was based
on data from one centre (5%). As a result, the
reoperation rate was changed in the sensitivity
analysis to either a ‘high’ rate of 10% or a ‘low’
rate of 1%. The distributions surrounding this
parameter remained similar. 
Changes to the relative effect size of the
reoperation rate for recurrent disease
No data were available to identify the difference in
reoperation rates between laparoscopic resection
and open resection. The base-case analysis
assumed that the relative effect size for this
difference would be one as it was deemed unlikely
that the initial method of resection would affect
management subsequent to a recurrence. As this
estimate was based solely on expert opinion, this
sensitivity analysis allowed the relative effect size
for the rate of reoperation to change from 0.5 to
two. Hence the rate of reoperation for
laparoscopic resection, in comparison with open
resection, was made to decrease to half the rate
and increase to double the rate of open resection.
A similar distribution to that used in the base-case
analysis was used.
Combination of previous two analyses
The relative effect size for the reoperation rate for
recurrent disease was assumed to be one in the
base-case analysis. This analysis combines the high
and low estimates of rates of reoperation from the
previous sensitivity analysis with different
estimates of the relative effect size of the
reoperation rate for laparoscopic compared with
open resection. The low reoperation rate (1%) was
combined with a relative effect size of 0.5. The
higher reoperation rate (10%) was combined with
a relative effect size of two. Similar distributions to
those used in the base-case analysis were used.
Changes to the rate of mortality for non-
operative management of recurrent disease
The risk of death for patients with non-operative
recurrent disease was based on the interpretation
of the survival curve from the study by Benoist
and colleagues.114 A constant mortality rate of 0.2
was used for the base-case analysis; however, the
mortality rate at 6-monthly intervals was also
estimated from the 24-month study period. This
analysis uses the high and low values for the
mortality rate for non-operative management of
recurrent disease, 0.31 and 0.11, respectively. A
distribution similar to that used in the base-case
analysis was utilised. 
Changes to the relative effect size of mortality
for non-operative management of recurrent
disease
The mortality rates for patients receiving non-
operative management for recurrent disease were
assumed to be the same for the two interventions
as it was deemed unlikely that the initial method
of resection would affect this rate of mortality. The
relative effect size was therefore assumed to be one
in the base-case analysis. This analysis considered
the implications of a relative effect size of 0.5 or
1.5, meaning that the mortality rate for patients in
the laparoscopic arm could decrease by 50% and
increase by 50% in comparison with patients in the
open arm. A relative rate of two (as opposed to
1.5) was not calculated as mortality became
greater than one.
Combination of previous two analyses
The relative effect size for the mortality of non-
operative management of recurrent disease was
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analysis combines the high and low estimates of
survival from the previous sensitivity analysis with
high and low estimates of the relative effect size of
mortality for laparoscopic compared with open
resection. The low mortality rate of 0.11 was
combined with a relative effect size of 0.5. The
higher mortality rate, 0.31, was combined with a
relative effect size of 1.5. A similar distribution to
that used in the base-case analysis was also used. 
Changes to the rate of hernia
No specified rate for the occurrence of hernias
associated with laparoscopic resection could be
found. The relative effect size of a hernia for
laparoscopic compared with open resection was
assumed to be one. This analysis allowed the
relative effect size for the rate of reoperation to
change from 0.5 to two. Thus, the rate of hernia
following laparoscopic surgery, in comparison with
open surgery, was made to decrease to half the
rate and increase to double the rate. 
Utilities
Use of alternative data to estimate QALYs
Although utilities data required to estimate QALYs
were sparse, alternative data were identified by
Petrou and Campbell.121 This study aimed to test
the hypothesis that when stabilisation of disease
(colorectal cancer) is achieved, chemotherapy can
bring positive quality of life benefits. These data
were derived from the responses of 30 nurses in
the UK experienced in the oncological care of
colorectal cancer patients. The nurses, acting on
behalf of patients, assessed the values of various
health states associated with the treatment of
metastatic colorectal cancer. The health states
defined by Petrou and Campbell,121 and those
defined within the model, are shown in Table 39.
Two variations for the value of non-operative
management were used (progressive disease and
terminal disease) to assess what difference these
alternative values might make to the results.
Further to the above sensitivity analysis, a second
sensitivity analysis using utility data from a
recently published NICE appraisal, which
addressed the use of oxaliplatin and capecitabine
for the adjuvant treatment of colon cancer, has
also been included to ascertain what differences in
QALY values might be apparent.122 Utility
estimates for patients with Dukes’ Stage III colon
cancer were sought as part of the systematic 
review and the estimates used in the assessment 
of quality of life for this report are shown in 
Table 40. It should be noted that the utility values
used for the analysis carried out by Pandor and
colleagues are from a number of sources and 
their usefulness is discussed in the aforementioned
review by Pandor and colleagues.122 As in the
previous analysis, two variations for the value of
non-operative management were used (‘adjuvant
chemotherapy without side-effects’ and ‘on
palliative chemotherapy’) to assess what difference
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TABLE 39 Alternative utility values (1)
Utilities Value
Health states defined by Petrou and Campbell121 Health states defined within the economic model
Best possible health Disease-free and disease-free after successfully treated  100
recurrence
Worst possible health Dead 0
Stable disease Initial operation and recur  95
Progressive disease (PD) Non-operative management (1) 57.5
Terminal disease (TD) Non-operative management (2) 10
TABLE 40 Alternative utility values (2)
Utilities Value
Health states defined by NICE Assessment Report Health states defined within the economic model
In remission Initial operation, recurrence, disease-free and disease-
free after successfully treated recurrence  0.92
On palliative chemotherapy Non-operative management (1) 0.24
On adjuvant chemotherapy (without significant  Non-operative management (2) 0.70
side-effects)these alternative values might make to the results.
It should be noted that these utility estimates
should be treated with care as the study
population does not include surgical patients or
patients with Dukes’ Stage I or II cancer. Further,
the study population for this review only refers to
patients with colon cancer, therefore excluding
rectal cancer.
Subgroup analysis
The model parameters, with respect to survival
and disease-free survival, were adjusted in order to
estimate relative cost-effectiveness for patients
given their stage of cancer. In terms of stage of
disease, few stage-dependent data were available;
however, the meta-analysis conducted by Bonjer
and colleagues (Bonjer J, QE II Health Sciences
Centre, Halifax, NS: personal communication,
2005) provided some limited data by stage which
were modelled to illustrate the impact that
different stages of disease might have on
recurrence and mortality rates. Estimation of the
risk of death was based on the survival curves from
Bonjer and colleagues for patients with Stages I, II
and III disease for both open and laparoscopic
resection, [Academic-in-confidence information
removed]. These data provided estimates of
survival up to 3 years post-surgery. Overall survival
for each 6-month period up to 36 months was
estimated from these curves. From these data, a
mortality rate for each 6-month cycle length was
calculated. A constant mortality rate was assumed
based on the mean value at each 6-month time
period.
Estimation of the risk of recurrence, either local or
metastatic disease, was based on data on disease-
free survival for Stages I, II and III, also provided
by Bonjer  and colleagues (Bonjer J, QE II 
Health Sciences Center, Halifax, NS: personal
communication, 2005). These data were estimated
using the same methods as for the risk of death
described above. As with the risk of death, a
constant risk of recurrence was assumed.
[Academic-in-confidence information removed.]
No CIs were provided by Bonjer and colleagues,
hence, distributions allowing the uncertainty
surrounding these parameters could not be
explored. The results, therefore, are expressed
purely as a deterministic analysis. 
Results
The results of the deterministic analyses of
incremental cost per life-year and incremental cost
per QALY are reported in Tables 41 and 42,
respectively. 
Laparoscopic resection is dominated by open
resection over the 25-year time horizon
considered. The point estimates of the
incremental cost-effectiveness provided in
Tables 41 and 42 do not provide any indication of
the uncertainty that surrounds the model
parameters. The uncertainty surrounding the
precision of many of the parameter estimates is
reflected in the likelihood that the two surgical
interventions are cost-effective at different
threshold values for society’s willingness to pay for
a life-year and a QALY. Figures 8 and 9 report the
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TABLE 41 Results of the deterministic model for a 25-year time horizon (life-years)
Scenario Procedure Cost (£) Life-years Incremental  Incremental Incremental cost 
cost (£) life-years per life year
Base-case Open 9613 15.35
Laparoscopic 9876 15.30 263 –0.05 Dominated
Equal survival Open 9613 15.35
Laparoscopic 9903 15.35 290 0 Dominated
TABLE 42 Results of the deterministic model for a 25-year time horizon (QALYs)
Scenario Procedure Cost (£) QALYs Incremental  Incremental  Incremental cost
cost (£) QALYs per QALY
Base-case Open 9613 14.68
Laparoscopic 9876 14.63 263 –0.05 Dominated
Equal survival Open 9613 14.68
Laparoscopic 9903 14.68 290 0 DominatedCEACs comparing laparoscopic with open surgery
in terms of life-years and QALYs, respectively.
The results presented for both life-years and
QALYs are driven by very small differences in
survival and disease-free survival observed at
3 years’ follow-up (see Chapter 3). An alternative
interpretation of the data on survival and disease-
free survival is that there are no meaningful
differences (see Figure 4 and results of meta-
analysis reported in Chapter 3). Figures 10 and 11
report alternative analyses for life years and
QALYs respectively that make this assumption.
As Figures 10 and 11 illustrate, the likelihood that
laparoscopic surgery might be considered cost-
effective is very similar to the likelihood that open
surgery would be considered cost-effective. 
The estimates of QALYs for the analysis presented
in Figures 9 and 11 do not capture the QALY gain
that might be associated with an earlier recovery.
Some indication of the relevance of any QALY
obtained associated with earlier recovery can be
obtained by looking at what value for this QALY
gain is implied should it be judged that
laparoscopic surgery was worthwhile. Assuming a
threshold value for society’s willingness to pay for
a QALY of £30,000 and given the mean
incremental cost of laparoscopic surgery of £263
(base-case analysis) and £290 (equal mortality and
disease-free survival), then the implied value of
the QALY gain would need to be 0.009 and 0.010,
respectively. In a comparison between laparoscopic
and open hernia repair, the observed gain in
QALYs was 0.006 at 3 months.123
Sensitivity analysis
Use of pooled estimate for relative difference in
mortality and recurrence from meta-analysis
conducted as part of review of effectiveness
The use of the pooled estimates from the
systematic review of effectiveness led to
laparoscopic surgery having a much greater
chance of being considered cost-effective.
Laparoscopic surgery was found to be more costly
(by approximately £300) but more effective (see
Table 43 for life-years and Table 44 for QALYs).
Alternative and additional costs data
Changes surrounding the use of alternative cost
data provided by a draft paper from a subset of
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FIGURE 8 CEACs showing society’s willingness to pay for a life-year for the comparison of laparoscopic with open surgery (base-case
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FIGURE 9 CEACs showing society’s willingness to pay for a QALY for the comparison of laparoscopic with open surgery (base-case
analysis)
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FIGURE 10 CEACs showing society’s willingness to pay for a life-year for the comparison of laparoscopic with open surgery assuming
equal survival and disease-free survivalpatients from the CLASICC trial produced
interesting results. In the first sensitivity analysis
using estimates from Franks and colleagues
(Franks PJ, Thames Valley University: personal
communication, 2005), cost data for the two
interventions were re-estimated using the methods
described in the section ‘Sensitivity analysis and
subgroup analysis’ (p. 44). The second sensitivity
analysis used the cost estimates for open resection
from Franks and colleagues but utilised the
difference in length of stay between open and
laparoscopic surgery from the review of
effectiveness. The results of these sensitivity
analyses were based on data supplied as academic-
in-confidence and have not been presented in this
report.
A cost analysis taking into account the cost for
preoperative staging of disease with respect to
each intervention was also performed [see the
section ‘Sensitivity analysis and subgroup analysis’
(p. 44)]. An increased difference in cost of £40
between laparoscopic and open resection was
observed and relatively little impact on the
likelihood that laparoscopic resection would be
considered cost-effective (see Table 43 for life-years
and Table 44 for QALYs). This is as would be
expected given the difference in cost for these two
imaging modalities (£73 for a CT scan and £32 for
an ultrasound scan; taken from the National
Reference Costs).
Changes in the rates of reoperations
Changing the rate at which patients with recurrent
cancer receive a further surgical resection had
little effect on cost-effectiveness in comparison
with the base-case analysis (Table 45 for life-years
and Table 46 for QALY results). This would be
expected given the similarities in mortality and
disease-free survival along with the assumption of
no difference in reoperation rates between the two
surgical approaches. Changing the RR of a
reoperation was shown to influence markedly the
likelihood that laparoscopic surgery would be cost-
effective. For example, adopting an RR of 0.5 (i.e.
patients originally receiving laparoscopic surgery
are less likely to be operated on for recurrent
disease than patients who originally receive an
open surgery) reduced the likelihood that
laparoscopic surgery would be considered cost-
effective. This is due to the strong assumption that
patients who receive a reoperation for subsequent
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FIGURE 11 CEACs showing society’s willingness to pay for a QALY for the comparison of laparoscopic with open surgery assuming
equal survival and disease-free survivalHealth Technology Assessment 2006; Vol. 10: No. 45
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T
ABLE 43
Sensitivity analysis around changes in costs and changes in survival and disease-free survival from pooled estimates taken from
 the systematic review of effectiveness (life years)
a
Sensitivity analysis
P
rocedure
Cost (£)
Life-years
ICER (£)
P
robability cost-effective for different threshold 
values for society
’s willingness to pay for a life-year (%)
£10,000
£20,000
£30,000
£50,000
Base-case
Open
9613
15.351
60.4
63.0
64.0
64.2
Laparoscopic
9876
15.298
Dominated
39.6
37.0
36.0
35.8
Equal survival
Open
9613
15.351
51.0
50.3
49.9
49.5
Laparoscopic
9903
15.351
Dominated
49.0
49.7
50.1
50.5
RR for overall survival and disease-free survival 
Open
9613
15.351
25.9
20.4
18.7
17.9
from meta-analysis conducted in 
Laparoscopic
9924
15.541
1641
74.1
79.6
81.3
82.1
systematic review of effectiveness
Additional cost data for preoperative staging
Open
9646
15.351
61.7
65.9
66.6
66.7
Laparoscopic
9949
15.298
Dominated
38.3
34.1
33.4
33.3
a 
The results from F
ranks and colleagues have been removed from this table as they were supplied as academic-in-confidence.
T
ABLE 44
Sensitivity analysis around changes in costs and changes in survival and disease-free survival from pooled estimates taken from
 the systematic review of effectiveness (QAL
Ys)
a
Sensitivity analysis
P
rocedure
Cost (£)
QAL
Ys
ICER (£)
P
robability cost-effective for different threshold values
for society
’s willingness to pay for a QAL
Y (%)
£10,000
£20,000
£30,000
£50,000
Base-case
Open
9613
14.679
59.9
61.2
62.0
62.2
Laparoscopic
9876
14.630
Dominated
40.1
38.8
38.0
37.8
Equal survival
Open
9613
14.679
50.8
49.8
50.2
49.3
Laparoscopic
9903
14.679
Dominated
49.2
50.2
49.8
50.7
RR for overall survival and disease-free survival 
Open
9613
14.679
26.1
20.5
18.8
18.0
from meta-analysis conducted in 
Laparoscopic
9924
14.864
1674
73.9
79.5
81.2
82.0
systematic review of effectiveness 
Additional cost data for preoperative staging
Open
9646
14.679
60.9
65.2
66.1
65.5
Laparoscopic
9949
14.630
Dominated
39.1
34.8
33.9
34.5
a 
The results from F
ranks and colleagues have been removed from this table as they were supplied as academic-in-confidence.Economic evaluation
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T
ABLE 45
Sensitivity analysis around changes in the risk of reoperation for recurrent disease (life-years)
Sensitivity analysis
P
rocedure
Cost (£)
Life-years
ICER (£)
P
robability cost-effective for different threshold values
for society
’s willingness to pay for a life-year (%)
£10,000
£20,000
£30,000
£50,000
Base-case
Open
9,613
15.351
60.4
63.0
64.0
64.2
Laparoscopic
9,876
15.298
Dominated
39.6
37.0
36.0
35.8
Equal survival
Open
9,613
15.351
51.0
50.3
49.9
49.5
Laparoscopic
9,903
15.351
Dominated
49.0
49.7
50.1
50.5
R
eoperation rate 1% (BC = 5)
Open
9,567
15.173
60.1
64.9
66.0
66.2
Laparoscopic
9,830
15.122
Dominated
39.9
35.1
34.0
33.8
R
eoperation rate 10% (BC = 5)
Open
9,671
15.574
60.7
64.5
64.5
64.7
Laparoscopic
9,933
15.518
Dominated
39.3
35.5
35.5
35.3
RR of 0.5 for reoperation rate (BC = 1)
Open
9,613
15.351
75.0
81.0
81.3
83.2
Laparoscopic
9,847
15.188
Dominated
25.0
19.0
18.7
16.8
RR of 2 for reoperation rate (BC = 1)
Open
9,613
15.351
28.1
22.6
20.8
19.0
Laparoscopic
9,933
15.518
1921
71.9
77.4
79.2
81.0
RR of 0.5 for reoperation rate (BC = 1) and 
Open
9,567
15.173
64.7
69.1
70.0
71.4
1% rate of reoperation (BC = 5%)
Laparoscopic
9,825
15.100
Dominated
35.3
30.9
30.0
28.6
RR of 2 for reoperation rate (BC = 1) and 
Open
9,671
15.574
9.7
4.4
2.8
1.8
10% rate of reoperation (BC = 5%)
Laparoscopic
10,047
15.957
980
90.3
95.6
97.2
98.2
BC, base-case,Health Technology Assessment 2006; Vol. 10: No. 45
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T
ABLE 46
Sensitivity analysis around changes in the risk of re-
operation for recurrent disease (QAL
Ys)
Sensitivity analysis
P
rocedure
Cost (£)
QAL
Ys
ICER (£)
P
robability cost-effective for different threshold values 
for society
’s willingness to pay for a QAL
Y (%)
£10,000
£20,000
£30,000
£50,000
Base-case
Open
9,613
14.679
59.9
61.2
62.0
62.2
Laparoscopic
9,876
14.630
Dominated
40.1
38.8
38.0
37.8
Equal survival
Open
9,613
14.679
50.8
49.8
50.2
49.3
Laparoscopic
9,903
14.679
Dominated
49.2
50.2
49.8
50.7
R
eoperation rate 10% (BC = 5%)
Open
9,671
14.912
59.7
63.0
62.6
62.4
Laparoscopic
9,933
14.860
Dominated
40.3
37.0
37.4
37.6
RR of 0.5 for reoperation rate (BC = 1)
Open
9,613
14.679
75.2
80.9
80.9
82.2
Laparoscopic
9,847
14.515
Dominated
24.8
19.1
19.1
17.8
RR of 2 for reoperation rate (BC = 1)
Open
9,613
14.679
26.5
20.4
18.4
16.7
Laparoscopic
9,933
14.860
1761
73.5
79.6
81.6
83.3
RR of 0.5 for reoperation rate (BC = 1) and 
Open
9,567
14.492
63.4
67.6
69.1
69.9
1% rate of reoperation (BC = 5%)
Laparoscopic
9,825
14.423
Dominated
36.6
32.4
30.9
30.1
RR of 2 for reoperation rate (BC = 1) and 
Open
9,671
14.911
8.6
3.4
1.4
1.1
10% rate of reoperation (BC=5%)
Laparoscopic
10,047
15.320
920
91.4
96.6
98.6
98.9
BC, base-case.disease would, if the operation were successful,
have the same mortality and disease-free survival
as someone following the initial surgery (Table 45
for life-years and Table 46 for QALY results). A
further sensitivity analysis was conducted to
examine the interaction between the baseline risk
of a reoperation and the relative risk of
reoperation (Table 45 for life-years and Table 46 for
QALY results). Allowing a higher rate of
operations for recurrent disease and increasing
the chance that patients who originally received
laparoscopic surgery would receive an operation
for any recurrent disease would greatly increase
the likelihood that laparoscopic resection would be
considered cost-effective. Given the model
assumptions, this is as would be expected. 
Non-operative mortality rates for recurrent
disease
As might be expected, changes in the baseline
level of mortality associated with recurrent disease
had little effect on the likelihood that laparoscopic
surgery would be considered cost-effective
(Table 47 for life-years and Table 48 for QALY
results). The model was highly sensitive to the
assumption that survival for patients in the state of
non-operative management of recurrent disease
would in any way be influenced by the choice of
initial surgery. Combining changes in the baseline
level of non-operative mortality and in the RR
between laparoscopic and open surgery provided a
similar finding to changes in RR alone (Table 47
for life-years and Table 48 for QALY results).
Risk of hernia
One area where limited data were available was on
the risk of hernia (and on other morbidities
associated with the method of surgery). Even
assuming a 50% fewer or twice the number of
hernias occurring after open surgery, little effect on
the cost-effectiveness of laparoscopic surgery was
shown. This was because the baseline risk of hernia
was low and the only impact on cost-effectiveness
was through cost, that is, the incidence and
treatment of a hernia had no effect on utility (Table
49 for life-years and Table 50 for QALY results). 
Alternative utility values
The data available on utilities were very limited
but some alternative utility values were available
from Petrou and Campbell121 and also from a
recently published NICE appraisal review.122 As
described in the section ‘Sensitivity analysis and
subgroup analysis (p. 44), values were available for
the health states in the model (although data
relevant to recovery from surgery and longer term
morbidities associated with the method of surgery,
such as hernias, were not available). However, two
alternative values were available for non-operative
management from Petrou and Campbell.121 In the
first sensitivity analysis, non-operative
management was assigned the value estimated by
this study for progressive disease.121 In this
analysis laparoscopic surgery was still dominated
by open surgery but was associated with a slightly
higher probability of being considered cost-
effective (Table 51). In the second analysis, non-
operative management was assigned the value
estimated by Petrou and Campbell for terminal
disease.121 In this analysis, laparoscopic surgery
was again dominated but slightly more likely to be
considered cost-effective in comparison with the
analysis using the value for progressive disease.
The reason for this is that, in the base-case
analysis, patients receiving open surgery have a
slightly worse disease-free survival compared with
laparoscopic surgery. Hence they are more likely
to spend time in this state and incur the lower
utilities associated with this state.
Further alternative utility data taken from the
NICE appraisal regarding the use of oxaliplatin
and capecitabine on the treatment of patients with
Stage III colon cancer also provided alternative
estimates of utility values to allow further
estimation of QALYs.122 Two separate values for
the non-operative management of recurrent
disease were, again, used within the model as
outlined in the section ‘Sensitivity analysis and
subgroup analysis (p. 44). The first sensitivity
analysis using utilities from this review used the
low rate of 0.24 for the non-operative
management state (Table 51). This state related to
those on palliative chemotherapy from the NICE
review. In this analysis, laparoscopic surgery was
still dominated by open surgery and the difference
in QALYs between the two interventions remained
similar to the results using utility values from
Petrou and Campbell.121 This serves to highlight
that the only factor driving these differences is
that of the small differences in survival and
disease-free survival at 3 years. The number of
QALYs gained in this analysis for both
interventions are, however, less than those using
data from Petrou and Campbell.121 This is because
the values for the disease-free state and disease-
free after a successfully treated recurrence state
were assumed to have the same value as that for
the initial operation and for recurrence, that is,
they were not assumed to be in full health with a
utility score equal to one and so could not incur
the higher utility when in these states. The results
from the second sensitivity analysis using the utility
values from the NICE review used a value of 0.7
Economic evaluation
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T
ABLE 47
Sensitivity analysis associated with non-
operative management for recurrent disease (life-years)
Sensitivity analysis
P
rocedure
Cost (£)
Life-years
ICER (£)
P
robability cost-effective for different threshold values
for society's willingness to pay for a life-year (%)
£10,000
£20,000
£30,000
£50,000
Base-case
Open
9,613
15.351
60.4
63.0
64.0
64.2
Laparoscopic
9,876
15.298
Dominated
39.6
37.0
36.0
35.8
Equal survival
Open
9,613
15.351
51.0
50.3
49.9
49.5
Laparoscopic
9,903
15.351
Dominated
49.0
49.7
50.1
50.5
High mortality rate of non-
OM (0.31). (BC = 0.2)
Open
8,924
14.520
58.3
60.6
61.6
61.9
Laparoscopic
9,193
14.475
Dominated
41.7
39.4
38.4
39.1
Low mortality rate for non-
OM (0.11) (BC = 0.2)
Open
10,961
17.120
66.5
71.5
73.4
73.2
Laparoscopic
11,211
17.049
Dominated
33.5
28.5
26.6
26.8
RR of 0.5 for mortality for non-
OM state (BC = 1)
Open
9,613
15.351
0.0
0.0
0.0
0.0
Laparoscopic
11,467
17.405
903
100.0
100.0
100.0
100.0
RR of 1.5 for mortality for non-
OM state (BC = 1)
Laparoscopic
9,237
14.530
0.8
0.1
0.1
0.1
Open
9,613
15.350
456
99.2
99.9
99.9
99.9
RR of 0.5 for non-
OM mortality (BC = 1) and 
Open
10,961
17.120
0.0
0.0
0.0
0.0
low (0.11) mortality rate for non-
OM state 
Laparoscopic
13,247
20.021
788
100.0
100.0
100.0
100.0
(BC = 0.2)
RR of 1.5 for non-
OM mortality (BC = 1) and 
Laparoscopic
8,745
13.961
2.3
0.8
0.5
0.4
high (0.31) mortality rate for non-
OM state 
Open
8,924
14.520
321
97.7
99.2
99.5
99.6
(BC = 0.2)
BC, base-case; OM, operative management.Economic evaluation
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T
ABLE 48
Sensitivity analysis associated with non-
operative management for recurrent disease (QAL
Ys)
Sensitivity analysis
P
rocedure
Cost (£)
QAL
Ys
ICER (£)
P
robability cost-effective for different threshold values 
for society
’s willingness to pay for a QAL
Y (%)
£10,000
£20,000
£30,000
£50,000
Base-case
Open
9,613
14.679
59.9
61.2
62.0
62.2
Laparoscopic
9,876
14.630
Dominated
40.1
38.8
38.0
37.8
Equal survival
Open
9,613
14.679
50.8
49.8
50.2
49.3
Laparoscopic
9,903
14.679
Dominated
49.2
50.2
49.8
50.7
High rate of non-
OM mortality (0.31) (BC = 0.2)
Open
8,924
13.989
57.7
60.2
60.5
60.6
Laparoscopic
9,193
13.947
Dominated
42.3
39.8
39.5
39.4
Low mortality rate for non-
OM (0.11) (BC = 0.2)
Open
10,961
16.146
64.1
69.8
70.1
71.1
Laparoscopic
11,211
16.084
Dominated
35.9
30.2
29.9
28.9
RR of 0.5 for mortality for non-
OM state (BC = 1)
Open
9,613
14.680
0.0
0.0
0.0
0.0
Laparoscopic
11,467
16.379
1,090
100.0
100.0
100.0
100.0
RR of 1.5 for mortality for non-
OM state (BC = 1)
Laparoscopic
9,237
13.989
1.7
0.6
0.3
0.1
Open
9,613
14.679
546
98.3
99.4
99.7
99.9
RR of 0.5 for non-
OM mortality (BC = 1) and 
Open
10,961
16.146
0.0
0.0
0.0
0.0
low (0.11) mortality rate for non-
OM state 
Laparoscopic
13,247
18.551
951
100.0
100.0
100.0
100.0
(BC = 0.2)
RR of 1.5 for non-
OM mortality (BC = 1) and 
Laparoscopic
8,745
13.520
3.7
2.0
1.6
1.3
high (0.31) mortality rate for non-
OM state 
Open
8,924
13.989
383
96.3
98.0
98.4
98.7
(BC = 0.2)
BC, base-case; OM, operative management.Health Technology Assessment 2006; Vol. 10: No. 45
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T
ABLE 49
Sensitivity analysis around changes in the risk of hernia (life-years)
Sensitivity analysis
P
rocedure
Cost (£)
Life-years
ICER (£)
P
robability cost-effective for different threshold values 
for society
’s willingness to pay for a life-year (%)
£10,000
£20,000
£30,000
£50,000
Base-case
Open
9613
15.351
60.4
63.0
64.0
64.2
Laparoscopic
9876
15.298
Dominated
39.6
37.0
36.0
35.8
Equal survival
Open
9613
15.351
51.0
50.3
49.9
49.5
Laparoscopic
9903
15.351
Dominated
49.0
49.7
50.1
50.5
RR of 0.5 for hernia rate (BC = 1)
Open
9613
15.351
60.0
62.5
63.4
63.9
Laparoscopic
9823
15.298
Dominated
40.0
37.5
36.6
36.1
RR of 2 for hernia rate (BC = 1)
Open
9613
15.351
61.9
64.1
64.7
64.9
Laparoscopic
9982
15.298
Dominated
38.1
35.9
35.3
35.1
BC, base-case.
T
ABLE 50
Sensitivity analysis around changes in the risk of hernia (QAL
Ys)
Sensitivity analysis
P
rocedure
Cost (£)
QAL
Ys
ICER (£)
P
robability cost-effective for different threshold values
for society
’s willingness to pay for a QAL
Y (%)
£10,000
£20,000
£30,000
£50,000
Base-case
Open
9613
14.679
59.9
61.2
62.0
62.2
Laparoscopic
9876
14.630
Dominated
40.1
38.8
38.0
37.8
Equal survival
Open
9613
14.679
50.8
49.8
50.2
49.3
Laparoscopic
9903
14.679
Dominated
49.2
50.2
49.8
50.7
RR of 0.5 for hernia rate (BC = 1)
Open
9613
14.679
58.5
60.3
61.6
61.9
Laparoscopic
9823
14.630
Dominated
41.5
39.7
38.4
38.1
RR of 2 for hernia rate (BC = 1)
Open
9613
14.679
60.8
62.3
63.1
62.8
Laparoscopic
9982
14.630
Dominated
39.2
37.7
36.9
37.2
BC, base-case.Economic evaluation
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T
ABLE 51
Sensitivity analysis around changes in the use of alternative utility values (QAL
Ys)
Sensitivity analysis
P
rocedure
Cost (£)
QAL
Ys
ICER (£)
P
robability cost-effectiveness for different threshold
values for society
’s willingness to pay for a QAL
Y (%)
£10,000
£20,000
£30,000
£50,000
Base-case
Open
9613
14.679
59.9
61.2
62.0
62.2
Laparoscopic
9876
14.630
Dominated
40.1
38.8
38.0
37.8
Equal survival
Open
9613
14.679
50.8
49.8
50.2
49.3
Laparoscopic
9903
14.679
Dominated
49.2
50.2
49.8
50.7
Alternative QAL
Y – P
etrou. Non-
OM utility 
Open
9613
14.246
57.9
59.6
60.4
60.1 
score 0.575 (see T
able 39)
Laparoscopic
9876
14.203
Dominated
42.1
40.4 39.6
39.9
Alternative QAL
Y – P
etrou. Non-
OM utility 
Open
9613
13.095
56.0
56.6
56.4
56.3
score 0.10 (see T
able 39)
Laparoscopic
9876
13.064
Dominated
44.0
43.4
43.6
43.7
Alternative QAL
Y – P
andor
. Non-
OM utility 
Open
9613
12.477
56.2
57.7
57.5
57.4
score 0.24 (see T
able 40)
Laparoscopic
9876
12.444
Dominated
43.8
42.3
42.5
42.6
Alternative QAL
Y – P
andor
. Non-
OM utility 
Open
9613
13.591
59.0
60.5
61.6
61.9
score 0.70 (see T
able 40)
Laparoscopic
9876
13.547
Dominated
41.0
39.5
38.4
38.1
BC, base-case; OM, operative management.for the non-operative management state, which
was classified by the NICE review122 as patients on
adjuvant chemotherapy (Table 51). Once again,
laparoscopic resection is dominated by open
resection and is slightly less likely to be considered
cost-effective in comparison with the value for
palliative chemotherapy. This is due to the fact that
patients receiving open surgery have a slightly
worse disease-free survival compared with
laparoscopic surgery and are therefore more likely
to spend time in the non-operative management
state. Hence they have a greater chance of accruing
the extra QALYs associated with this state when it
has the higher utility value of 0.7.
Results of subgroup analysis
A deterministic analysis was performed to assess
the cost-effectiveness for each intervention by
stage of cancer (Table 52 for life-years and Table 53
for QALYs). The input parameters for mortality
and recurrence, by stage of disease, were obtained
from the survival curves taken from Bonjer and
colleagues (Bonjer J, QE II Health Sciences
Centre, Halifax, NS: personal communication,
2005) [Academic-in-confidence information
removed]. The results are limited and do not
reflect the degree of statistical uncertainty which
might surround the mortality and recurrence
parameters [Academic-in-confidence information
removed], although some difference in mean costs
and effects between the stage of disease can be
seen from the results in Table 52 for life-years and
Table 53 for QALYs. Curiously, for both life-years
and QALYs, it appears that patients with Stage III
disease, treated laparoscopically, actually had
improved overall and disease-free survival
compared with open patients, as this was the only
instance where neither intervention clearly
dominated the other. The results for patients with
Stage I disease are broadly consistent with the
base-case analysis with a similar cost and quality-
of-life difference between the two interventions
(Table 52 for life-years and Table 53 for QALYs).
Patients with Stage II colorectal cancer appear to
Health Technology Assessment 2006; Vol. 10: No. 45
59
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
TABLE 52 Deterministic results of subgroup analysis for different stages of cancer (life-years)
Scenario Procedure Cost (£) Life-years Incremental  Incremental  Incremental cost 
cost (£) life-years per life-year
Base-case Open 9613 15.35
Laparoscopic 9876 15.30 263 –0.05 Dominated
Equal survival Open 9613 15.35
Laparoscopic 9903 15.35 290 0 Dominated
Stage I Open 8994 24.04
Laparoscopic 9247 23.63 253 –0.41 Dominated
Stage II Open 9458 16.84
Laparoscopic 9764 14.67 306 –2.17 Dominated
Stage III Open 9802 11.14
Laparoscopic 9812 13.11 10 1.97 5
TABLE 53 Deterministic results of subgroup analysis for different stages of cancer (QALYs)
Scenario Procedure Cost (£) QALYs Incremental  Incremental Incremental cost 
cost (£) QALYs per QALY
Base-case Open 9613 14.68
Laparoscopic 9876 14.63 263 –0.05 Dominated
Equal survival Open 9613 14.68
Laparoscopic 9903 14.68 290 0 Dominated
Stage I Open 8994 23.50
Laparoscopic 9247 23.10 253 –0.40 Dominated
Stage II Open 9458 16.20
Laparoscopic 9764 14.03 306 –2.18 Dominated
Stage III Open 9802 10.43
Laparoscopic 9812 12.45 10 2.02 5be worse off when treated laparoscopically
compared with being treated with open surgery,
with an increased cost and decreased effectiveness.
Clinical opinion normally suggests that patients
whose disease progression is the least advanced
(patients with early stages of cancer) might be the
best candidates for laparoscopic surgery. The
evidence from the subgroup analysis performed is
inconclusive and appears not to be consistent with
this assumption. The data used to allow this
analysis should be treated with caution and further
randomised evidence and/or meta-analyses with
data on stage-dependent outcomes is warranted
for any conclusions to be reached with regard to
the suitability of laparoscopic candidates by stage
of disease.
Summary of evidence on 
cost-effectiveness
The results presented in the balance sheet suggest
that if it is assumed that there is no difference in
long-term outcomes, then a judgement is required
as to whether the shorter recovery associated with
laparoscopic resection is worth the additional cost
of £250–300 per patient. Preliminary results from
the cost analysis conducted within the CLASICC
trial were supplied as academic-in-confidence and
have not been presented in this report.
The available data were explicitly synthesised in
an economic model. In the base-case of this
model, and almost all of the sensitivity analyses
(making many of the same assumptions about
survival and disease-free survival as the base-case
analysis), laparoscopic surgery was dominated (i.e.
no more effective but more costly) by open
surgery. However, the likelihood that laparoscopic
surgery might be considered cost-effective varied
between 30 and 50%, regardless of whether
outcomes were measured in life-years or QALYs. If
an assumption was made of equal survival and
disease-free survival, then the mean estimates of
incremental cost-effectiveness still suggest that
laparoscopic surgery is dominated by open surgery
although, as costs and outcomes are similar, both
approaches had a similar likelihood of being
considered cost-effective.
A major concern with this analysis is that few data
were available on the utilities. More importantly,
the model fails, because of lack of data, to include
the QALY gain that might be associated with an
earlier recovery following laparoscopic surgery.
The implied value of the QALY gain would need
to be 0.009 and 0.010, respectively. In a
comparison between laparoscopic and open groin
hernia repair, the observed gain in QALYs was
0.006.123 It could be argued that as open resection
of colorectal cancer involves a larger incision than
open repair of inguinal hernia, the magnitude of
QALY gain for laparoscopic compared with open
resection might be greater than that observed for
hernia repair. What this fundamentally illustrates
is that relatively small differences in QALYs may,
in strict economic terms, be key to conclusions.
This is especially the case when it is remembered
that a single day in full health is equal to 0.00274
QALYs. 
Similarly, few data were available on morbidities
associated with the method of surgery, such as
hernia and persisting pain. The risk of such
outcomes along with their associated management
costs and utilities may, as with the evaluation of
surgery for inguinal hernia,124 be central to
determining relative cost-effectiveness.
The model was also sensitive to the patient
pathways and their associated probabilities, costs
and utilities following recurrent disease. In the
context of the available data, which suggested
similar mortality and disease-free survival, this is
likely to be unimportant, especially if the patient
pathway following recurrence is not influenced by
the initial choice of surgery. Should further data
become available suggesting the contrary, however,
then the sensitivity analysis suggests that the
results produced by the model would be sensitive
to the management of recurrent disease and
further work to develop this aspect of the model
might be warranted.
The analysis was repeated for different stages of
disease and results were broadly similar to those of
the base-case analysis. Further evidence to allow
data synthesis with regard to outcomes by stage is
required.
Economic evaluation
60Quality of life for the family and
carers
The data reported in Chapter 3 and summarised
in Table 35 (p. 39) suggest that laparoscopic
resection is associated with some short-term
benefit but takes longer to perform. There is no
evidence for a difference in long-term outcomes
measured by either surrogate endpoints (e.g.
lymph node retrieval and resection margins) or
final outcomes up to 3 years postoperation (e.g.
death, disease-free survival and hernia for 3 years
after surgery). Laparoscopic surgery is therefore an
approach that offers patients some short-term
advantages without appearing to compromise
safety or long-term outcomes (at least up to
3 years). Furthermore, should the short-term
benefits of laparoscopic surgery be realised and
associated with a quicker recovery, this may reduce
the time and effort that a patient’s family or other
carers devote to care following discharge from
hospital. 
Financial impact for the patient
and others
Although the mean age of patients receiving
surgery for colorectal cancer is past the age of
retirement, a significant proportion of patients will
still be in employment. Faster recovery following
surgery might result in an earlier return to work.
People who would otherwise experience financial
hardship as a result of being away from work
would benefit from the shorter recovery period of
laparoscopic surgery. Employers might benefit by
having their employees back to work earlier. 
It has been argued that an enhanced recovery
programme may offer advantage in terms of
earlier discharge. If so, such policies may be
associated with some transfer of cost from the
NHS to the families and carers of patients
compared with conventional discharge policies.
Whether such an effect occurs is not clear and a
recent Cochrane Review reported that evidence on
cost shifting was limited.125
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Implications for other partiesTraining
Currently, few surgeons routinely perform
laparoscopic surgery within the UK. Training
courses and a preceptorship programme have been
organised by relevant professional groups in
collaboration with industry. It has been argued that
such training should reduce operation time and
conversion rates (Ethicon Endo-Surgery submission
to NICE, 2005) and possibly improve other
outcomes. Despite such programmes, it will take
time to increase the number of surgeons capable of
providing laparoscopic surgery for colorectal
cancer. The pool of surgeons within the UK with
the necessary experience to act as a preceptor
(experience of at least 100 such resections) is small
(Ethicon Endo-Surgery submission to NICE, 2005).
However, there are increasing numbers of training
courses and schemes available for surgeons wishing
to develop the necessary skills.
The Association of Perioperative Practice has also
suggested that in addition to the training of the
surgeon, training would also be required for the
rest of the perioperative team. This would include
nurses and operating department practitioners
involved with the laparoscopic technology or
assisting the operating surgeons (Association of
Perioperative Practice submission to NICE, 2006).
HALS may be technically easier to perform (and
hence easier to learn) than laparoscopic surgery.
However, few data are available to assess its role as
a substitute for, or complement to laparoscopic
surgery.
Fair access and equity issues
Laparoscopic equipment does not appear to be a
restriction, because it is available in the majority of
NHS hospitals where colorectal resections take
place. An issue will be matching the distribution of
appropriately skilled surgeons with the distribution
of colorectal cancer surgery within the UK.
Resource transfers between
primary and secondary care
The potentially quicker recovery associated with
laparoscopic surgery may result in less call on
primary care services compared with open surgery,
although earlier discharge from hospital may
negate this. The implementation of an enhanced
recovery programme, as described by Basse and
colleagues,38 for laparoscopic or open surgery may
result in a shift in balance of care from secondary
to primary care irrespective of the type of surgery
performed. Given the experience of early
discharge schemes for other conditions, the
magnitude of such a shift is likely to be modest in
cost terms, but the shift of work may not be
accompanied by any additional resource.126
Availability of theatre space
The evidence available from the systematic review
of effectiveness reported in Chapter 3 indicates
that the duration of operation is greater for
laparoscopic resection (by approximately
40 minutes). Given the limited availability of
theatre space, the increased use of laparoscopic
resection may cause problems for theatre
managers and others involved in managing
theatre capacity.
Budgetary impact on the NHS
The budgetary impact of increasing use of
laparoscopic surgery from current level of
provision of open surgery is estimated in the
section ‘Expected costs’ (p. 7). As outlined in that
section, the additional cost of increasing
laparoscopic surgery to 25% of all resections may
range from less than £100,000 from the current
level of provision of 0.1% of all resections to an
additional cost of £2.1 million.
Such estimates are subject to considerable
uncertainty. Furthermore, they do not include
long-term costs (although this review suggests that
they will not differ between treatments) or
differences in the cost of presurgery, which may
differ between laparoscopic and open resection.
One reason for a difference in presurgery costs
would be if laparoscopic surgery were limited to
less complicated cases. If this occurs, then such
cases would need to be identified. This may
require routine CT staging of the tumour,
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Implications for the NHSalthough an increasing number of open
operations already require such detailed imaging.
However, in some centres, owing to the limited
availability of CT, an ultrasound is performed
instead. Hence any increase in the use of
laparoscopic surgery may lead to increased
demand for CT imaging. 
An enhanced recovery programme may result in a
shorter length of stay; however, cost saving is only
realised if beds are closed as a consequence. In
practice, the freed bed-days may be used to
provide other desirable care (providing additional
benefit at further cost). This is in addition to the
cost of establishing the enhanced recovery
programme. Such a programme therefore may not
result in reduced overall costs to the NHS.
Implications for the NHS
64Main results
As stated in Chapter 1, previous guidance from
NICE on the use of laparoscopic surgery for
colorectal cancer was that open rather than
laparoscopic surgery was the preferred procedure
and that laparoscopic surgery should only be
undertaken as part of an RCT.1 This guidance was
based on a technology assessment review
conducted in 2000.21
The 2000 review included data from five RCTs
and 18 non-randomised comparisons. It found
some evidence of short-term benefits for
laparoscopic resection. In particular, it found that
the use of analgesia and length of stay were less
following laparoscopic surgery. The additional cost
of laparoscopic resection was estimated to be
approximately £200 per patient. There was
insufficient evidence to judge whether the
procedures differed in respect of long-term
outcomes such as survival or disease-free survival. 
Long-term outcome remains the most important
issue. There were concerns that cure rates may be
less after laparoscopic surgery, with the possibility
of port-site metastases. However, early trial results
suggested better long-term results after
laparoscopic surgery, possibly due to less
disruption to the immune system.
This updated review identified 19 RCTs and one
individual patient data meta-analysis of four of the
largest trials comparing laparoscopic with open
surgery. Data from the RCTs related to 4568
patients. The long-term evidence was enhanced by
the individual patient data meta-analysis,
providing evidence on survival and disease-free
survival up to 3 years after surgery. Furthermore,
the data from the individual patient data meta-
analysis allowed consideration of the relative time
to either death or disease recurrence, whereas only
limited data on how outcomes changed over the
duration of follow-up were available from the trial
reports. 
Although the results are associated with some
uncertainty, laparoscopic surgery is likely to be
more costly than open surgery. The magnitude of
the extra cost from studies appears to be about
£250–300 per patient. Although only limited data
are available, the costs of laparoscopic surgery
were sensitive to the additional costs of the
equipment required for laparoscopic surgery and
the extent of reduction in length of stay compared
with open surgery. The other likely cost driver is
the extra theatre costs associated with the longer
operating time. 
The results of the updated review of data for
short-term outcomes have not fundamentally
changed the overall picture: convalescence is more
rapid after laparoscopic surgery and this is
reflected in less postoperative pain, shorter
hospital stay and more rapid return to usual
activities. Few cases of wound and port-site
recurrences were reported. The major change
since the 2000 review has been in the evidence on
recurrence, disease-free survival and overall
survival. [Academic-in-confidence information
removed.] The updated review presented in this
report also attempted to assess relative
effectiveness in terms of differences in wound-
related morbidities such as incisional and port-site
hernias and persisting pain. Few data were
identified for hernia and none on persisting pain.
With respect to the risk of hernias, a decision was
taken to focus on data from studies comparing
laparoscopic and open resection. Alternative data
on incisional hernia and port-site hernias may
have been obtained from studies reporting the
outcomes for open and laparoscopic surgery for
other conditions. Such data may not, however, be
generalisable to this surgery.
The results of the updated review along with
results of the individual patient meta-analyses have
been incorporated into the economic evaluation
outlined in Chapter 5. The balance sheet approach
illustrates the trade-offs that have to be taken into
account when making decisions about which type
of surgery to use. Assuming that there are no
differences in long-term outcomes, a judgement is
required as to whether the short-term benefits
following laparoscopic surgery are worth the
estimated additional £250–300 per patient.
The base-case analysis suggests that laparoscopic
resection is dominated by open resection in terms
of incremental cost per life-year and incremental
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Discussioncost per QALY. These findings reflect two things:
(1) the similarity in survival and disease-free
survival between laparoscopic and open surgery
and (2) the very limited data on utilities which do
not capture the short-term benefits associated with
laparoscopic surgery. There is a likelihood of
between 40 and 50% that laparoscopic surgery
would be considered cost-effective at an
incremental cost per life-year or QALY that society
might be willing to pay. The 50% likelihood of
being cost-effective occurs under the assumption
of no difference in survival or disease-free survival,
[Academic-in-confidence information removed].
There were no utility data available to model the
gain in QALYs associated with more rapid
recovery. However, it was possible to estimate the
implied value for the QALY gain associated with
an earlier recovery that would be needed for
laparoscopic surgery to be considered cost-
effective. The results of the sensitivity analyses
suggest that, should society be willing to pay
£30,000 per QALY, then earlier recovery following
laparoscopic surgery would need to be associated
with an increase of QALYs of between 0.009 and
0.010 QALYs compared with open surgery. To put
these figures in context, in the MRC Laparoscopic
Groin Hernia trial, laparoscopic repair was found
to be associated with a mean gain in QALYs at a 
3-month follow-up of 0.00583 QALYs (i.e. about
two-thirds of the threshold for laparoscopic
colorectal cancer).123 Arguably, it might be
expected that the differences in recovery between
laparoscopic and open surgery for colorectal
cancer would be greater than those between
laparoscopic and open surgery for inguinal hernia.
Nevertheless, a judgement is required as to
whether the magnitude of additional QALYs
identified by the implied value calculation can
plausibly be provided by laparoscopic surgery.
Furthermore, it should be noted that this implied
valuation indicates that their relatively small
differences in QALYs, which cannot be identified
with the data available, may be crucial
determinants of conclusions. For example, the
difference in QALYs would be equivalent to an
additional 3–4 days of full health. 
Little evidence was available on the relative merits
of HALS or the use of an enhanced recovery
programme for both laparoscopic and open
surgery. The limited evidence available suggests
that overall HALS might be expected to provide
similar costs and outcomes to laparoscopic surgery.
It has been suggested that HALS may be best
thought of as complementary to laparoscopic
surgery, with a role for particular cases rather than
as a substitute (Ethicon Endo-Surgery submission
to NICE, 2005).
With respect to the role of enhanced recovery, the
one economic evaluation (based on an RCT) that
formally compared laparoscopic with open surgery
in the context of such a programme still found
that the mean length of stay between the two
procedures was less for laparoscopic surgery.
However, such an approach appeared to offer
advantages in terms of freeing up bed days for
other uses following both forms of surgery. The
precise magnitude of any difference in length of
stay between laparoscopic and open surgery is
important as it has a significant impact on both
the incremental cost and cost-effectiveness. For
example, should there be no difference in length
of stay, the incremental cost of laparoscopic
surgery would be approximately £700; the cost of
the two forms of surgery would be equivalent if the
length of stay was approximately 4 days less for
laparoscopic surgery (a greater difference than
suggested by the results of the systematic review
presented in Chapter 3).
There were relatively few data for any of the
subgroups. The data that were available suggest
that there may be important differences between
colon and rectal cancer. However, this is tentative,
and it was impossible to judge whether or not
there are potentially important differences
between treatments within clinical subgroups of
colorectal cancer patients.
Assumptions, limitations and
uncertainties
The systematic review of effectiveness identified
considerably more RCTs than were available for
the review in 2000.21 Unfortunately, for many of
the review outcomes the data were sparse. For
example, only one RCT (from Hong Kong)
reported data on return to usual activities.53
Furthermore, even where data were available, it
was not always reported in a format suitable for
inclusion in the meta-analysis. Nonetheless, the
direction and magnitude of effect of these data
appeared to be consistent and, had it been
possible to include the data in the meta-analysis,
the precision of the estimate available would have
been increased.
Several limitations must be noted when
interpreting the results of the review of
effectiveness (Chapter 3). An extensive literature
search was conducted and both published and
Discussion
66unpublished data were sought. Despite these
efforts, it is possible that some unpublished studies
may have been missed. The impact on direction of
effect is unknown. The criteria for inclusion and
exclusion of patients vary considerably between
the studies. For example, some trials exclude
patients with advanced disease whereas other trials
include only patients with colon cancer. This
therefore limited our subgroup analysis. Hence the
results might not be generalisable to all groups of
patients who might undergo laparoscopic surgery.
Differences in patient group and variation in
operative technique and treatment protocols
existed between studies. However, the review
attempted to identify and explore sources of
heterogeneity. In most trials, outcome assessors
and patients were not blinded, which might have
influenced some of the outcomes. Moreover,
quality of life and pain scores were reported using
a variety of instruments and therefore
comparisons were difficult. Furthermore, in most
trials, around 20% of participants randomised to
laparoscopic surgery had open surgery, which
could have blunted any true differences between
the two approaches. Despite these limitations, the
overall findings obtained from these trials were
similar.
The best available evidence on disease-free
survival and overall survival are likely to come
from the individual patient data meta-analyses
conducted by Bonjer and colleagues (Bonjer J, QE
II Health Sciences Center, Halifax, NS: personal
communication, 2005). This meta-analysis did not
include all the data from all the available RCTs
and it had a follow-up of only 3-years. [Academic-
in-confidence information removed.]
Nonetheless, had the data from the other trials
been incorporated, it is likely that the precision of
the estimates would have been improved. The
greatest limitation of this review is that the data
available relate to at most a 3-year time horizon.
More long-term follow-up data are therefore
required before it could be certain that there is no
difference in longer term recurrence and survival.
The data available were very limited for some of
the outcomes and also for the subgroups and
insufficient to draw firm conclusions about the
relative effectiveness of the techniques being
compared. Further studies would be useful to
address these deficiencies in the evidence base. 
There was little information on the longer term
risks of wound-related morbidity. Insufficient data
were available to incorporate the risk of and the
different types of hernia (port-site and incisional
hernias) into the economic model. In studies
comparing laparoscopic with open surgery for
other conditions, the risks (and associated costs
and utilities) of these wound-related morbidities
have been central determinants of cost-
effectiveness. Further data are needed on the risks
of outcomes, such as hernias and persisting pain
(along with their costs of management and
associated effects on utility).
Very meagre data were available for the
comparison of HALS and open surgery. This
paucity of data highlights the need for more
studies for this comparison. 
In common with other laparoscopic procedures,
laparoscopic surgery for colorectal cancer is
technically more difficult than open surgery. The
cost-effectiveness (and also almost certainly the
safety) of laparoscopic surgery will be influenced
by where operators are on their learning curves.
The effect of learning may explain why some trial
patients randomised to laparoscopic surgery
actually received open surgery (‘opposite method
initiated’) and why so many trial patients allocated
to laparoscopic surgery were converted during the
procedure from laparoscopic to open surgery.
Increased experience in selecting which patients
are suitable for laparoscopic surgery and in
improving operator expertise might be expected
to reduce both of these rates.
In addition, the systematic review was conducted
on an intention-to-treat basis. Therefore, any
reduction in the rate at which patients undergoing
laparoscopic surgery are converted to open
surgery might be expected to increase the
difference observed between laparoscopic and
open surgery.
As with any economic evaluation, a number of
assumptions have been made. These assumptions
have mostly been made in response to the very
limited data available. For example, as mentioned
above, the economic evaluation did not
differentiate between port-site and incisional
hernia, which may in fact differ in terms of cost of
treatment and effect on patients’ well-being.
Similarly, no usable data with which to
differentiate the two interventions were available
for such aspects as rates for reoperations,
following a recurrence. As a result, these rates
were assumed to be the same, which may not be
justified given the lack of data to support this. A
further simplifying assumption was the constant
rate of all-cause mortality. Although this
assumption is unrealistic, it will have little effect
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mortality, but similar mortality for each type of
surgery, for colorectal cancer.
One concern about the economic model is the
quantity and quality of data available. In
particular, data on two key components, cost and
utilities, were very limited. In the case of costs, the
data available were subject to considerable
imprecision, as they had been derived from a
small RCT.40 Alternative cost data from the
CLASICC trial were also explored within the
economic model, in sensitivity analysis, and
produced similar results to the base-case analysis
(Franks PJ, Thames Valley University: personal
communication, 2005). It should be noted that the
data from CLASICC are preliminary and may be
subject to change, hence they should be treated
with caution. With respect to utilities, data were
almost entirely absent and the results presented in
terms of incremental cost per QALY in Chapter 5
should be treated with extreme caution. This is
because data on the potential QALY gain that
might be apparent after laparoscopic resection,
such as shorter hospitalisation, earlier return to
usual activities and less postoperative pain, are
non-existent, making the results with regard to
quality of life extremely tenuous. Additional
relevant data may soon be available from the UK-
based CLASICC trial in which data are being
collected on costs and QALYs (based on responses
to the EQ-5D). A revised economic analysis based
on the best available data on effectiveness from
the systematic review should be conducted once
data on costs and utilities from CLASICC are
available.
The nature of the data available also had an
impact on the economic evaluation. Data on
survival and disease-free survival were only
available for a 3-year time horizon. In the
economic model, it was assumed that such data
could be extrapolated up to a 25-year time
horizon. Having data available for a longer time
horizon would greatly strengthen the results of the
economic model. An important clinical outcome,
not explicitly incorporated into the economic
model, is conversion due to lack of useable data.
There are very few data on the impact that
conversion might have on cost and both short-
and long-term effects. Another area where the
paucity of data might have impacted on results is
recurrence of disease. The model has not allowed
recurrence of disease to be split by type, that is,
residual disease, local recurrence, wound and port-
site recurrence. As a result, important differences
by type of recurrence, and therefore method of
surgical resection, could not be observed. It should
be noted, however, that the 3-year disease-free
survival data used within the analysis suggest no
difference in rates, although longer term data are
needed to substantiate this. A further area in
which the data available are limited is the
management of patients following a recurrence.
The likelihood that a recurrence would occur and
the likelihood that a reoperation would be
performed could not be differentiated between the
two forms of resection. Similarly, the likelihood of
non-operative management for patients with
recurrent disease also could not be differentiated
between the two forms of resection. If differences
are found to lie in these areas in the future, then
these costs and consequences will have to be
addressed. Finally, the rates of mortality in the
economic model were assumed to be constant over
time, which is unrealistic given the time horizon of
the model (25 years). Nonetheless, as the available
data suggested no difference in survival at 3 years,
the effect of changing mortality rates over time
would not be expected to have much effect on
relative efficiency. Should longer term data
become available that suggest a difference in
survival, further work to develop this aspect of the
model estimates would be warranted.
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● The use of laparoscopic surgery within the NHS
will depend on judgements about the balance
between additional cost, shorter recovery and
apparently similar long-term effectiveness at
3 years.
● Laparoscopic surgery costs (approximately
£250–300 per patient) more than open surgery
(the current standard). This higher cost is
associated with longer operation times.
Furthermore, the additional equipment cost is
not fully compensated by the reductions in
length of stay.
● Laparoscopic surgery is associated with short-
term benefits in terms of less postoperative pain
and more rapid recovery.
● Overall and disease-free survival appear to be
similar after each type of procedure at 3 years.
● There is a scarcity of data relating to HALS.
The one small RCT identified reports similar
outcomes to laparoscopic surgery. 
● An enhanced recovery programme offers the
possibility of freeing bed-days. It also reduces the
difference in length of stay between laparoscopic
and open surgery and therefore reduces one of
the advantages of laparoscopic surgery. 
● Should the use of laparoscopic surgery increase,
this would require surgeons to become
proficient in the technique. Rates of conversion
between laparoscopic and open surgery are
associated with a ‘learning curve’. Appropriate
training, such as the preceptorship programme
developed by professional organisations, is
needed for both patient selection and the
technical aspects of the procedure.
● If laparoscopic surgery is to be increased, long-
term audit is required for quality assurance
purposes.
Implications for patients and carers
● Laparoscopic surgery is less invasive than open
surgery and likely to reduce the recovery
period, while providing similar long-term
outcomes compared with open surgery. 
● Laparoscopic (or open surgery) may be
provided in the context of an enhanced
recovery programme, which leads to a shorter
hospital stay. This is a benefit only if there is no
increased burden of care after discharge. There
is no evidence to clarify this.
Implications for research
● Direct measurements of utilities from recovery
through to the long term are required to
confirm the study findings. These data should
become available from the CLASICC trial.
● Better data on the resources and costs of both
laparoscopic and open surgery are required.
Again, although data from a preliminary
analysis conducted as part of the CLASICC trial
have been used to inform sensitivity analysis,
more detailed data should become available
when this trial is completed.
● Further long-term follow-up of all RCT cohorts
is required. 
● Bonjer and colleagues should be encouraged to
extend their individual patient data meta-
analysis in terms of both follow-up and
inclusion of other relevant studies by involving
other relevant groups, as has been done for
other laparoscopic procedures. 
● In other evaluations of laparoscopic surgery, the
RR of wound-related morbidity has played an
important part in assessing relative effectiveness
and cost-effectiveness. Further data are needed
on the risks of outcomes, such as hernias and
persisting pain (along with their costs of
management and associated effects on utility). 
● If HALS is to be adopted widely,
methodologically sound RCTs comparing HALS
with both laparoscopic and open surgery are
necessary.
● Further research is required relating to the
alternative surgical approaches for the different
locations and stages of colon and rectal cancer,
taking account of surgical competence. 
● Further research is required on the effectiveness
and cost-effectiveness of an enhanced recovery
programme for both open and laparoscopic
surgery compared with conventional open
surgery.
● Laparoscopic surgery for colorectal cancer is
technically challenging and performance is
likely to improve with experience. This issue is
important, and further methodologically robust
research is warranted.
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78Clinical effectiveness
Search strategies used to identify
reports of randomised controlled trials
and systematic reviews of laparoscopic
surgery for colorectal cancer
MEDLINE (2000–May Week 1, 2005)/EMBASE
(2000–Week 19, 2005) (MEDLINE Extra, 
11 May 2005) 
Ovid Multifile Search URL:
http://gateway.ovid.com/athens
1 exp colorectal neoplasms/su use medf 
2 exp colon cancer/su use emef 
3 exp rectum cancer/su use emef 
4 exp colectomy/ 
5 exp colon resection/ use emef 
6 exp rectum resection/ use emef 
7 (colectom$ or hemicolect$ or colotom$).tw. 
8 (mesorect$ adj3 excision$).tw. 
9 or/1-8
10 exp colorectal neoplasms/ use medf 
11 exp colon cancer/ use emef 
12 exp rectum cancer/ use emef 
13 (cancer adj3 (colorectal or colon$ or rectal or
rectum or intestin$ or bowel)).tw. 
14 (carcinoma adj3 (colorectal or colon$ or rectal
or rectum or intestin$ or bowel)).tw. 
15 (neoplas$ adj3 (colorectal or colon$ or rectal
or rectum or intestin$ or bowel)).tw. 
16 (adenocarcinoma$ adj3 (colorectal or colon$
or rectal or rectum or intestin$ or bowel)).tw. 
17 (malignan$ adj3 (colorectal or colon$ or rectal
or rectum or intestin$ or bowel)).tw. 
18 or/10-17 
19 adenocarcinoma/ 
20 carcinoma/ 
21 neoplasms/ 
22 or/19-21 
23 exp colon/ 
24 rectum/ use medf 
25 exp rectum/ use emef 
26 or/23-25 
27 22 and 26 
28 colorectal surgery/ 
29 Surgical procedures,operative/ use medf 
30 surgery/ use emef 
31 su.fs. 
32 (surgery or surgical or surgeon$).tw. 
33 resect$.tw. 
34 operat$.tw. 
35 or/28-34 
36 (18 or 27) and 35 
37 9 or 36 
38 laparoscopy/ 
39 laparoscopic surgery/ use emef 
40 Surgical procedures,minimally invasive/ use
medf 
41 Minimally invasive surgery/ use emef 
42 (minimal$ adj3 (invasiv$ or access$)).tw. 
43 laparoscop$.tw. 
44 (key hole or keyhole).tw. 
45 hand assist$.tw.
46 robotic$.tw.
47 robotics/ 
48 or/38-47 
49 37 and 48 
50 limit 49 to yr=2000-2005 
51 animal/ not human/ use medf 
52 (animal/ or nonhuman/) not human/ use emef 
53 50 not (51 or 52) 
54 clinical trial.pt. use medf 
55 exp controlled clinical trials/ use medf 
56 randomised controlled trial/ use emef 
57 clinical trial/ use emef 
58 random allocation/ use medf 
59 randomization/ use emef
60 random$.tw. 
61 or/54-60 
62 53 and 61 
63 meta analysis.tw. 
64 meta analysis.pt. use medf 
65 meta analysis/ use emef 
66 review.ab. 
67 review.pt. use medf 
68 systematic review/ use emef 
69 or/63-68 
70 53 and 69 
71 62 or 70 
72 remove duplicates from 71 
Science Citation Index (2000–27 May 2005)
Web of Knowledge URL: http://wok.mimas.ac.uk/ 
#1 TS=(colectom* OR hemicolect* OR colotom*)
#2 TS=(mesorect* SAME excision*)
#3 TS=((colon or colorectal) SAME resect* )
#4 #1 OR #2 OR #3
#5 TS=(cancer SAME (colorectal or colon* OR
rectal OR rectum OR intestin* OR bowel)) 
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Appendix 1
Search strategies#6 TS=(carcinoma SAME (colorectal OR colon*
OR rectal OR rectum OR intestin* OR bowel))
#7 TS=(neoplas* SAME (colorectal OR colon*
OR rectal OR rectum OR intestin* OR bowel))
#8 TS=(adenocarcinoma* SAME (colorectal OR
colon* OR rectal OR rectum OR intestin*
OR bowel)) 
#9 TS=(malignan* SAME (colorectal OR colon*
OR rectal OR rectum OR intestin* OR bowel)) 
#10 #5 OR #6 OR #7 OR #8 OR #9
#11 TS=laparoscop*
#12 TS=(minimal* SAME (invasiv* OR access*))
#13 TS=(key hole or keyhole)
#14 TS=robotic*
#15 TS=hand assist* 
#16 #11 OR #12 OR #13 OR #14 OR #15
#17 (#4 OR #10) AND #16
#18 TS=(randomised OR randomized)
#19 TS=random* allocat*
#20 TS=review*
#21 TS=meta analysis
#22 TS= #18 OR #19 OR #20 OR #21
#23 #17 AND #22
BIOSIS (2000–May 2005)
Edina URL: http://edina.ac.uk/biosis/
((al: (random*) or al: (trial*) or al: (control*)) and
((((((al: (minimal* n3 invasiv*) or al: (minimal* n3
access*)) or (al: (hand assist*) or al: (robotic*))) or
(al: (laparoscop*) or al: (key hole) or al:
(keyhole)))) and ((((((((((al: (rectum n3 surgical) or
al: (intestin* n3 surgical) or al: (bowel n3 surgical))
or (al: (colorectal n3 surgical) or al: (colon* n3
surgical) or al: (rectal n3 surgical))) or (al: (rectum
n3 surgery) or al: (intestin* n3 surgery) or al:
(bowel n3 surgery))) or (al: (colorectal n3 surgery)
or al: (colon* n3 surgery) or al: (rectal n3
surgery)))) and (al: (neoplas*) or al:
(adenocarcinoma*)))) or (((((((al: (rectum n3
surgical) or al: (intestin* n3 surgical) or al: (bowel
n3 surgical)) or (al: (colorectal n3 surgical) or al:
(colon* n3 surgical) or al: (rectal n3 surgical))) or
(al: (rectum n3 surgery) or al: (intestin* n3
surgery) or al: (bowel n3 surgery))) or (al:
(colorectal n3 surgery) or al: (colon* n3 surgery)
or al: (rectal n3 surgery)))) and (al: (cancer ) or al:
(carinoma) or al: (malignan*))))) or (((al:
(mesorect* n3 excision*) or al: (colon* n3 resect*))
or (al: (colectom*) or al: (hemicolectom*) or al:
(colotom*)))))))))
Cochrane Library (Issue 2, 2005)
URL: http://www3.interscience.wiley.com/
cgi-bin/mrwhome/106568753/HOME
#1 MeSH descriptor Colorectal Neoplasms
explode all trees with qualifier: SU in MeSH
products 
#2 MeSH descriptor Colectomy explode all trees
in MeSH products 
#3 colectom* in All Fields or hemicolect* in All
Fields or colotom* in All Fields
#4 (mesorect* NEAR/3 excision*) in All Fields
#5 (#1 OR #2 OR #3 OR #4) 
#6 MeSH descriptor Colorectal Neoplasms
explode all trees in MeSH prodcuts
#7 (cancer NEAR/3 (colorectal OR colon* OR
rectal OR rectum OR intestin* OR bowel)) in
All Fields
#8 (carcinoma NEAR/3 (colorectal OR colon*
OR rectal OR rectum OR intestin* OR
bowel)) in All Fields
#9 (neoplas* NEAR/3 (colorectal OR colon* OR
rectal OR rectum OR intestin* OR bowel)) in
All Fields
#10 (adenocarcinoma* NEAR/3 (colorectal OR
colon* OR rectal OR rectum OR intestin*
OR bowel)) in All Fields
#11 (malignan* NEAR/3 (colorectal OR colon*
OR rectal OR rectum OR intestin* OR
bowel)) in All Fields
#12 (#6 OR #7 OR #8 OR #9 OR #10 OR #11) 
#13 MeSH descriptor Adenocarcinoma, this term
only in MeSH products 
#14 MeSH descriptor Carcinoma, this term only
in MeSH products 
#15 MeSH descriptor Neoplasms, this term only
in MeSH products 
#16 (#13 OR #14 OR #15)
#17 MeSH descriptor Colon explode all trees in
MeSH products 
#18 MeSH descriptor Rectum, this term only in
MeSH products 
#19 (#17 OR #18) 
#20 (#16 AND #19) 
#21 MeSH descriptor Colorectal Surgery, this
term only in MeSH products
#22 MeSH descriptor Surgical Procedures,
Operative, this term only in MeSH products 
#23 su.fs in All Fields 
#24 (surgery OR surgical OR surgeon*) in All
Fields
#25 (resect* OR operation*) in All Fields
#26 (#21 OR #22 OR #23 OR #24 OR #25) 
#27 (( #12 OR #20 ) AND #26) 
#28 (#5 OR #27) 
#29 MeSH descriptor Laparoscopy, this term only
in MeSH products 
#30 MeSH descriptor Robotics, this term only in
MeSH products 
#31 MeSH descriptor Surgical Procedures,
Minimally Invasive, this term only in MeSH
products 
#32 (minimal* NEAR/3 (invasiv* or access*)) in
All Fields
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80#33 laparoscop* OR key hole OR keyhole OR
hand assist* OR robotic* in All Fields
#34 (#29 OR #30 OR #31 OR #32 OR #33) 
#35 (#28 AND #34), from 2000 to 2005 
Journals@Ovid Full Text (21 July 2005)
URL: http://gateway.ovid.com/athens
Journals searched: Annals of Surgery; Archives of
Surgery; British Journal of Surgery; Surgical
Laparoscopy
1 annals of surgery.jn. 
2 archives of surgery.jn. 
3 british journal of surgery.jn. 
4 surgical laparoscopy endoscopy &
percutaneous techniques.jn. 
5 or/1-4 
6 (random$ or control$ or trial?).tw. 
7 (colectom$ or hemicolect$ or colotom$).tw. 
8 (mesorect$ adj3 excision$).tw. 
9 ((colorectal or colon$ or rectal or rectum or
intestin$ or bowel) adj3 (cancer or carcinoma
or neoplas$ or surg$)).tw. 
10 laparoscop$.tw. 
11 (minimal$ adj3 (invasiv$ or access$)).tw.
12 (key hole or keyhole).tw. 
13 hand assist$.tw. 
14 robotic$.tw. 
15 or/7-9 
16 or/10-14 
17 6 and 15 and 16 
18 5 and 17 
19 limit 18 to yr="2000 - 2005" 
National Research Register (Issue 2,2005)
URL: http://www.update-software.com/National/
#1. COLORECTAL NEOPLASMS [su] explode
all trees (MeSH) 
#2. COLECTOMY single term (MeSH) 
#3. colectom* or hemicolect* or colotom*
#4. (#1 or #2 or #3) 
#5. COLORECTAL NEOPLASMS explode all
trees (MeSH) 
#6. (cancer near (colorectal or colon* or rectal
or rectum or intestin* or bowel))
#7. (carcinoma near (colorectal or colon* or
rectal or rectum or intestin* or bowel))
#8. (neoplasm* near (colorectal or colon* or
rectal or rectum or intestin* or bowel))
#9. (adenocarcinom* near (colorectal or colon*
or rectal or rectum or intestin* or bowel))
#10. (mailignan* near (colorectal or colon* or
rectal or rectum or intestin* or bowel))
#11. (#5 or #6 or #7 or #8 or #9 or #10) 
#12. ADENOCARCINOMA single term (MeSH)
#13. CARCINOMA single term (MeSH)
#14. NEOPLASMS single term (MeSH)
#15. (#12 or #13 or #14) 
#16. COLON explode all trees (MeSH) 
#17. RECTUM single term (MeSH)
#18. #16 or #17
#19. (#15 and #18) 
#20. COLORECTAL SURGERY single term
(MeSH)
#21. SURGICAL PROCEDURES, OPERATIVE
single term (MeSH)
#22. (surgery or surgical or surgeon*)
#23. (resect* or operation*)
#24. (#20 or #21 or #22 or #23)
#25. ((#11 or #19) and #24)
#26. (#4 or #25)
#27. LAPAROSCOPY single term (MeSH)
#28. ROBOTICS single term (MeSH)
#29. SURGICAL PROCEDURES, MINIMALLY
INVASIVE single term (MeSH) 
#30. (minimal * near (invasiv* OR access*))
#31. (laparoscop* or key hole or keyhole or hand
assist* or robotic*)
#32. (#27 or #28 or #29 or #30 or #31)
#33. (#26 and #32) from 2000 to 2005
Clinical Trials (May 2005)
URL: http://clinicaltrials.gov/ct/gui/c/r
Colorectal and laparoscopy
Current Controlled Trials (May 2005) 
URL: http://www.controlled-trials.com/
Colorectal and laparoscop%
Cost-effectiveness and economic
evaluations
Search strategies used to identify
reports of cost-effectiveness and
economic evaluations of laparoscopic
surgery for colorectal cancer
MEDLINE (2000–May Week 2, 2005)/EMBASE
(2000–Week 21, 2005) (MEDLINE Extra, 
23 May 2005) 
Ovid Multifile Search URL:
http://gateway.ovid.com/
1 exp colorectal neoplasms/su use medf 
2 exp colon cancer/su use emef 
3 exp rectum cancer/su use emef 
4 exp colectomy/ (8272)
5 exp colon resection/ use emef 
6 exp rectum resection/ use emef 
7 (colectom$ or hemicolect$ or colotom$).tw.
8 (mesorect$ adj3 excision$).tw. 
9 or/1-8 
10 exp colorectal neoplasms/ use medf 
11 exp colon cancer/ use emef 
12 exp rectum cancer/ use emef
Health Technology Assessment 2006; Vol. 10: No. 45
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rectum or intestin$ or bowel)).tw. 
14 (carcinoma adj3 (colorectal or colon$ or rectal
or rectum or intestin$ or bowel)).tw. 
15 (neoplas$ adj3 (colorectal or colon$ or rectal
or rectum or intestin$ or bowel)).tw. 
16 (adenocarcinoma$ adj3 (colorectal or colon$
or rectal or rectum or intestin$ or bowel)).tw. 
17 (malignan$ adj3 (colorectal or colon$ or rectal
or rectum or intestin$ or bowel)).tw. 
18 or/10-17 
19 adenocarcinoma/ 
20 carcinoma/ 
21 neoplasms/ 
22 or/19-21
23 exp colon/ 
24 rectum/ use medf
25 exp rectum/ use emef 
26 or/23-25 
27 22 and 26 
28 colorectal surgery/ 
29 Surgical procedures,operative/ use medf 
30 surgery/ use emef
31 su.fs. 
32 (surgery or surgical or surgeon$).tw. 
33 resect$.tw. 
34 operation$.tw. 
35 or/28-34 
36 (18 or 27) and 35 
37 9 or 36 
38 laparoscopy/ 
39 laparoscopic surgery/ use emef 
40 Surgical procedures,minimally invasive/ use
medf 
41 Minimally invasive surgery/ use emef 
42 (minimal$ adj3 (invasiv$ or access$)).tw.
43 laparoscop$.tw. 
44 (key hole or keyhole).tw. 
45 hand assist$.tw.
46 robotic$.tw. 
47 robotics/ 
48 or/38-47 
49 37 and 48 
50 limit 49 to yr=2000-2005 
51 exp "costs and cost analysis"/ 
52 economics/ 
53 exp economics,hospital/
54 exp economics,medical/ 
55 economics,pharmaceutical/ 
56 exp budgets/ 
57 exp models, economic/ 
58 exp decision theory/ 
59 ec.fs. 
60 monte carlo method/ 
61 markov chains/ 
62 exp quality of life/ 
63 "Value of Life"/ 
64 cost of illness/ 
65 exp health status indicators/
66 cost$.ti. 
67 (cost$ adj2 (effective$ or utilit$ or benefit$ or
minimis$)).ab. 
68 economics model$.tw. 
69 (economics$ or pharmacoeconomic$ or
pharmo-economic$).ti. 
70 (price$ or pricing$).tw. 
71 (financial or finance or finances or
financed).tw. 
72 (value adj2 (money or monetary)).tw. 
73 quality adjusted life.tw. 
74 disability adjusted life.tw. 
75 (qaly? or qald? or qale? or qtime? or daly?).tw. 
76 (euroqol or euro qol or eq5d or eq 5d).tw. 
77 (hql or hqol or h qol or hrqol or hr qol).tw. 
78 (hye or hyes).tw. 
79 (health adj3 (indicator? or status or utilit?)).tw. 
80 markov$.tw. 
81 monte carlo.tw. (
82 (decision$ adj2 (tree? or analy$ or model$)).tw. 
83 or/51-82 
84 50 and 83 
85 remove duplicates from 84
Science Citation Index (2000–27 May 2005)
Web of Knowledge URL: http://wok.mimas.ac.uk/ 
#1 TS=(colectom* OR hemicolect* OR
colotom*)
#2 TS=(mesorect* SAME excision*) 
#3 TS=((colon OR colorectal) SAME resect*)
#4 #1 OR #2 OR #3 
#5 TS=(cancer SAME (colorectal OR colon* OR
rectal OR rectum OR intestin* OR bowel))
#6 TS=(carcinoma SAME (colorectal OR colon*
OR rectal OR rectum OR intestin* OR
bowel))
#7 TS=(neoplas* SAME (colorectal OR colon*
OR rectal OR rectum OR intestin* OR
bowel))
#8 TS=(adenocarcinoma* SAME (colorectal OR
colon* OR rectal OR rectum OR intestin*
OR bowel))
#9 TS=(malignan* SAME (colorectal OR colon*
OR rectal OR rectum OR intestin* OR
bowel))
#10 #5 OR #6 OR #7 OR #8 OR #9
#11 TS=laparoscop*
#12 TS=(minimal* SAME (invasiv* OR access*))
#13 TS=(key hole OR keyhole)
#14 TS=hand assist*
#15 TS=robotic*
#16 #12 OR #13 OR #14 OR #15 OR #16
#17 (#4 OR #10) AND #16
#18 TS=economic*
#19 TS=cost*
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82#20 TS=(price* OR pricing*)
#21 TS=(financial or finance*)
#22 TS=(decision* SAME (tree* OR analy* or
model*))
#23 TS=markov*
#24 TS=monte carlo
#25 TS=(health SAME (indicator* or status or
utilit*))
#26 TS=quality of life
#27 TS=quality adjusted life
#28 TS=disability adjusted life
#29 TS=(qaly* or qald* or qale* or qtime* or
daly*)
#30 TS=(euroqol* or euro qol* or eq5d or eq 5d)
#31 TS=(hql or hqol or h qol or hrqol or hr qol)
#32 TS=(hye or hyes)
#33 #18 or #19 or #20 or #21 or #22 or #23
or #24 or #25 or #26 or #27 or #28 or
#29 or #30 or #31 or #32 
#34 #17 AND #30
NHS Economic Evaluation Database (May 2005)
URL: http://www.york.ac.uk/inst/crd/nhsdhp.htm
Colorectal-neoplasms (exploded)
and
laparoscop or surgery or surgical
General searches
Search strategies used to identify
reports of clinical or cost-effectiveness
of laparoscopic surgery for colorectal
cancer
Health Management Information Consortium
2000–May 2005
URL: http://gateway.ovid.com/
1 (colectom$ or hemicolect$ or colotom$).tw. 
2 (mesorect$ adj3 excision$).tw. 
3 ((colon$ or colrect$) adj3 resect$).tw. 
4 1 or 2 or 3 
5 (cancer adj3 (colorectal or colon$ or rectal or
rectum or intestin$ or bowel)).tw. 
6 (carcinoma adj3 (colorectal or colon$ or rectal
or rectum or intestin$ or bowel)).tw. 
7 (neoplas$ adj3 (colorectal or colon$ or rectal
or rectum or intestin$ or bowel)).tw. 
8 (adenocarcinoma adj3 (colorectal or colon$ or
rectal or rectum or intestin$ or bowel)).tw. 
9 (malignan$ adj3 (colorectal or colon$ or rectal
or rectum or intestin$ or bowel)).tw. 
10 or/5-9 
11 (surgery or surgical or surgeon$).tw. 
12 resect$.tw. 
13 operat$.tw. 
14 surgery/ 
15 or/11-14 
16 4 or (10 and 15) 
17 limit 16 to yr=2000 - 2005 
DARE and HTA databases (May 2005)
NHS Centre for Reviews and Dissemination
URL: http://nhscrd.york.ac.uk/welcome.htm
Colorectal-neoplasms (exploded)
and
laparoscop or surgery or surgical
Conference Proceedings Abstracts screened
Association of Coloproctology of Great Britain and
Ireland: 
Annual Meeting, Manchester, July 2002
Annual Meeting, Edinburgh, July 2003
Annual Meeting, Birmingham, June 2004
European Association of Coloproctology:
Scientific Annual Meeting, Barcelona, September
2003
Scientific Annual Meeting, Geneva, September
2004
Society of American Gastrointestinal and Endoscopic
Surgeons:
8th World Congress, New York, March 2002
9th World Congress, Los Angeles, March 2003
10th World Congress, Colorado, March 2004
11th World Congress, Fort Lauderdale, April 
2005
European Association for Endoscopic Surgery:
10th International Congress, Lisbon, June 2002
12th International Congress, Barcelona, June
2004
13th International Congress, Venice, June 2005
Association of Endoscopic Surgeons of Great Britain and
Ireland (AESGBI):
Annual Meeting, Dublin, April 2002
American Society of Colon and Rectal Surgeons:
Annual Meeting, Chicago, April 2002
Annual Meeting, New Orleans, April 2003
Annual Meeting, Dallas, April 2004
Annual Meeting, Philadelphia, April 2005
Websites searched for other evidence-based
reports and background information
American Society for Colon and Rectal Surgeons
URL: http://www.fascrs.org/index.cfm. Accessed
July 2005]
Association of Coloproctology of Great Britain and
Ireland (ACPGBI)
URL: http://www.acpgbi.org.uk/. Accessed June
2005
Health Technology Assessment 2006; Vol. 10: No. 45
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URL: http://www.cancerresearchuk.org/. Accessed
July 2005
NHS Health and Social Care Cancer Information
Services 
URL: http://www.icservices.nhs.uk/cancer/pages/
dataset/. Accessed July 2005
Society of American Gastrointestinal and
Endoscopic Surgeons
URL: http://www.sages.org/index.html. Accessed
July 2005
Trip database. 
URL: http://www.tripdatabase.com/. Accessed May
2005
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Appendix 2
Study eligibility form
Paper number:  Assessor initials:  Date assessed: 
Study identifier
(surname of first author + year of publication)
Type of study Yes Unclear No
Q1. Is the study a systematic review or meta-analysis of randomised 
controlled trials, a randomised controlled trial, or a cohort study or 
UK registry with a minimum of three years follow-up? 
Go to  Exclude
(If Yes, please indicate which type of study design) Next question
Participants in the study Yes Unclear No
Q2. Are some or all of the participants in the study adults with 
colorectal cancer?
Go to Exclude
Next question
Interventions in the study Yes Unclear No
Q3. Did some or all of the participants receive open surgical procedure, 
laparoscopic, laparoscopic-assisted or hand-assisted laparoscopic surgery?
Go to Exclude
Next question
Outcomes in the study Yes Unclear No
Q4. Does the study report short-term and/or long-term outcome data 
on the patients that underwent the intervention (s)?
Include, subject Exclude
to clarification of 
‘unclear’ points
Final decision Include Unclear ExcludeHealth Technology Assessment 2006; Vol. 10: No. 45
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Data extraction formAppendix 3
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Laparoscopic and hand-assisted laparoscopic versus
Open surgery for the treatment of colorectal cancer
Reviewer ID: 
Study
Study ID:                                                                      Country:
Funding:  government / private / manufacturer / other (specify)
RCT
Quasi-RCT
Cohort study
Unclear
Participants
Recruitment dates: 
Number of eligible patients:  Number of patients randomised: 
Criteria for Inclusion:
Criteria for Exclusion:
Intervention
Surgical technique No. of Patients
Intervention 1
Intervention 2
Intervention 3
Comments: (i.e. operator information, adjuvant therapy, length of incision)Health Technology Assessment 2006; Vol. 10: No. 45
89
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Patient Characteristics
                                   Specify
Intervention 1 Intervention 2 Intervention 3 Overall
Age (years)
Sex (M/F)
Body Weight (kg)
Follow-up period:                                                    Number of patients lost to follow-up: 
Comments:
Location of cancer
                                         Specify
Intervention 1 Intervention 2 Intervention 3 Overall
Total (No.)
Colon (No.)
• Caecum
• Ascending  colon
• Hepatic  flexure
• Transverse  colon
• Splenic  flexure
• Descending  colon
• Sigmoid  colon
• Rectosigmoid  junction
Rectum (No.)Appendix 3
90
Stage of cancer
Specify
Intervention 1 Intervention 2 Intervention 3 Overall
TNM or Dukes stage (No.)
(Specify)
Comments:Health Technology Assessment 2006; Vol. 10: No. 45
91
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Short-term Outcomes
Intra-operative Intervention 1 Intervention 2 Intervention 3
Duration of operation (min)
Blood loss
Anastomotic leakage
Abdominal wound breakdown
Lymph node retrieval
Number of ports used for laparoscopic 
resection
Opposite method initiated
Completeness of resection/margins of 
tumours clearance
Conversion
Post-operative
Seroma
Infection
•  Specify
Port site hernia
Vascular injury
Visceral injury
30-day mortality
Length of hospital stay
Post-operative pain
•  Specify
Time to return to usual activities (days)
OtherAppendix 3
92
Long-term Outcomes Intervention 1 Intervention 2 Intervention 3
Survival (years)
Disease-free survival (years)
Health-related quality of life
Tumour recurrence type
•  Port site metastasis
•  Wound metastasis
Time to recurrence (months)
Incidence of incisional hernia
Long term pain
OtherHealth Technology Assessment 2006; Vol. 10: No. 45
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Additional information/Other comments
Contact with Author
Date: ………/………/……… Signature: ……………………………Health Technology Assessment 2006; Vol. 10: No. 45
95
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Appendix 4
Quality assessment form – systematic reviews
Question Yes No Partially Unknown
1. Were the search methods used to find evidence 
(primary studies) on the primary question(s) stated? 
2. Was the search for evidence reasonably comprehensive?
3. Were the criteria used for deciding which studies to 
include in the review reported? 
4. Was bias in the selection of articles avoided?
5. Were the criteria used for assessing the validity of the 
studies that were reviewed reported? 
6. Was the validity of all of the studies referred to in the 
text assessed using appropriate criteria (either in 
selecting studies for inclusion or in analysing the 
studies that are cited)? 
7. Were the methods used to combine the findings of the 
relevant studies (to reach a conclusion) reported? 
8. Were the findings of the relevant studies combined 
appropriately relative to the primary question the 
review addresses? 
9. Were the conclusions made by the author(s) supported 
by the data and/or the analysis reported in the review?Health Technology Assessment 2006; Vol. 10: No. 45
97
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Appendix 5
Quality assessment form – RCTs
Question Yes No Unclear
1. Was a method of randomisation performed? 
Adequate approaches to sequence generation
• computer-generated random tables
• random number tables
Inadequate approaches to sequence generation
• use of alternation, case record numbers, birth dates or week days
2. Was the treatment allocation concealed?
Adequate approaches to concealment of randomisation
• centralised or pharmacy-controlled randomisation
• serially-numbered identical containers
• on-site computer based system with a randomisation sequence 
that is not readable until allocation
• other approaches with robust methods to prevent foreknowledge 
of the allocation sequence to clinicians and patients
Inadequate approaches to concealment of randomisation
• use of alternation, case record numbers, birth dates or week days
• open random number lists
• serially numbered envelopes
3. Were the groups similar at baseline regarding the most important 
prognostic indicators?
4. Were the eligibility criteria specified?
5. Was the outcome assessor blinded?
6. Was the care provider blinded?
7. Was the patient blinded?
8. Were point estimates and measures of variability presented for 
the primary outcome measures?
9. Did the analysis include an intention-to-treat analysis?Araujo, 2003
Primary reference
Araujo SE, da Silva eSousa AH Jr, de Campos FG,
Habr-Gama A, Dumarco RB, Caravatto PP, et al.
Conventional approach × laparoscopic
abdominoperineal resection for rectal cancer
treatment after neoadjuvant chemoradiation:
results of a prospective randomized trial. Rev Hosp
Clin Fac Med Sao Paulo 2003;58:133–40.
Bonjer (unpublished)
Primary reference
The Trans Atlantic Laparoscopically-Assisted
versus Open Colectomy Trials Study Group.
Laparoscopically assisted versus open colectomy
for colon cancer – a meta-analysis.
COLOR, 2005
Primary reference
Veldkamp R, Kuhry E, Hop WC, Jeekel J,
Kazemier G, Bonjer HJ, et al. Laparoscopic
surgery versus open surgery for colon cancer:
short-term outcomes of a randomised trial. Lancet
Oncol 2005;6:477–84.
Related references
Janson M, Bjorholt I, Carlsson P, Haglind E,
Henriksson M, Lindholm E, et al. Randomized
clinical trial of the costs of open and laparoscopic
surgery for colonic cancer. Br J Surg 2004;
91:409–17.
Wu FP. Systemic and peritoneal inflammatory
response after laparoscopic or conventional colon
resection in cancer patients. Dis Colon Rectum
2003;46:147–55.
Wu FP, Hoekman K, Sietses C, von Blomberg BM,
Meijer S, Bonjer HJ, et al. Systemic and peritoneal
angiogenic response after laparoscopic or
conventional colon resection in cancer patients: 
a prospective, randomized trial. Dis Colon Rectum
2004;47:1670–4.
COST, 2004
Primary reference
Clinical Outcomes of Surgical Therapy Study
Group. A comparison of laparoscopically assisted
and open colectomy for colon cancer. N Engl J
Med 2004;350:2050–9.
Related references
Nelson H. Laparoscopic colectomy for colon
cancer – a trial update. Swiss Surg 2001;7:248–51.
Nelson H. Laparoscopically assisted colectomy is
as safe and effective as open colectomy in people
with colon cancer. Cancer Treat Rev 2004;30:707–9.
Stocchi L, Nelson H, Sargent D, Larson D,
Fleshman J, Stryker S, et al. Morbidity following
laparoscopic-assisted vs open colectomy: Results
from a multicenter prospective randomized trial.
Dis Colon Rectum 2005;48:636–7.
Weeks JC, Nelson H, Gelber S, Sargent D,
Schroeder G, Clinical Outcomes of Surgical
Therapy (COST) Study Group. Short-term quality-
of-life outcomes following laparoscopic-assisted
colectomy vs open colectomy for colon cancer: a
randomized trial. JAMA 2002;287:321–8.
Winslow ER, Fleshman JW, Birnbaum EH, Brunt
LM. Wound complications of laparoscopic vs open
colectomy. Surg Endosc 2002;16:1420–5.
Young-Fadok TM, Sargent DJ, Nelson H,
Fleshman JW. Conversion does not adversely affect
oncologic outcomes after laparoscopic colectomy
for colon cancer: results from a multicenter
prospective randomized trial. Dis Colon Rectum
2005;48:637–8.
CLASICC, 2005
Primary reference
Guillou PJ, Quirke P, Thorpe H, Walker J, 
Jayne D, Smith AM, et al. Short-term endpoints of
conventional versus laparoscopic-assisted surgery
in patients with colorectal cancer (MRC CLASICC
trial): multicentre, randomised controlled trial.
Lancet 2005;365:1718–26.
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Curet, 2000
Primary reference
Curet MJ, Putrakul K, Pitcher DE, Josloff RK,
Zucker KA. Laparoscopically assisted colon
resection for colon carcinoma: perioperative
results and long-term outcome. Surg Endosc 2000;
14:1062–6.
Hasegawa, 2003
Primary reference
Hasegawa H, Kabeshima Y, Watanabe M,
Yamamoto S, Kitajima M. Randomized controlled
trial of laparoscopic versus open colectomy for
advanced colorectal cancer. Surg Endosc 2003;
17:636–40.
Related reference
Hasegawa H, Watanabe M, Kabeshima Y,
Yamamoto S, Kitajima M. Short-term results of a
randomised controlled trial of laparoscopic vs
open colectomy for colorectal cancer. Colorectal Dis
2001;3 (1 Suppl 1):8.
Hewitt, 1998
Primary reference
Hewitt PM, Ip SM, Kwok SP, Somers SS, Li K,
Leung KL, et al. Laparoscopic-assisted vs open
surgery for colorectal cancer: comparative study 
of immune effects. Dis Colon Rectum 1998;
41:901–9.
Kaiser, 2004
Primary reference
Kaiser AM, Kang JC, Chan LS, Vukasin P, 
Beart RW Jr. Laparoscopic-assisted vs open
colectomy for colon cancer: a prospective
randomized trial. J Laparoendosc Adv Surg Tech A
2004;14:329–34.
Kim, 1998
Primary reference
Kim SH, Milsom JW, Gramlich TL, Toddy SM,
Shore GI, Okuda J, et al. Does laparoscopic vs
conventional surgery increase exfoliated cancer
cells in the peritoneal cavity during resection of
colorectal cancer? Dis Colon Rectum 1998;
41:971–8.
King, 2006
King PM,Blazeby JM, Ewings P, Franks PJ,
Longman RJ, Kendrick AH, et al. Randomized
clinical trial comparing laparoscopic and open
surgery for colorectal cancer within an enhanced
recovery programme. Br J Surg 2006;93:300–8. 
Lacy, 2002
Primary reference
Lacy AM, Garcia-Valdecasas JC, Delgado S,
Castells A, Taura P, Pique JM, et al. Laparoscopy-
assisted colectomy versus open colectomy for
treatment of non-metastatic colon cancer: a
randomised trial. Lancet 2002;359:2224–9.
Related references
Delgado S, Lacy AM, Valdecasas JCG, Balague C,
Pera M, Salvador L, et al. Could age be an
indication for laparoscopic colectomy in colorectal
cancer? Surg Endosc 2000;14:22–6.
Delgado S, Lacy AM, Filella X, Castells A, 
Garcia-Valdecasas JC, Pique JM, et al. Acute phase
response in laparoscopic and open colectomy in
colon cancer: randomized study. Dis Colon Rectum
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Appendix 7
Detailed quality assessment score for each of
the included studies
Randomised controlled trials
Study ID Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9
Araujo, 2003 Y U Y Y U N U N U
CLASICC, 2005 YYYYUNUYY
COLOR, 2005 YYYYNNNY a Y
COST, 2004 YYYYYNUY a Y
Curet, 2000 Y N Y Y U N U Yb N
Hasegawa, 2003 Y U Y Y U N U Yb N
Hewitt, 1998 Y U N Y U N U Ya N
Kaiser, 2004 Y U N Y U N U Yb N
Kim, 1998 Y N N Y U N U Ya U
King, 2006 YYYYUNUYY
Lacy, 2002 Y N Y Y U N U Y U
Leung, 2004 YYYYUNUYN
Milsom, 1998 Y U Y Y NNNY a N
Neudecker, 2003 YYYYUNNY a U
Schwenk, 1998a Y U Y Y U N U Y Y
Stage, 1997 Y U N Y U N U Ya N
Tang, 2001 Y N Y Y U N U Ya Y
Vignali, 2004 Y N N Y U N U Y Y
Zhou, 2004 U U Y Y U N U Y U
N, No; U, Unclear; Y, Yes.
a Median (range).
b Mean (range).
Systematic reviews and meta-analyses
Study ID Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9
Bonjer, 2005 [Academic-in-confidence information removed]Health Technology Assessment 2006; Vol. 10: No. 45
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Characteristics of included studiesAppendix 8
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R
andomised controlled trials published from 2000 onwards
Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
Araujo, 2003
47
Study design:
RCT
Location: Brazil
Mean follow
-up
:
47.2 months
R
ecruitment
dates: September
1997–September
2000
Funding: not
reported
Inclusion criteria: distal
rectal adenocarcinoma with
preoperative staging
favourable to radical resection
by abdominoperineal resection
Number of eligible patients:
28
Number of patients
randomised: 28
Laparoscopic (
n
= 13) versus
open (n
= 15)
Additional information
: 
4 trocars were used; 
all patients underwent
chemoradiation before
surgery
Mean age (range): 59.1 
(31–75) years
Gender (M/F): 9/4
Mean BMI (range)
: 23.5
(21.7–24.6)
Location of cancer
: rectum
Stage of cancer (Aster–Coller)
:
A:
 4
B
1
: 1
B
2
: 5
C
1
: 2
C
2
: 1
D: 0
Mean age (range): 56.4 
(24–78) years
Gender (M/F): 10/5
Mean BMI (range)
: 25.6
(17.1–38.5)
Location of cancer
: rectum
Stage of cancer (Aster–Coller)
:
A:
 1
B
1
: 5
B
2
: 3
C
1
: 2
C
2
: 3
D: 0
Duration of operation
L
ymph node retrieval
Conversion
Abdominal wound
breakdown
Length of hospital stay
R
ecurrence 
CLASICC, 2005
3
Study design:
RCT
Location: UK
R
ecruitment
dates: July 1996 to
July 2002
Follow
-up range
:
1–3 months
Funding: UK
Medical R
esearch
Council
continued
Inclusion criteria: patients
suitable for hemicolectomy
,
left hemicolectomy
, sigmoid
colectomy
, anterior resection
or abdominoperineal resection
Ex
clusion criteria:
adenocarcinoma of the colon,
contraindications to
pneumoperitoneum (chronic
cardiac or pulmonary disease),
acute intestinal obstruction,
malignant disease in the past
5
years, synchronous
adenocarcinoma, pregnancy
and associated gastrointestinal
disease needing surgical
intervention
Number of eligible patients:
794
Number of patients
randomised: 794
Laparoscopic-assisted
(n
=
526) versus open
(n
=
268)
Additional information
:
the trial design required that
every surgeon had
undertaken at least 20
laparoscopic-assisted
resections
Mean age (SD): 69 (11) years
Gender (M/F): 296/230
Mean BMI (SD): 25 (4)
Location of cancer
:
Colon: 273
R
ectum: 253
Stage of cancer (TNM):
T stage:
T0: 4
T1: 26
T2: 68
T3: 261
T4: 70
N stage:
N0: 244
N1: 107
N2: 72
M stage:
M0: 167
M1: 12
Mean age (SD): 69 (12) years
Gender (M/F): 145/123
Mean BMI (SD): 26 (4)
Location of cancer
:
Colon: 140
R
ectum: 128
Stage of cancer (TNM):
T stage:
T0: 1
T1: 12
T2: 35
T3: 136
T4: 33
N stage:
N0: 129
N1: 52
N2: 38
M stage:
M0: 91
M1: 7
Anastomotic leakage
L
ymph node retrieval
Completeness of
resection/margins of
tumour clearance
Conversions
W
ound infection
30-day mortality
Quality of life
P
ostoperative painHealth Technology Assessment 2006; Vol. 10: No. 45
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Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
COL
OR
, 2005
4
Study design:
RCT
Location: Europe
R
ecruitment
dates: March
1997–March 2003
Follow
-up: not
reported
Funding: Ethicon
Endo
-Surgery
(Hamburg,
Germany)
Linked reports:
W
u, 2003,
84
2004
85
Janson, 2004
66
Inclusion criteria: patients with
adenocarcinoma localised in the
caecum, ascending colon, descending
colon or sigmoid colon above the
peritoneal deflection who were age
18 years or older and who gave
written informed consent
Ex
clusion criteria: BMI
>
3
0
kg/m
2
;
adenocarcinoma of the transverse
colon or splenic flexure; metastases
in the liver or lungs; acute intestinal
obstruction; multiple primary
tumours of the colon; scheduled
need for synchronous intra-
abdominal surgery; preoperative
evidence of invasion of adjacent
structures, as assessed by CT
,
magnetic resonance imaging or
ultrasonography; previous epsilateral
colon surgery; previous malignant
disease (except those who had had
curative treatment for basocellular
carcinoma of the skin or 
in situ
carcinoma of the cervix); absolute
contraindications to general
anaesthesia; and a long-term
pneumoperitoneum. After
randomisation, patients were
excluded if metastasis was detected
during surgery
, microscopic
examination of the resected sample
showed no signs of malignant disease,
other malignant disease was
discovered before or during surgery
,
patients needing emergency surgery
or if patients withdrew consent
Number of eligible patients: 1248
Number of patients randomised:
1248
Laparoscopic (
n
= 627; 536
analysed) versus open
(n
=
621; 546 analysed)
153 patients were excluded
post-randomisation, 13 had
missing data
Additional information
:
for laparoscopy
, all surgical
teams had done at least 20
laparoscopic-assisted
colectomies. All open
surgeries were done by
surgical teams who had at
least one staff member
with credentials in colon
surgery
Median age (range): 71
(27–92) years
Gender (M/F): 326/301
Median BMI (range)
: 24.5
(12.1–37.1) 
Location of cancer
:
Right colon: 259
Left colon: 57
Sigmoid colon: 199
Other: 21
Stage of cancer (TNM):
I: 129
II: 218
III: 181
Data were missing for some
patients
Median age (range): 71
(31–95) years
Gender (M/F): 336/285
Median BMI (range)
: 24.9
(14.5–40.5)
Location of cancer
:
Right colon: 253
Left colon: 56
Sigmoid colon: 212
Other: 25
Stage of cancer (TNM):
I: 125
II: 239
III: 175
Data were missing for some
patients
Duration of operation
Blood loss
Abdominal wound
breakdown
L
ymph node retrieval
Conversion
W
ound infection
Urinary tract infection
Length of hospital stay
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Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
COST
, 2004
2
Study design:
RCT
Location: USA
R
ecruitment
dates: August
1994–August 2001
Median Follow
-
up
: 4.4 years
Funding: National
Cancer Institute
Linked reports:
Nelson, 2001,
73
2004
74
Stocchi, 2005
81
W
eeks, 2002
82
Winslow
, 2002
83
Y
oung-Fadok,
2005
86
Inclusion criteria: clinical diagnosis
of adenocarcinoma of the colon
(histological confirmation was
required at surgery), an age of at
least 18 years and the absence of
prohibitive abdominal adhesions
Ex
clusion criteria: advanced local
or metastatic disease, rectal or
transverse colon cancer
, acute bowel
obstruction or perforation from
cancer and severe medical illness.
Inflammatory bowel disease, familial
polyposis, pregnancy or concurrent
or previous malignant tumour
Number of eligible patients: 872
Number of patients randomised:
872
Laparoscopic-assisted
(n
=
435) versus open
(n
=
437; 428 analysed, 
9 excluded post-
randomisation)
Additional information
:
66 credentialed surgeons at
48 institutions. Each
surgeon had performed at
least 20 laparoscopic-
assisted colorectal
operations
Length of incisions was 18
(3–35) cm in the open
group and 6 (2–35) cm in
the laparoscopic-assisted
group
Median age (range): 70
(28–96) years
Gender (M/F): 223/212
Location of cancer
: 
Right colon: 237
Left colon: 32
Sigmoid colon: 166
Stage of cancer (TNM):
0: 20
I: 153
II: 136
III: 112
IV
: 10
Unknown: 4
Median age (range): 69
(29–94) years
Gender (M/F): 208/220
Location of cancer
: 
Right colon: 232
Left colon: 32
Sigmoid colon: 164
Stage of cancer (TNM):
0: 33
I: 112
II: 146
III: 121
IV
: 16
Unknown: 0
Duration of operation
L
ymph node retrieval
Conversion
30-day mortality
Length of hospital stay
Disease-free survival
R
ecurrence
Number of ports used
for laparoscopic
resection
W
ound infection
Incidence of incisional
hernia
Survival
P
ostoperative pain
Quality of life
continued
Curet, 2000
48
Study design:
RCT
Location: USA
R
ecruitment
dates: January
1993–November
1995
Follow
-up range
:
2.5–63 months
(mean: 4.9 years)
Funding: not
reported
Inclusion criteria: patients with
colon cancer
Exclusion criteria: individuals
undergoing colostomy placement
alone or its removal, patients aged
<18 years, concurrent pregnancy
,
complete colon obstruction resulting
in significant proximal distention and
the presence of malignant fistulisation
or fixation in adjacent tissues 
Number of eligible patients: 43
Number of patients randomised:
43
Laparoscopic-assisted
(n
=
25) versus open
(n
=
18)
Additional information
:
all surgery was performed
either by attending
surgeons or residents
under direct supervision.
All attending surgeons had
performed multiple
laparoscopically assisted
colectomies for benign
disease and palliation
before participation in this
study
. A total of 4 and 5
laparoscopic trocars were
used
Mean age (range): 65.6
(45–83); converted: 66.3
(51–76)
Gender (M/F): 11/7;
converted: 4/3
Location of cancer
(conversion):
Right colon: 6 (4)
Left colon: 1 (1)
Sigmoid colon: 7 (1)
Low anterior resection: 4 (1)
Stage of cancer (Dukes)
(conversion):
A
: 1 (0)
B: 10 (2)
C: 7 (3)
D: 0 (2)
Mean age (range): 69.2
(49–82) years
Gender (M/F): 14/4
Location of cancer
:
Right colon: 5
Left colon: 5
Sigmoid colon: 3
Low anterior resection: 5
Stage of cancer (Dukes)
:
A:
 0
B: 2
C: 3
D: 2
Duration of operation
Blood loss
L
ymph node retrieval
Conversion
Infection
Length of hospital stay
R
ecurrence
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Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
Hasegawa, 2003
49
Study design:
RCT
Location: Japan
R
ecruitment
dates: June
1998–October
2000
Follow
-up: not
reported
Funding: not
reported
Linked report:
Hasegawa, 2001
65
Inclusion criteria: patients with
preoperative diagnosis of T
2
or T
3
colorectal cancer (N
0
) who
underwent curative surgery
Ex
clusion criteria: patients with T
2
and T
1
tumours. P
atients with T
3
tumours in the upper and lower
rectum. P
atients with T
3
tumours in
the transverse colon 
Number of eligible patients: 97
Number of patients randomised:
59
Laparoscopic (
n
= 29; 24
analysed) versus open
(n
=
30; 26 analysed)
Additional information
:
length of incision was 5.9
(3–12) cm in the
laparoscopic group
compared with 17.8
(12–23) cm in the open
group; 5-port technique in
the laparoscopic group and
bowel was delivered
through a small wound and
divided extra-corporeally
Mean age (range): 61 (33–75)
years
Gender (M/F): 14/10
Location of cancer
:
Caecum: 1
Ascending colon: 7
Descending colon: 1
Sigmoid colon: 13
R
ectosigmoid junction: 2
Stage of cancer (Dukes)
:
A:
 2
B: 14
C: 8
D: 0
Mean age (range): 61 (37–78)
years
Gender (M/F): 18/8
Location of cancer
:
Caecum: 8
Ascending colon: 4
Descending colon: 0
Sigmoid colon: 12
R
ectosigmoid junction: 2
Stage of cancer (Dukes)
:
A:
 1
B: 16
C: 9
D: 0
Duration of operation
Blood loss
Anastomotic leakage
L
ymph node retrieval
Conversion
W
ound infection
Length of hospital stay
R
ecurrence
K
aiser
, 2004
51
Study design:
RCT
Location: USA
R
ecruitment
dates: January
1995–February
2001
Follow
-up range
:
3–69 months
(median:
35
months)
Funding: not
reported
Inclusion criteria: patients
diagnosed with colon cancer and
scheduled for an elective colon
resection, elective surgery in curative
intent, primary right, left or sigmoid
colon adenocarcinoma, age >18
years, ability to participate in follow
-
up evaluation, American Society of
Anaesthesiology class I–III
Ex
clusion criteria: emergency or
urgent surgery (acutely obstructed or
perforated colon cancer), tumour
Stage IV
, rectal or transverse colon
cancer
, known prohibitive adhesions
from previous abdominal surgery
,
A
SA class IV
, V
, associated
gastrointestinal disease (Crohn
’s
disease, chronic ulcerative colitis,
F
AP), pregnancy 
Number of eligible patients: 49
Number of patients randomised:
49
Laparoscopic-assisted
(n
=
28; 13 were
converted) versus open
(n
=
20)
Additional information
:
surgical teams headed by
two surgeons who had
previously demonstrated
experience in laparoscopic-
assisted colon surgery for
either benign or malignant
disease before participation
in this study
Mean age (range): 59.0
(4–83); converted: 60.5 
(48–68) years
Gender (M/F): 7/8; converted:
5/8
Location of cancer;
conversion:
Caecum: 3; 3
Ascending colon: 6; 4
Sigmoid colon: 6; 6
Stage of cancer; conversion:
I: 2; 2
II: 10; 5
III: 3; 2
IV
: 0; 4
Mean age (range): 60.5
(42–80) years
Gender (M/F): 9/11
Location of cancer
:
Caecum: 6
Ascending colon: 6
Sigmoid colon: 8
Stage of cancer:
I: 7
II: 3
III: 10
IV
: 0
Additional information
:
patients in this group had
significantly more advanced
disease than the intervention
group
Duration of operation
Blood loss
L
ymph node retrieval
Conversion
Infection
Length of hospital stay
R
ecurrence
Survival
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Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
King, 2006
40
Study design: RCT
Location: UK
R
ecruitment dates
:
January 2002–March 2004
Follow
-up: not reported
Funding: NHS
Developments in the
Organisation of Care
P
roject Grant
Inclusion criteria: patients diagnosed
with adenocarcinoma of the colon or
rectum. P
atients with transverse 
colon carcinomas and those who had
had another cancer within the
preceding 5 years
Ex
clusion criteria: any non-elective
admission, those with preoperative
evidence of haematogenous
metastases, patients less than 18
years
old, those who were pregnant and
patients who did not consent to
randomisation. P
atients not able to
have epidural anaesthetic 
Number of eligible patients: 94
Number of patients randomised: 62
Laparoscopic-assisted 
(n
= 43; 41 analysed)
versus open (n
= 19) 
Additional information
:
Laparoscopic-assisted and
open surgeries are both
embedded in an enhanced
recovery programme
Mean age (SD): 72.3 
(11) years
Gender (M/F): 23/18
Body weight (SD): 26.1 
(3.8) kg
Location of cancer
:
Colon: 27
R
ectum: 14
Stage of cancer (Dukes)
:
A:
 9
B: 19
C
1
: 11
C
2
: 2
Mean age (SD): 70.4 
(10.5) years
Gender (M/F): 8/11
Body weight (SD): 27.2 
(4.6) kg
Location of cancer
:
Colon: 14
R
ectum: 5
Stage of cancer (Dukes)
:
A:
 1
B: 11
C
1
: 6
C
2
: 1
Duration of operation
Blood loss
Abdominal wound
breakdown
Anastomotic leakage
Conversion
W
ound infection
Length of hospital stay
Quality of life
Lacy
, 2005
22
Study design: RCT
Location: Spain
R
ecruitment dates
:
November 1993–July
1998
Follow
-up range
: 
27–85 months (median:
43 months)
Funding: Fonde de
Investigaciones Sanitarias,
Ministerio de Ciencia y
T
ecnologia and Agencia
d’A
valuacio de T
ecnologia
Medica of the Generalitat
de Catalunya
Linked reports:
Delgado, 2000,
63
2001
64
Lacy
, 1995,
68
1998,
69
2001,
67
2002
70
Inclusion criteria: adenocarcinoma
of the colon, 15 cm above the anal
verge
Ex
clusion criteria: cancer located at
the transverse colon, distant
metastasis, adjacent organ invasion,
intestinal obstruction, past colonic
surgery and no consent to participate
in the study
Number of eligible patients: 442
Number of patients randomised:
219
Laparoscopic-assisted 
(n
= 111) versus open 
(n
= 108) 
Additional information
:
both laparoscopic-assisted
and open colectomies were
done by a single
gastrointestinal surgical
team with wide experience
in laparoscopic procedures
After surgery
, 68 (61%) of
the laparoscopic assisted
group received adjuvant
chemotherapy according to
the established protocol
Mean age (SD): 68 (12)
years
Gender (M/F): 56/55
Location of cancer
:
Caecum: 32
Ascending colon: 7
Hepatic flexure: 10
Descending colon: 8
Sigmoid colon: 54
Stage of cancer (TNM):
I: 27
II: 42
II: 37
IV
: 5
Mean age (SD): 71 (11)
years
Gender (M/F): 50/58
Location of cancer
:
Caecum: 21
Ascending colon: 17
Hepatic flexure: 11
Descending colon: 11
Sigmoid colon: 48
Stage of cancer (TNM):
I: 18
II: 48
III: 36
IV
: 6
Duration of operation
Blood loss
Anastomotic leakage
Infection
Length of hospital stay
R
ecurrence
P
ort-site metastasis 
Time to recurrence
Survival
Disease-free survival
Opposite method
initiated
continuedHealth Technology Assessment 2006; Vol. 10: No. 45
111
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
Leung, 2004
53
Study design: RCT
Location: Hong K
ong
R
ecruitment dates
:
September
1993–October 2002
Follow
-up: median
(IQR):
Laparoscopic group 52.7
(38.9) months
Open group 49.2 (35.4)
months
Funding: not reported
Linked reports:
Leung, 2000,
71
2003
72
Inclusion criteria: patients diagnosed
to have rectosigmoid carcinoma seen
in P
rince of W
ales Hospital, Hong
K
ong. F
rom July 1995 onwards,
patients from United Christian
Hospital, Hong K
ong, were included 
Ex
clusion criteria: patients with
distal tumour requiring anastomosis
within 5 cm of the dentate line,
patients with tumours larger than
6
cm or with tumour infiltration to
the adjacent organs on sonography or
CT
, patients with previous abdominal
operations near the field of the
colorectal operation, patients who
did not give consent to the
procedure and patients with intestinal
obstruction or perforation
Number of eligible patients: 825
Number of patients randomised:
403
Laparoscopic (
n
= 203)
versus open (n
= 200) 
Additional information
:
the operations were
performed by surgeons
experienced in both
laparoscopic and colorectal
surgery
Mean age (SD): 67.1
(11.7) years
Gender (M/F): 104/99
Location of cancer
:
rectosigmoid junction
Stage of cancer (TNM):
I: 31
II: 72
III: 64
IV
: 36
Mean age (SD): 66.5
(12.3) years
Gender (M/F): 114/86
Location of cancer
:
rectosigmoid junction
Stage of cancer (TNM):
I: 28
II: 73
III: 69
IV
: 30
Duration of operation
Blood loss
Anastomotic leakage
L
ymph node retrieval
Completeness of
resection/margins of
tumour clearance
Conversion
W
ound infection
Urinary tract infection
30-day mortality 
P
ostoperative pain
Survival
Disease-free survival
R
ecurrence
Neudecker
, 2003
55
Study design: RCT
Location: Germany
R
ecruitment dates
:
April 1999–August 2000
Follow
-up: not reported
Funding: Deutsche
Forschunsgemeinschaft
Linked report:
Neudecker
, 2002
75
Inclusion criteria: patients
scheduled to elective colorectal
cancer resection. Only
sigmoidectomies, anterior rectal
resections and right hemicolectomies
Ex
clusion criteria: emergency
surgery
, operative risk greater than
A
SA class III; coagulopathy
,
trombopathy
, or history of
thromboembolic complications;
tumour size >8
cm in preoperative
CT scan, BMI > 30
kg/m
2
;
intraabdominal abscess or sepsis
Number of eligible patients: 30
Number of patients randomised:
30
Laparoscopic (
n
= 14)
versus open (n
= 16)
Median age (range): 62
(46–76) years
Gender (M/F): 7/7
BMI (range): 25.7
(21.3–28.5) 
Location of cancer
:
Right colon: 3
Sigmoid colon: 11
Median age (range): 64
(52–82) years
Gender (M/F): 10/6
BMI (range): 26.2
(22.7–29.6)
Location of cancer
:
Right colon: 4
Sigmoid colon: 12
Duration of operation
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P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
T
ang, 2001
58
Study design: RCT
Location: Singapore
R
ecruitment dates
:
March 1997–August 1999
Follow
-up: not reported
Funding: National
Medical R
esearch Council
Inclusion criteria: patients with
clinical diagnosis of colorectal cancer
based on colonoscopy or barium
enema following histological
confirmation. At least 18 years old
and suitable for elective surgical
resection or abdominoperineal
resection
Ex
clusion criteria: adenocarcinoma
of the transverse colon, any
contraindications to
pneumoperitoneum, acute intestinal
obstruction, any malignancy within
the previous 5 years, synchronous
multiple adenocarcinomas and
pregnancy
Number of eligible patients: 236
Number of patients randomised:
236
Laparoscopic (
n
= 118)
versus open (n
= 118) 
Additional information
:
incision length was 9 
(1–40) cm for the
laparoscopic group and 15
(5–40) cm for the open
group
Median age (range): 64
(33–87) years
Gender (M/F): 61/57
Location of cancer
: colon
Stage of cancer (Dukes)
:
A:
 9
B: 45
C: 42
D: 14
Histopathological
examination not performed
in some patients
Median age (range): 62
(31–89) years
Gender (M/F): 70/48
Location of cancer
: colon
Stage of cancer (Dukes)
:
A:
 8
B: 50
C: 43
D: 11
Histopathological
examination not performed
in some patients
Duration of operation
Anastomotic leakage
Conversion
W
ound infection
Urinary tract infection
Vignali, 2004
59
Study design: RCT
Location: Italy
R
ecruitment dates
:
from February 2001
Funding: not reported
Linked report:
Braga, 2002
62
Inclusion criteria: age at least
18
years and suitability for elective
surgery
Ex
clusion criteria: cancer infiltrating
adjacent organs as assessed by CT or
magnetic resonance imaging,
cardiovascular dysfunction (New
Y
ork Heart Association class >3),
respiratory dysfunction (arterial 
PO
2
< 70
mmHg), hepatic
dysfunction (Child–Pugh class C),
ongoing infection and plasma
neutrophil level less than 2.0 
×
10
9
/l
Number of eligible patients: 384
Number of patients randomised:
384
Laparoscopic (
n
= 190
including 144 with cancer)
versus open (n
= 194
including 145 with cancer) 
Location of cancer
:
Right colon: 48
T
ransverse colon: 2
Descending colon: 27
Sigmoid colon: 21
R
ectum: 48
Stage of cancer (TNM):
I: 34
II: 38
III: 57
IV
: 15
Location of cancer
:
Right colon: 44
T
ransverse colon: 2
Descending colon: 25
Sigmoid colon: 23
R
ectum: 49
Stage of cancer (TNM):
I: 32
II: 35
III: 64
IV
: 14
L
ymph node retrieval
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Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
Zhou, 2004
60
Study design: RCT
Location: China
R
ecruitment dates
: June
2001–September 2002
Follow
-up range
: 
1–16 months 
Funding: National
Outstanding Y
outh
Foundation of China
Inclusion criteria: patients
diagnosed with rectal carcinoma,
with the lowest margin of tumour
located under the peritoneal
reflection and 1.5 cm above the
dentate line. Obese patients and
those with a history of inferior
abdominal surgery
, hypertension
(blood pressure well controlled),
chronic cholecystitis or/and
cholecystolithiasis, pediculotorsion of
ovarian cysts and multiple primary
rectal cancer
Ex
clusion criteria: patients
diagnosed with low rectal cancer of
other pathological type (e.g.
lymphoma), those with the lowest
margin of tumour within 1.5 cm
above the dentate line, those in
emergency situations (e.g. acute
obstruction during enema,
haemorrhage, and perforation), those
in Dukes’ stage D with local
infiltration affecting adjacent organs
and those unwilling to take part in
the study
Number of eligible patients: 171
Number of patients randomised:
171
Laparoscopic (
n
= 82)
versus open (n
= 89) 
Additional information
:
all 171 patients underwent
total mesorectal excision
and anal sphincter
preservation. Both
laparoscopic and open
procedures were
performed by 4 colon and
rectal surgeons
Mean age (range): 44
(26–85) years
Gender (M/F): 46/36 
Stage of cancer (Dukes)
:
A:
 5
B: 10
C
1
: 33
C
2
: 30
D: 4
Mean age (range): 45
(30–81) years
Gender (M/F): 43/46
Stage of cancer (Dukes)
:
A:
 6
B: 8
C
1
: 35
C
2
: 33
D: 7
Duration of operation
Blood loss
Anastomotic leakage
Infection
Length of hospital stay
R
ecurrence Appendix 8
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R
andomised controlled trials published before 2000
Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
Hewitt, 1998
50
Study design: RCT
Location: Hong K
ong
R
ecruitment dates
: not
reported
Follow
-up: not reported
Funding: Chinese
University of Hong K
ong
Ex
clusion criteria: Age older than
80 years, previous abdominal surgery
,
a rectal tumour less than 10 cm from
the anal verge, advanced local
disease, evidence of metastatic
disease, concurrent debilitating
disease or infection, administration of
any immune-modulating drugs, blood
or blood products within 6 months of
surgery
Number of eligible patients: 25
Number of patients randomised:
16
Laparoscopic-assisted
(n
=
8) versus open (n
=8
)
Additional information
:
all operations were
performed by surgeons
who had significant
experience with both
laparoscopic and open
techniques
Median age (range): 54
(40–72) years
Gender (M/F): 4/4
Location of cancer
: 
T
ransverse colon: 1
Sigmoid colon: 4
Anterior resection : 3
Stage of cancer (Dukes)
:
A:
 1
B
1
: 1
B
2
: 2
C
1
: 1
C
2
: 3
Median age (range): 70
(38–77) years
Gender (M/F): 3/5
Location of cancer
:
Sigmoid colon: 4
Anterior resection: 3
Left hemicolectomy: 1
Stage of cancer (Dukes)
:
A:
 1
B
1
: 2
B
2
: 1
C
1
: 1
C
2
: 3
Duration of operation
Length of hospital stay
Kim, 1998
52
Study design: RCT
Location: USA
R
ecruitment dates
: June
1996–May 1997
Follow
-up range
: 
1–12 months
Funding: Minimally
Invasive Surgery Center
,
The Cleveland Clinic
Foundation
Inclusion criteria: patients
diagnosed with colorectal cancer
Ex
clusion criteria: patients who had
a lesion in the lower or middle
rectum that required a sphincter
-
saving operation or a lesion located
at the splenic flexure. If diagnostic
laparoscopy revealed a direct
invasion of cancer to adjacent organs
(en bloc
resection is not suitable using
a laparoscopic technique), distant
metastasis or peritoneal
carcinomatosis, the patient was
excluded
Number of eligible patients: 38
Number of patients randomised:
38
Laparoscopic (
n
= 19)
versus open (n
= 19) 
Median age (range): 70
(43–84) years
Gender (M/F): 8/11
Location of cancer
: 
Right colectomy: 9
Extended right colectomy: 2
Left colectomy: 0
P
roctosigmoidectomy: 8
Stage of cancer (TNM): 
I: 7
II: 3
III: 9
Median age (range): 65
(40–81) years
Gender (M/F): 8/10
Location of cancer
:
Right colectomy: 7
Extended right colectomy: 1
Left colectomy: 1
P
roctosigmoidectomy: 9
Stage of cancer:
I: 9
II: 3
III: 6
T
umour recurrence
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Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
Milsom, 1998
54
Study design: RCT
Location: USA
R
ecruitment dates
:
October 1993–July 1997
Follow
-up range
: 
1.5–48 months (median in
the laparoscopic group:
1.5 years; median in the
open group: 1.7 years)
Funding: US Surgical
Corporation and the
Minimally Invasive Surgery
Center of The Cleveland
Clinical Foundation
Inclusion criteria: curative elective
surgery
, primary right or sigmoid
colon cancer or polyps, upper or
lower primary rectal cancers or
polyps, American Society of
Anaesthesiology class I–III, aged
>18
years
Ex
clusion criteria: emergency or
urgent surgery
, evidence for
dissemination disease or adjacent
organ invasion, primary tumour size
>8
cm in cancer or polyps,
BMI
>32
kg/m
2
Number of eligible patients: 109
Number of patients randomised:
109
Laparoscopic (
n
= 55,
including 42 with cancer)
versus open (n
= 54,
including 38 with cancer) 
Additional information
:
incision length in the
intervention group was 
15 ±
1.5 versus 22 ±
5 cm
in the comparator group
Median age (range): 69
(41–89) years
Gender (M/F): 26/29
Stage of cancer (TNM):
I: 10
II: 13
II: 16
IV
: 3
Median age (range): 69
(44–86) years
Gender (M/F): 36/18
Stage of cancer (TNM):
I: 9
II: 11
III: 14
IV
: 4
Duration of operation
Blood loss
L
ymph node retrieval
a
Completeness of
resection
a
Conversion
Length of hospital stay
30-day mortality 
R
ecurrence
a
a
Cancer patients only
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Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
Schwenk, 1998a
56
Study design: RCT
Location: Germany
R
ecruitment dates
: May
1995–November 1996
Follow
-up: not reported
Funding: not reported
Linked reports:
Bohm, 1999
61
Ordemann, 2001
76
Schwenk, 1998b,
77
1998c,
78
1999,
79
2000
80
Inclusion criteria: colorectal
tumour
, elective resection by right
colectomy
, sigmoid resection,
anterior rectum resection or
abdominoperineal rectum extirpation
Ex
clusion criteria: rectum
carcinoma within 12 cm of the anus,
scheduled for sphincter
-preserving
anterior rectum resection with total
mesorectal excision, tumour of the
transverse colon or flexures
scheduled for extended colectomy
,
tumour infiltration of adjacent organs,
anaesthesia risk >A
SA III, scheduled
for abdominoperineal rectum
extirpation with dynamic gracilis
plasty
, excessive obesity with
BMI
>32 kg/m
2
, pronounced
peritoneal adhesions from previous
interventions, synchronous second
tumour in extracolonic location,
coagulopathy not responding to
treatment; intestinal obstruction,
transverse tumour diameter >8 cm
on CT
, immunopathy
, pregnancy
Number of eligible patients: 60
Number of patients randomised:
60
Laparoscopic (
n
= 30)
versus open (n
= 30)
Mean age ±
SD: 63.3 ±
12.2 years
Gender (M/F): 14/16
Location of cancer
:
Right colectomy: 4 
Sigmoid resection: 15 
Abdominal peritoneal
extirpation: 4
R
ectum: 7
Stage of cancer (TNM):
0: 1
I: 9
II: 12
III: 6
IV
: 2
Mean age ±
SD: 64.8 ±
14.7 years
Gender (M/F): 16/14
Location of cancer
:
Right colectomy: 3
Sigmoid resection: 17 
Abdominal peritoneal
extirpation: 3
R
ectum: 7
Stage of cancer (TNM):
0: 3
I: 8
II: 5
III: 8
IV
: 6
Duration of operation
Infection
Length of hospital stay
P
ostoperative pain
Quality of life
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Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
Stage, 1997
57
Study design: RCT
Location: Denmark
R
ecruitment dates
: not
reported
Follow
-up range
: 
7–19 months (median: 
14 months)
Funding: not reported
Ex
clusion criteria: patients with
preoperative signs of extensive local
tumour growth, as judged from these
investigations, and patients scheduled
for low anterior resection and
abdominoperineal resection, patients
randomised to laparoscopic surgery
in whom the operation was
converted to open surgery 
Number of eligible patients: 34
Number of patients randomised:
29
Laparoscopic (
n
= 15)
versus open (n
= 14) 
Additional information
:
incision for tumour removal
3–5
cm
Median age (range): 72
(61–93) years
Gender (M/F): 8/7
Location of cancer
:
Right side colon: 7
Left side colon: 2
Sigmoid resection: 6
Stage of cancer (Dukes)
:
A:
 3
B: 8
C: 2
D: 2
Median age (range): 73
(48–87) years
Gender (M/F): 5/9
Location of cancer
:
Right side colon: 7
Left side colon: 3
Sigmoid resection: 4
Stage of cancer (Dukes)
:
A:
 4
B: 4
C: 2
D: 4
Duration of operation
Conversion
Blood loss
L
ymph node retrieval
Number of ports used
Completeness of
resection
Length of hospital stay
P
ostoperative pain
R
ecurrence
Individual patient data meta-analysis
Study details 
P
articipant characteristics
Intervention/comparator
Intervention population 
Comparator population 
Outcomes
characteristics
characteristics
Bonjer
, 2005
(unpublished)
Study design: individual
patient data meta-analysis
Location: multicenter
R
ecruitment dates
:
before April 2000
Follow
-up: 
[Academic-
in-confidence
information removed.]
Funding: not reported
Inclusion criteria: randomised
clinical trials comparing laparoscopic
and open surgery for colonic cancer
.
Only trials which accrued more than
150 patients with colonic cancer
were included: Barcelona, CLA
SICC,
COST and COL
OR trials
[Academic-in-confidence
information removed.]
Additional information
:
the different trials
contributed to the meta-
analysis as follows: 
[Academic-in-confidence
information removed.]
[Academic-in-confidence
information removed.]
[Academic-in-confidence
information removed.]
[Academic-in-
confidence
information
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Appendix 9
Results of meta-analysis: laparoscopic resection
versus conventional open resection
Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome: 01  Duration of operation
Study
or subcategory NN
 Laparoscopic
Mean (SD)
 Open
Mean (SD)
WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
Lacy, 2002
Leung, 2004
Schwenk 1998
Total (95% CI)
Test for heterogeneity: 2 = 12.61, df = 2 (p = 0.002), I2 = 84.1%
Test for overall effect: z = 9.70 (p < 0.00001)
111 142.00 (52.00)  108  118.00 (45.00)
203 189.90 (55.40)  200  144.20 (57.80)
  30 219.00 (64.00)    30  146.00 (41.00)
344   338
38.78
52.54
8.68
100.00
24.00 (11.13 to 36.87)
45.70 (34.64 to 56.76)
73.00 (45.80 to 100.20)
39.65 (31.64 to 47.67)
Laparoscopic Open
–100 –50 0 50 100
Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair (random effects model)
Outcome: 01  Duration of operation
Study
or subcategory NN
 Laparoscopic
Mean (SD)
 Open
Mean (SD)
WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
Lacy, 2002
Leung, 2004
Schwenk 1998
Total (95% CI)
Test for heterogeneity: 2 = 12.61, df = 2 (p = 0.002), I2 = 84.1%
Test for overall effect: z = 3.93 (p < 0.0001)
111 142.00 (52.00)  108  118.00 (45.00)
203 189.90 (55.40)  200  144.20 (57.80)
  30 219.00 (64.00)    30  146.00 (41.00)
344   338
36.53
37.73
25.74
100.00
24.00 (11.13 to 36.87)
45.70 (34.64 to 56.76)
73.00 (45.80 to 100.20)
44.80 (22.43 to 67.16) 
Laparoscopic Open
–100 –50 0 50 100
Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome:  02  Anastomotic leakage
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
CLASICC, 2005
COLOR
Hasegawa, 2003
King, 2006
Lacy, 2002
Leung, 2004
Tang, 2001
Zhou, 2004
Total (95% CI)
Total events: 55 (Laparoscopic), 34 (Open)
Test for heterogeneity: 2 = 5.73, df = 6 (p = 0.45), I2 = 0%
Test for overall effect: z = 0.55 (p = 0.58)
35/526 13/268
15/535 10/545
  0/24    0/26
  1/41    1/19
  0/111     2/108
  1/203    4/200
  2/118    1/118
  1/82    3/89
     1640     1373
44.23
25.44
3.51
6.51
10.35
2.57
7.39
100.00
1.37 (0.74 to 2.55)
1.53 (0.69 to3.37)
Not estimable
0.46 (0.03 to 7.02)
0.19 (0.01 to 4.01)
0.25 (0.03 to 2.18)
2.00 (0.18 to 21.76)
0.36 (0.04 to 3.41)
1.13 (0.74 to 1.73)
Laparoscopic Open
0.001 0.01 0.1 1 10 100 1000Appendix 9
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Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome:  03 Abdominal wound breakdown     
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
Araujo, 2003
COLOR
King, 2006
Total (95% CI)
Total events: 7 (Laparoscopic), 11 (Open)
Test for heterogeneity: 2 = 2.80, df = 2 (p = 0.25), I2 = 28.7%
Test for overall effect: z = 1.03 (p = 0.30)
  4/13    3/15
  2/534    7/544
  1/41    1/19
     588       578
25.12
62.55
12.33
100.00
1.54 (0.42 to 5.64)
0.29 (0.06 to 1.39)
0.46 (0.03 to 7.02)
0.63 (0.26, 1.52)
Laparoscopic Open
0.01 0.01 1 10 1000
Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome: 05  Completeness of resection –  positive resection margins
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
CLASICC, 2005
COLOR
Milsom, 1998
Zhou, 2004
Total (95% CI)
Total events: 56 (Laparoscopic), 30 (Open)
Test for heterogeneity: 2 = 0.09, df = 1 (p = 0.76), I2 = 0%
Test for overall effect: z = 0.62 (p = 0.53)
46/439 20/228
10/526 10/538
  0/42    0/42
  0/82    0/89
     1089       897
72.70
27.30
100.00
1.19 (0.72 to 1.97)
1.02 (0.43 to 2.44)
Not estimable
Not estimable
1.15 (0.74 to 1.77)
Laparoscopic Open
0.1 0.2 0.5 1 2 5 10
Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome: 04  Lymph node retrieval
Study
or subcategory NN
 Laparoscopic
Mean (SD)
 Open
Mean (SD)
WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
Lacy, 2002
Leung, 2004
Vignali, 2004
Total (95% CI)
Test for heterogeneity: 2 = 1.18, df = 2 (p = 0.55), I2 = 0%
Test for overall effect: z = 0.80 (p =0.42)
111  11.10 (7.90)  108  11.10 (7.40)
203  11.10 (7.90)  200  12.10 (7.10)
144  15.20 (8.60)  145  15.00 (7.70)
458   453
24.57
46.95
28.48
100.00
  0.00 (–2.03 to 2.03)
–1.00 (–2.47 to 0.47)
  0.20 (–1.68 to 2.08)
–0.41 (–1.42 to 0.59)
Laparoscopic Open
–10 –5 0 5 10Health Technology Assessment 2006; Vol. 10: No. 45
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Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome: 06  Wound infection
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
CLASICC, 2005
COLOR
Curet,  2000
Hasegawa, 2003
King, 2006
Lacy, 2002
Leung, 2004
Tang, 2001
Winslow, 2002 (COST) 
Total (95% CI)
Total events: 96 (Laparoscopic), 86 (Open)
Test for heterogeneity: 2 = 9.64, df = 8 (p = 0.29), I2 = 17.0%
Test for overall effect: z = 1.05 (p = 0.29)
47/526 22/268
20/535 16/545
  2/25    1/18        
  1/24    3/26
  1/41    3/19
  8/111  18/108
  9/203  15/200              
  3/118    3/118
  5/37    5/46
    1620      1348
31.02
16.87
1.24
3.07
4.36
19.42
16.08
3.19
4.74
100.00
1.09 (0.67 to 1.77)
1.27 (0.67 to 2.43)
1.44 (0.14 to 14.69)
0.36 (0.04 to 3.24)
0.15 (0.02 to 1.39)
0.43 (0.20 to 0.95)
0.59 (0.26 to 1.32)
1.00 (0.21 to 4.85)
1.24 (0.39 to 3.97)
0.86 (0.64 to 1.14)
Laparoscopic Open
0.01 0.1 1 10 100
Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome: 07  Urinary tract infections
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
COLOR
Curet, 2000
Kaiser, 2004
Lacy, 2002
Leung, 2004
Schwenk, 1998 
Tang, 2001
Total (95% CI)
Total events: 25 (Laparoscopic), 21 (Open)
Test for heterogeneity: 2 = 2.41, df = 6 (p = 0.88), I2 = 0%
Test for overall effect: z = 0.49 (p = 0.62)
12/535 13/545
  1/25    0/18        
  1/28    0/19
  1/111    0/108
  8/203    7/200
  2/30    0/30   
  0/118    1/118
    1050      1039
54.58
2.45
2.46
2.15
29.89
2.12
6.36
100.00
0.94 (0.43 to 2.04)
2.19 (0.09 to 50.93)
2.17 (0.09 to 50.74)
2.92 (0.12 to 70.89)
1.13 (0.42 to 3.05)
5.00 (0.25 to 99.95)
0.33 (0.01 to 8.10)
1.15 (0.66, 1.98)
Laparoscopic Open
0.01 0.1 1 10 100
Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome: 08  Operative mortality
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
Curet, 2000
Lacy, 2002
Leung, 2004
Total (95% CI)
Total events: 6 (Laparoscopic), 7 (Open)
Test for heterogeneity: 2 = 1.02, df = 1 (p = 0.31), I2 = 2.0%
Test for overall effect: z = 0.31 (p = 0.75)
  0/25    0/18        
  1/111    3/108
  5/203    4/200
    339      326
43.01
56.99
100.00
Not estimable
0.32 (0.03 to 3.07)
1.23 (0.34 to 4.52)
0.84 (0.29 to 2.47)
Laparoscopic Open
0.01 0.1 1 10 100Appendix 9
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Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome:  08 30-day mortality
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
COLOR
COST
King, 2006
Total (95% CI)
Total events: 9 (Laparoscopic), 15 (Open)
Test for heterogeneity: 2 = 0.07, df = 2 (p = 0.97), I2 = 0%
Test for overall effect: z = 1.35 (p = 0.18)
  6/535  10/545
  2/435    4/428
  1/41    1/19
    1011      992
64.73
26.34
8.93
100.00
0.61 (0.22 to 1.67)
0.49 (0.09 to 2.67)
0.46 (0.03 to 7.02)
0.57 (0.25 to 1.29)
Laparoscopic Open
0.01 0.1 1 10 100
Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome: 09  Length of hospital stay
Study
or subcategory NN
 Laparoscopic
Mean (SD)
 Open
Mean (SD)
WMD (fixed)
95% CI
WMD (fixed)
(95% CI)
Weight
%
COLOR
Lacy, 2002
Schwenk, 1998
Zhou, 2004
Total (95% CI)
Test for heterogeneity: 2 = 42.73, df = 3 (p < 0.00001), I2 = 93.0%
Test for overall effect: z = 9.26 (p < 0.00001)
536  8.20 (6.60)  546  9.30 (7.30)
111  5.20 (5.10)  108  7.90 (9.30)
  30  10.10 (3.00)  30  11.60 (2.00)
  82  8.10 (3.10)  89  13.30 (3.40)
759   773
43.30
7.48
17.87
31.35
100.00
–1.10 (–1.93 to –0.27)
–2.70 (–4.69 to –0.71)
–1.50 (–2.79 to –0.21)
–5.20 (–6.17 to –4.23)
–2.58 (–3.12 to –2.03)
Laparoscopic Open
–10 –5 0 5 10
Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair (random effects model)
Outcome: 09  Length of hospital stay
Study
or subcategory NN
 Laparoscopic
Mean (SD)
 Open
Mean (SD)
WMD (fixed)
95% CI
WMD (fixed)
(95% CI)
Weight
%
COLOR
Lacy, 2002
Schwenk, 1998
Zhou, 2004
Total (95% CI)
Test for heterogeneity: 2 = 42.73, df = 3 (p < 0.00001), I2 = 93.0%
Test for overall effect: z = 2.35 (p = 0.02)
536  8.20 (6.60)  546  9.30 (7.30)
111  5.20 (5.10)  108  7.90 (9.30)
  30  10.10 (3.00)  30  11.60 (2.00)
  82  8.10 (3.10)  89  13.30 (3.40)
759   773
26.45
22.39
25.09
26.07
100.00
–1.10 (–1.93 to –0.27)
–2.70 (–4.69 to –0.71)
–1.50 (–2.79 to –0.21)
–5.20 (–6.17 to –4.23)
–2.63 (–4.82 to –0.44)
Laparoscopic Open
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Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome: 10  Overall survival
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
COST
Curet, 2000
Kaiser, 2004
Lacy, 2002
Leung, 2004
Zhou, 2004
Total (95% CI)
Total events: 684 (Laparoscopic), 655 (Open)
Test for heterogeneity: 2 = 1.98, df = 4 (p = 0.74), I2 = 0%
Test for overall effect: z = 1.07 (p = 0.28)
344/435 333/428
  19/25    12/18
  25/28    19/20
  87/106    78/102
127/167 124/170
  82/82    89/89
       843         827
58.46
2.43
3.86
13.84
21.40
100.00
1.02 (0.95 to 1.09)
1.14 (0.77 to 1.69)
0.94 (0.80 to 1.11)
1.07 (0.93 to 1.23)
1.04 (0.92 to 1.18)
Not estimable
1.03 (0.98 to 1.09)
Laparoscopic Open
0.1 0.2 0.5 1 2 5 10
Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome: 12  Tumour recurrence – total
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
Araujo, 2003
COST
Curet, 2000
Kaiser, 2004
Lacy, 2002
Leung, 2004
Stage, 1997
Total (95% CI)
Total events: 135 (Laparoscopic), 144 (Open)
Test for heterogeneity: 2 = 4.84, df = 4 (p = 0.30), I2 = 17.3%
Test for overall effect: z = 0.77 (p = 0.44)
  0/13    0/13
76/435 84/428
  1/25    1/18
  3/28    1/20
18/106 28/102
37/167 30/170
  0/15    0/14
     789       765
58.29
0.80
0.80
19.64
20.47
100.00
Not estimable
0.89 (0.67 to 1.18)
0.72 (0.05 to 10.76)
2.14 (0.24 to 19.13)
0.62 (0.37 to 1.05)
1.26 (0.82 to 1.93)
Not estimable
0.92 (0.74 to 1.14)
Laparoscopic Open
0.01 0.1 1 10 100
Review: Colorectal cancer
Comparison: 01  Laparoscopic repair vs Conventional open repair
Outcome: 11  Disease-free survival
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
COST
Kaiser, 2004
Lacy, 2002
Leung, 2004
Total (95% CI)
Total events: 513 (Laparoscopic), 496 (Open)
Test for heterogeneity: 2 = 7.27, df = 3 (p = 0.06), I2 = 58.7%
Test for overall effect: z = 0.22 (p = 0.83)
317/435 311/428
  22/28    18/20
  48/53    34/48
126/167 133/170
       683         666
62.45
4.18
7.11
26.26
100.00
1.00 (0.92 to 1.09)
0.87 (0.69 to 1.11)
1.28 (1.05 to 1.56)
0.96 (0.86 to 1.08)
1.01 (0.95 to 1.07)
Laparoscopic Open
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Review: Colorectal  cancer
Comparison:  01 Laparoscopic repair vs Conventional open repair
Outcome:  13 Tumour recurrence – wound
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
COST
Kaiser, 2004
Kim, 1998
Leung, 2004
Total (95% CI)
Total events: 2 (Laparoscopic), 1 (Open)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.55 (p = 0.58)
2/435 1/428
0/28 0/20
0/19 0/19
0/167 0/170
   649     637
100.00
100.00
1.97 (0.18 to 21.62)
Not estimable
Not estimable
Not estimable
1.97 (0.18 to 21.62)
Laparoscopic Open
0.01 0.1 1 10 100
Review: Colorectal  cancer
Comparison:  01 Laparoscopic repair vs Conventional open repair
Outcome: 14  Incisional  hernia
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
Leung, 2004
Winslow, 2002 (COST) 
Total (95% CI)
Total events: 17 (Laparoscopic), 13 (Open)
Test for heterogeneity: 2 = 0.40, df = 1 (p = 0.53), I2 = 0%
Test for overall effect: z = 1.15 (p = 0.25)
8/203 4/200
9/37 9/46
   240     246
33.43
66.57
100.00
1.97 (0.60 to 6.44)
1.24 (0.55 to 2.81)
1.49 (0.76 to 2.92)
Laparoscopic Open
0.001 0.01 0.1 1 10 100 1000
Review: Colorectal  cancer
Comparison:  01 Laparoscopic repair vs Conventional open repair
Outcome:  15 Anastomotic leakage
Study
or subcategory
 Laparoscopic
N/n
 Open
N/n
RR (fixed)
95% CI
RR (fixed)
(95% CI)
Weight
%
01 Colon
 CLASICC,  2005
 COLOR
 Lacy,  2002
 Tang,  2001
Subtotal (95% CI)
Total events: 26 (Laparoscopic), 17 (Open)
Test for heterogeneity: 2 = 1.85, df = 3 (p = 0.60), I2 = 0%
Test for overall effect: z = 0.77 (p = 0.44)
02 Rectum
 CLASICC,  2005
 Zhou,  2004
Subtotal (95% CI)
Total events: 27 (Laparoscopic), 12 (Open)
Test for heterogeneity: 2 = 1.35, df = 1 (p = 0.25), I2 = 26.0%
Test for overall effect: z = 0.64 (p = 0.52)
Total (95% CI)
Total events: 53 (Laparoscopic), 29 (Open)
Test for heterogeneity: 2 = 3.21, df = 5 (p = 0.67), I2 = 0%
Test for overall effect: z = 1.00 (p = 0.32)
  9/273    4/140
15/535 10/545
  0/111    2/108
  2/118    1/118
     1037       911
26/253    9/128
  1/82    3/89
     335       217
     1372       1128
15.76
29.52
7.55
2.98
55.81
35.62
8.57
44.19
100.00
1.15 (0.36 to 3.68)
1.53 (0.69 to 3.37)
0.19 (0.01 to 4.01)
2.00 (0.18 to 21.76)
1.27 (0.70 to 2.31)
1.46 (0.71 to 3.03)
0.36 (0.04 to 3.41)
1.25 (0.63 to 2.46)
1.26 (0.80 to 1.97)
Laparoscopic Open
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Appendix 10
Summary of outcomes reported in converted 
patientsAppendix 10
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Study ID
Laparoscopic
Open
Converted
p-
V
alue
Comments
n
V
alue
n
V
alue
n
V
alue
Duration of operation (minutes)
Curet, 2000
48
18
210 (128–275)
18
138 (95–240)
7
194 (105–485)
<0.05
a
CLA
SICC, 2005
3
345
180 (140–220)
276
135 (100–175)
143
180 (135–223)
Median (IQR)
K
aiser
, 2004
51
15
125 (70–155)
20
65 (45–125)
13
125 (80–270)
<0.05
b
Mean (range)
Blood loss (ml)
Curet, 2000
48
18
284 (100–700)
18
407 (100–1000)
7
683 (100–12000)
<0.05
a
K
aiser
, 2004
51
15
100 (100–300)
20
100 (100–800)
13
200 (100–1000)
Mean (range)
Anastomotic leakage
CLA
SICC, 2005
3
345
20
276
15
143
13
L
ymph node retrieval
Curet, 2000
48
18
11 (2–23)
18
10 (1–21)
7
12 (1–29)
K
aiser
, 2004
51
15
11 (4–26)
20
14 (3–27)
13
16 (1–32)
Mean (range)
W
ound infection
Curet, 2000
48
18
1
18
1
7
1
CLA
SICC, 2005
3
345
24
276
23
143
21
Urinary tract infection
Curet, 2000
48
18
0
18
0
7
1
K
aiser
, 2004
51
15
1
20
0
13
0
Length of hospital stay (days)
Curet, 2000
48
18
5.2
18
7.3
7
8
<0.05
a
CLA
SICC, 2005
3
345
9 (7–13)
276
11 (8–15)
143
12 (9–16)
Median (IQR)
K
aiser
, 2004
51
15
5 (3–8)
20
6 (5–9)
13
7 (5–13)
<0.05
a
Mean (range)
Overall survival
Curet, 2000
48
18
14
18
12
7
6
Follow
-up: 2.5–6.3 years, mean 4.9 years
K
aiser
, 2004
51
15
14
20
19
13
11
Follow
-up: 3–69 months, median 35 months
Disease-free survival
K
aiser
, 2004
51
15
14
20
18
13
8
Follow
-up: 3–69 months, median 35 months
R
ecurrence
Curet, 2000
48
18
0
1
8
1
7
1
Follow
-up: 2.5–6.3 years, mean 4.9 years
K
aiser
, 2004
51
15
0
2
0
1
13
3
Follow
-up: 3–69 months, median 35 months
a
Laparoscopic compared with open procedure.
b
Open compared with laparoscopic procedure.Health Technology Assessment 2006; Vol. 10: No. 45
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Appendix 11
Summary of included economic evaluations
continued
Study identification:
Franks, 2005 (Franks PJ,
Thames Valley University:
personal communication,
2005)
Authors and year
Interventions studied/
comparators
Hypothesis/question
Franks et al., 2005
Laparoscopic resection compared with open resection in the
treatment of colorectal cancer
Total cost to society of laparoscopic resection would be
similar to or less than those of open resection within 
3 months of operation. The authors reported that the
societal perspective was adopted for the analysis
Key elements of the study Type of study
Target population/study sample
Setting
Dates to which data relate
Source of effectiveness data
Modelling
Link between effectiveness
and cost data
A preliminary cost analysis based on an RCT (CLASICC trial)
A subset of the patients recruited to the CLASICC trial.
Included patients were those who agreed to participate in
the quality of life/health economics component or for whom
details of the operative procedure were missing at the time
of the analysis (n = 682 in economic analysis, n = 794 in
trial). Details of inclusion/exclusion criteria not described in
this paper but are described elsewhere (see descriptions of
the CLASICC trial reported earlier)
Secondary care. 27 centres and 32 surgeons, UK
Patients recruited to the trial from 1996
The effectiveness data were derived from the whole sample
(n = 794) of the CLASICC RCT
NA
Costs are derived from a subgroup of the patients included
in the CLASICC trial. Approximately 86% of the whole
sample from CLASICC was included in the economic study.
It is assumed (although not stated) that the costs of those
recruited into the economic study are applicable to the
patients included in the whole study (which provides
evidence on effectiveness)
Details about clinical
evidence: study design
and main outcomes
Eligibility/patient group/study
sample
Study design
Analysis of effectiveness
Effectiveness results/outcome
measures
Clinical conclusions
Details of the eligibility and study sample were not reported
but are provided elsewhere. For details, see the summary of
the CLASSICC trial provided earlier. The data from the
CLASICC trial were stratified by surgeon, site of operation,
presence of liver metastases and preoperative radiotherapy.
Subgroup analysis was conducted by colon and rectum
cancer
A multicentre RCT with 27 centres and 32 surgeons
contributing data
The analysis was done on an intention-to-treat basis. The
primary end-points were resection margins, Dukes’ C
tumours and in-hospital mortality. Secondary outcomes
were complication rates, transfusion requirements and
quality of life up to 3 months after surgery
Details of primary and secondary end-points were not
reported. The results from Franks and colleagues have been
removed from this table as they were supplied as academic-
in-confidence
The results from Franks and colleagues have been removed
from this table as they were supplied as academic-in-
confidenceAppendix 11
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Economic analysis Measure of health benefits
used in the economic analysis
Direct costs
Indirect costs
Currency
Statistical analysis of quantities/
costs
Sensitivity analysis
The results from Franks and colleagues have been removed
from this table as they were supplied as academic-in-
confidence. A cost-analysis was performed
The 682 patients who consented to be part of the economic
study and for whom operative data were available. In
CLASICC, patients were randomised in a 2:1 ratio to either
laparoscopic or open resection and costs were based on
452 patients allocated to laparoscopic resection and 230 to
open resection. The costing was undertaken prospectively
on a subset of the whole trial population. Detailed theatre
resource use was based on a subgroup of patients (10
laparoscopic and 10 open patients for each recruiting
surgeon). These data were used to impute values for the
rest of the sample. Hospital stay was from date of operation
to discharge (or death) plus one day for a preoperative
admission. Stay was divided into intensive, high-dependency
and surgical ward care. Postoperative complications were
obtained for each patient. For complications resulting in
surgery, costs were based on detailed descriptions of the
operation, which included anaesthetic time, length of
hospitalisation (including stay in ICU and HDU). Other
complications were costed according to national figures.
Post-discharge resource use was based on patient-
completed questionnaires. Unit costs were based on
national figures or study specific estimates based on data
from manufacturers. The same unit costs were used for all
patients
Cost of productivity loss was based on the time taken for
individuals to return to employment and costed using
average salary costs for full or part-time workers based on
the Department of Work and Pensions
Pounds sterling. Year not stated but between 2002 and 2004
Non-parametric bootstrap method was used to provide CIs
around each difference in cost for area or resource use and
the difference in total cost
One-way sensitivity analysis on the perioperative costs,
equipment costs, recovery costs, ICU costs and hospital
costs (ward, ICU and HDU). Costs were varied by either
+20% or –20% of base-case values. Subgroup analysis was
conducted by site of the cancer (colon or rectum)
Results Estimated benefits used in the
economic evaluation
Costs results
Synthesis of costs and benefits
Authors’ conclusions
The results from Franks and colleagues have been removed
from this table as they were supplied as academic-in-
confidence
The results from Franks and colleagues have been removed
from this table as they were supplied as academic-in-
confidence
The results from Franks and colleagues have been removed
from this table as they were supplied as academic-in-
confidence
The results from Franks and colleagues have been removed
from this table as they were supplied as academic-in-
confidenceHealth Technology Assessment 2006; Vol. 10: No. 45
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continued
Study identification: 
Janson, 200466
Authors and year
Interventions studied/
comparators
Hypothesis/question
Janson et al., 2004
Laparoscopic colonic resection (LCR) compared with open
colonic resection (OCR) in the treatment of colonic cancer
1. Total cost to society of LCR would be less than those of
OCR within 12 weeks of operation. 2. Higher operating
room costs of LCR would be compensated for by a faster
recovery, shorter duration of hospital stay and reduction in
use of outpatient healthcare resources. The authors
reported that the societal perspective was adopted for the
analysis
Key elements of the study Type of study
Target population/study sample
Setting
Dates to which data relate
Source of effectiveness data
Modelling
Link between effectiveness
and cost data
A CCA based on an RCT (COLOR trial)
A subset of the Swedish contribution to the COLOR trial.
The inclusion criteria focus on selection of patients admitted
for elective surgery with potentially curable colonic cancer
best treated by right or left hemicolectomy or sigmoid
resection. Exclusion criteria: cancer in the transverse colon
or rectum, synchronous colonic cancers, distant metastases,
BMI >30, previously treated malignant disease, pregnancy
and preoperative signs of a fixed tumour or acute intestinal
obstruction
Secondary care. 10 centres in Sweden
January 1999–May 2002
The effectiveness data were derived from this subgroup of
the COLOR trial (RCT)
NA
The costing was undertaken prospectively on the same
sample as that used for the effectiveness study. Allocations
for all inpatient services costs were retrieved from one
centre, which contributed with 33% of the patients to the
cost analysis. This centre has a well-developed cost per
patient accounting system
Details about clinical
evidence: study design
and main outcomes
Eligibility/patient group/study
sample
Study design
Analysis of effectiveness
Effectiveness results/outcome
measures
12 Swedish centres that contributed to the COLOR trial
were invited to participate, and 10 agreed. These centres
contributed with 263 patients to the trial and 234 entered
into the cost analysis (111 LCR, 123 OCR). Of these 234
patients, 24 were excluded from the primary cost analysis
(13 LCR, 11 OCR); then, 98 patients were included in the
cost analysis for the LCR group and 112 for the OCR group
A multicentre RCT. 10 centres agreed to participate.
Randomisation was performed in the original trial. Follow-up
was 3 years
The analysis was done on an intention-to-treat basis. The
primary end-point was cancer-free 3-year survival. Other
outcomes were number of complications and reoperations
and deaths. Complications include anastomotic leak, bowel
perforation, wound rupture, ileus, postoperative bleeding,
incarcerated abdominal hernia, endoscopic dilatation,
closure loop ileostomy
Primary end-point results were not reported. During the
first admission, 21 patients had complications in the LCR
group and 18 in the OCR group. 8 patients had reoperations
in the LCR group and 4 in the OCR group (anastomotic leak
4 LCR, 1 OCR; bowel perforation 1 LCR, 0 OCR; wound
rupture 1 LCR, 3 OCR; ileus 1 LCR, 0 OCR; postoperative
bleeding 1 LCR, 0 OCR). After discharge, 12 patients had
complications in the LCR group and 8 in the OCR group.
There was 1 death in the LCR group and 0 in the OCRAppendix 11
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continued
Clinical conclusions
group. 6 patients had reoperations in the LCR group and 3
in the OCR group (anastomotic leak 1 LCR, 1 OCR; wound
rupture 1 LCR, 0 OCR; ileus 1 LCR, 1 OCR; incarcerated
abdominal hernia 1 LCR, 0 OCR; endoscopic dilatation 
1 LCR, 1 OCR; closure loop ileostomy 1 LCR, 1 OCR)
The results from the present cohort of patients showed
significant but clinically modest differences in HRQoL 2 and
4 weeks after operation (data not shown)
Economic analysis Measure of health benefits
used in the economic analysis
Direct costs
Indirect costs
Currency
Statistical analysis of quantities/
costs
Sensitivity analysis
No summary of health benefit was used in the economic
analysis. Clinical outcomes were left disaggregated. 
A cost–consequences analysis was performed
Data related to perioperative period and postoperative
follow-up were retrieved by use of case record forms,
which were completed by the relevant surgical departments.
Data on costs after discharge were registered by the patient
in a diary. Direct costs included staff, drugs, physicians,
laboratory testing, overheads and maintenance, operating
room resources, anaestegiology and recovery room
services. Capital costs of expensive equipment were
calculated after estimating the yearly use of these items at
Huddings University Hospital (HUH). Mean cost per item of
disposable material between centres was used in the
analysis. Cost of medical services, including radiological and
endoscopic investigations, blood products and
bacteriological testing, were allocated using the internal
price list of services at HUH. Costs of outpatient care
services were retrieved from the internal reinbursements
system in the county of Stockholm, Sweden. Discounting
was performed at a 5% rate. This was relevant as the
follow-up period was over 2 years
Costs of productivity loss were calculated from official
Swedish statistics. Average income rates were converted to
a daily cost of productivity loss. Whether a patient was
retired or not was taken into account when considering
number of days off work. No commuting costs were
considered as they were not relevant. Discounting was
performed at a 5% rate
Euros, 2001 prices
Non-parametric bootstrap method was used for checking
the robustness of results from standard parametric
approaches. Other statistical tests used were t-test, 2 and
Fisher’s exact test. p < 0.05 was considered statistically
significant
One-way sensitivity analyses on the cost per minute for the
operating room, anaesthesia and recovery room time were
explored (–50 to +100% range from original mean values)
Results Estimated benefits used in the
economic evaluation
Costs results
No health benefit summary measure for economic analysis
was used. A cost–consequences analysis was performed.
However, the authors stated that the results from the
present cohort of patients showed significant but clinically
modest differences in HRQoL at 2 and 4 weeks after
operation
Total costs, including productivity loss, were not significantly
different between LCR and OCR groups (€11,660 vs
€9814; p = 0.104). Total costs, excluding productivity loss,
that is, cost to the healthcare system, were significantly
higher for LCR (€9474 vs €7235; p = 0.018), as were costs
related to the first admission (€6931 vs €5375; p = 0.015)Health Technology Assessment 2006; Vol. 10: No. 45
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continued
Synthesis of costs and benefits
Authors’ conclusions
and costs of primary surgery (€3493 vs €2322, p = 0.001).
The secondary cost analysis, which included 24 patients who
were excluded in the primary analysis after randomisation,
yielded similar data; figures calculated in a secondary analysis
were within a range of €–35 to +316, and the statistical
significance of the results remained unchanged
The cost of extra resources consumed during the first
admission and resources used after discharge, because of
readmissions and reoperations, appeared to be higher in the
LCR group. Although there was no difference in
complication rates, reoperations were more frequent in the
LCR group during the first admission and after discharge.
However, this difference was not tested for statistical
significance owing to the small number of observations. The
mean total costs, excluding productivity loss, for reoperated
patients were €19,376 (range €5543–49,835) for LCR and
€13,637 (range €6080–29,305) for OCR
Within 12 weeks of surgery for colonic cancer, there was no
difference in total costs to society incurred by LCR and
OCR. The LCR procedure, however, was more costly to the
healthcare system
Study identification: 
King, 200640
Author and year
Interventions studied/
comparators
Hypothesis/question
King, 2006
Laparoscopic resection versus open resection for colorectal
cancer with enhanced recovery programme
This study examined the null hypothesis that there is no
difference in short-term outcomes after laparoscopic or
open resection for colorectal cancer when both are
embedded within an enhanced recovery programme
Details about clinical
evidence: study design
and main outcomes
Eligibility/patient group/study
sample
During the study period, 94 patients were assessed for entry
into the trial. 21 did not meet the inclusion criteria, 5 were
excluded as they were not suitable for laparoscopic surgery
and 6 were excluded for other reasons. 62 patients with
adenocarcinoma of the colon or rectum were randomised
(2:1) to receive either laparoscopic (n = 43) or open
surgery (n = 19) and were entered into an enhanced
recovery programme. Sample size was determined by a
calculation performed for a parallel study involving the same
patients, comparing enhanced recovery with a historical
cohort of patients receiving conventional care
Key elements of the study Type of study
Target population/study sample
Setting
Dates to which data relate
Source of effectiveness data
Modelling
Link between effectiveness
and cost data
CCA based on an RCT
Adult patients diagnosed with colorectal cancer. Exclusion
criteria: any non-elective admission, those patients with
preoperative evidence of haematogenous metastases,
patients less than 18 years old, those who were pregnant
and patients who did not consent to randomisation. A
protocol amendment to exclude patients not able to have
epidural anaesthesia was made after 1 year
Secondary care. Yeovil District Hospital, Yeovil, UK
January 2002–March 2004
The evidence for effectiveness data was derived from a
single study
NA
Costing was undertaken on the same sample as used for the
effectiveness study. Cost outcomes were collected
prospectivelyAppendix 11
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Study design
Analysis of effectiveness
Effectiveness results/outcome
measures
Clinical conclusions
A single-centre RCT. Maximum follow-up was 3 months. 
3 patients were lost to follow-up in the laparoscopic arm 
(1 benign histology, 1 unsuitable for epidural, 1 death) and 
1 patient was lost to follow-up in the open arm (death)
The analysis of effectiveness data was based on intention-to-
treat. Hospital stay was calculated as from the date of
operation to the date of discharge. Hospital stay including
convalescent stay and readmission stay was a secondary
outcome. Other clinical end-points included mortality,
requirement of opioid analgesia and antiemetic
administration. Major morbidity was defined as haemorrhage
(requiring transfusion), reoperation, readmission,
anastomotic leak, wound dehiscence and sepsis requiring at
least high-dependency support. Patient-based outcomes
included quality of life (measure by EORTC QLQ-C30 and
QLQ-CR38 colorectal module). A series of performance
tests to assess balance, gait and lower extremity strength
and endurance were taken before and after surgery. Sleep
and oxygen saturation were also monitored
Patients undergoing laparoscopic surgery had a 32% (95%
CI 7 to 51, p = 0.018) shorter hospital stay than those in
open surgery. Geometric mean for postoperative stay
5.2 days (95% CI 4.2 to 6.5) for laparoscopic group and 7.4
(95% CI 6.0 to 9.2) for open group. Hospital +
convalescent stay 5.4 (95% CI 4.2 to 6.8) for laparoscopic
group and 7.4 (95% CI 6.0 to 9.2) for open group; ratio
laparoscopic to open 0.69 (95% CI 0.49 to 0.78), 
p = 0.036. Hospital + convalescent + readmission stays
were also significantly shorter after laparoscopic surgery: 5.5
(95% CI 4.3 to 7.0) for laparoscopic group and 8.3 (95% CI
6.3 to 10.8) for open group; ratio laparoscopic to open 0.63
(95% CI 0.44 to 0.90), p = 0.012. There were 11 cases
(27%) of blood loss >100 ml in the laparoscopic group and
18 (95%) cases in the open group, p < 0.001. Statistically
significant differences were reported also for epidural
insufficiency requiring opioid supplements: 9 (22%)
laparoscopic group and 14 (74%) open group, p < 0.001;
duration of surgery in minutes (geometric mean): 187 for
laparoscopic group (95% CI 168 to 207), open group 140
(95% CI 121 to 163), p = 0.00
Laparoscopic resection for colorectal cancer within an
enhanced recovery programme is likely to provide the best
short-term clinical outcomes for patients with resectable
colorectal cancer
Economic analysis Measure of health benefits
used in the economic analysis
Direct costs
No summary of health benefit is used in the economic
analyses and clinical outcomes are left disaggregated; 
a cost–consequences analysis was performed
Cost analysis was undertaken from the NHS perspective.
The follow-up was 3 months postoperatively. Information on
cost of theatre equipment was provided from hospital
invoices. Detailed records were taken of staffing including
surgical/anaesthetic and nursing grades present at each
operation. Disposable equipment was routinely recorded
and was considered to be additional to standard theatre
costs. One day preoperative was included for hospital stay
analysis purposes. Patients were sent questionnaires about
their use of health resources at both 2 weeks and 3 months
after operation (inpatient days, outpatient visits, GP visits,
use of district (community) and stoma nursing services.
Staffing costs were estimated as a mid-point in the scaleHealth Technology Assessment 2006; Vol. 10: No. 45
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Indirect costs
Currency
Statistical analysis of quantities/
costs
Sensitivity analysis
given in the UK literature. Cost of theatre equipment
specific to procedures undertaken was provided from the
manufacturers’ invoices. Post-discharge health resource unit
costs were estimated from national published figures.
Discounting was not performed
Indirect costs were assessed by determining the number of
days patients in paid work (full- or part-time) took off for
their condition and multiplying by the average daily pay
sterling Pounds, 2002
Costs data were treated stochastically. The authors used
bootstrap estimates (10,000 iterations) to derive values for
mean and CIs
The base-case analysis indicated the there were two areas
where costs were likely to vary between groups, namely the
duration of inpatient stay and the consumption of
community resources after hospital discharge. The costs of
these resources were challenged using a sensitivity analysis,
with each varying by ±20% of the base case
Results Estimated benefits used in the
economic evaluation
Costs results
Synthesis of costs and benefits
Authors’ conclusions
A cost–consequences analysis was developed, then the
reader is referred to the effectiveness results reported
previously
As expected, the theatre costs were higher in patients
randomised to laparoscopic surgery (£2885 versus £1964,
difference £921.6, 95% CI –1250.6 to –586.0), partly
reflecting the increased duration of these procedures, but
also the increased use of disposable equipment in theatre.
These costs were more than offset by lower postoperative
costs such as reoperations (£287 for laparoscopic group and
£1039 for open group, difference £752, 95% CI –278.5 to
2466.6), and indirect costs (£448 for laparoscopic group and
£721 for open group, difference £274.2, 95% CI –386.2 to
983.2). Total cost for laparoscopic group was £6433.4 and
for open group £6789.8 (difference £353.4, 95% CI –2167.1
to 2991.5). Sensitivity analysis had little effect on this overall
mean difference, with variations in perioperative and
inpatient costs affecting the difference by less than £100 in
either direction
Not combined
Laparoscopic resection of colorectal cancer within the
enhanced recovery programme is likely to provide the best
short-term clinical outcomes for patients with resectable
colorectal cancer. Despite applying enhanced recovery
techniques to open surgery for colorectal cancer, short-term
outcomes are better with laparoscopic-assisted surgery.
There is no deterioration in quality of life or increased cost
associated with laparoscopic surgery compared with the
open approach
Study identification: 
Leung, 200453
Authors and year
Interventions studied/
comparators
Hypothesis/question
Leung et al., 2004
Laparoscopic-assisted or conventional open resection for
rectosigmoid carcinoma
The authors aimed to test the null hypothesis that there was
no difference in survival after laparoscopic and open
resection for rectosigmoid cancer
Key elements of the study Type of study
Target population/study sample
CCA based on an RCT
The study involved adult patients with rectosigmoid
carcinomaAppendix 11
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continued
Setting
Dates to which data relate
Source of effectiveness data
Modelling
Link between effectiveness
and cost data
Secondary care; 2 institutions (Prince of Wales Hospital and
United Christian Hospital) in Hong Kong
21 September 1993–21 October 2002
The effectiveness data were derived from a single study
NA
Costing was undertaken on the same sample as used in the
effectiveness study. Cost outcomes were collected
prospectively
Details about clinical
evidence: study design
and main outcomes
Eligibility/patient group/study
sample
Study design
Analysis of effectiveness
Effectiveness results/outcome
measures
The authors considered the study sample in a planning
phase: to show a difference of 15% in 5-year survival (from
60 to 70%) with an 80% probability ( = 0.2) and a 5%
significance threshold ( = 0.05), 150 patients were needed
in each group). Patients diagnosed to have rectosigmoid
carcinoma seen in the participating institutions were
randomly allocated to laparoscopic-assisted or conventional
open sigmoid colectomy or anterior resection. There were
825 eligible patients and 422 were excluded as they did not
fulfil the inclusion criteria. 203 patients were allocated to the
laparoscopic group and 200 to the open group. Exclusion
criteria: distal tumour needing anastomosis within 5 cm of
the dentate line; tumour larger than 6 cm or with tumour
infiltration to adjacent organs on sonography with or
without CT scan; patients with previous abdominal
operations near the region of the colorectal operation;
individuals who did not consent to randomisation; and
patients with intestinal obstruction or perforation
The patients were recruited from two hospitals. Patients
were randomly allocated to laparoscopic-assisted or
conventional open sigmoid colectomy or anterior resection
by a computer-generated random sequence kept concealed
by an independent operating theatre coordinator. The
follow-up time of living patients (months) was 52.7 (SD
38.9) for the laparoscopic group and 49.2 (SD 35.4) for the
open group. Patients were followed up regularly at 
3-monthly intervals in the first 2 years, then 6-monthly
thereafter for clinical examination and carcinoembryonic
antigen testing. One patient was lost to follow-up in the
laparoscopic group and 3 in the open group
Survival and disease-free interval were the main outcomes.
Other outcomes were duration of operation, blood loss,
anastomotic leakage, lymph node retrieval, completeness of
resection/margins of tumour clearance, conversion, wound
infection, urinary tract infection, 30-day mortality,
postoperative pain, recurrence. Operation time and hospital
length of stay data were also collected. The analysis was
based on intention-to-treat. The two groups of patients had
similar baseline demographic data
No statistically significant differences were reported for
overall mortality 38 (22.8%) for laparoscopic group and 40
(23.5%) for open group, p = 0.97; probability of survival at
5 years 76.1% (3.7%) for laparoscopic group and 72.9%
(4.0%) for open group, p = 0.61, recurrence 37 (22.2%)
for laparoscopic group and 30 (17.6%) for open group,
p = 0.37 and probability of disease free at 5 years 75.3%
(3.7%) for laparoscopic group and 78.3% (3.7%) for open
group, p = 0.45. Operation time was statistically significantly
higher in the laparoscopic group 189.9 minutes (SD 55.4)
and 144.2 minutes (SD 57.2) for the open group. Hospital
stay was also statistically significantly higher in theHealth Technology Assessment 2006; Vol. 10: No. 45
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continued
Clinical conclusions
laparoscopic group 8.2 days (range 2–99) and 8.7 days
(range 3–39) in the open group. 40 complications were
reported for the laparoscopic group and 45 for the open
group (anastomotic bleeding 2 laparoscopic, 3 open;
anastomotic leak 1 laparoscopic, 4 open; wound infection 
9 laparoscopic, 15 open; strangulated incisional hernia 
2 laparoscopic, 0 open; reoperation 6 laparoscopic, 5 open;
operative death 5 laparoscopic, 4 open; others: 
15 laparoscopic, 17 open)
Laparoscopic resection did not worsen survival and disease
control for patient with rectosigmoid cancer compared with
open resection and its benefits in reducing pain and allowing
earlier postoperative recovery were confirmed. The
justification for preferential use of the laparoscopic technique
would depend on the perceived value of its effectiveness in
improving short-term postoperative outcomes
Economic analysis Measure of health benefits
used in the economic analysis
Direct costs
Indirect costs
Currency
Statistical analysis of quantities/
costs
Sensitivity analysis
No summary of health benefit is used in the economic
analyses and clinical outcomes are left disaggregated; 
a cost–consequences analysis was performed
Direct cost of operation was estimated by market value of
theatre time, the disposable instrument and hospital
inpatient service. Operation time and hospital length of stay
were reported for the two groups but no further details on
disposable instruments or unit costs were reported. No
adjustments for inflation or discounting were reported and
no details on unit price dates were presented. Average costs
for each arm were reported
No indirect costs were reported
US dollars
t-Tests were used to test significance of operational time,
hospital stay and direct cost differences
The authors explored the cost implications of the subgroups
with local invasion
Results Estimated benefits used in the
economic evaluation
Costs results
Synthesis of costs and benefits
Authors’ conclusions
A cost–consequences analysis was developed, then the
reader is referred to the effectiveness results reported
previously
Direct cost of operation for the laparoscopic group was
$9297 (SD 2091) and $7148 (SD 2164) for the open group,
p < 0.001. The direct cost of operation for the local
invasion subgroups were $9729 (SD 2854) for the
laparoscopic subgroup and $9850 (SD 2955) for the open
subgroup
Not combined
Laparoscopic resection of rectosigmoid carcinoma does not
jeopardise survival and disease control of patients. The
justification for adoption of the laparoscopic technique
would depend on the perceived value of its effectiveness in
improving short-term postoperative outcomes
Study identification: 
Zheng, 2005109
Authors and year
Interventions studied/
comparators
Hypothesis/question
Zheng et al., 2005
Laparoscopic versus open right hemicolectomy for colon
carcinoma
This study was designed to compare the outcomes of
laparoscopic right hemicolectomy (LRH) with open right
hemicolectomy (ORH) in the treatment of colon carcinoma.
The authors did not state the perspective of the analysis but
a hospital perspective seems to have been adoptedAppendix 11
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continued
Key elements of the study Type of study
Target population/study sample
Setting
Dates to which data relate
Source of effectiveness data
Modelling
Link between effectiveness
and cost data
CCA based on a matched cohort study
Patient with colon carcinoma
Secondary care, 1 institution (Ruijin Hospital) in Shanghai,
China
September 2000–February 2003
The evidence for effectiveness data was derived from a
single study
NA
Costing was undertaken on the same sample as used in the
effectiveness study. Cost outcomes were collected
prospectively
Details about clinical
evidence: study design
and main outcomes
Eligibility/patient group/study
sample
Study design
Analysis of effectiveness
Effectiveness results/outcome
measures
30 patients with colon carcinoma underwent LHR in the
setting hospital and there were 34 patients for the
comparative ORH group. Exclusion criteria: patients with
tumours larger than 6 cm in diameter, or with tumours
infiltrating the adjacent organs as detected by ultrasonography
and/or CT, patients who did not consent to the procedure,
patients with intestinal obstruction or perforation and
patients whose oncological staging was Dukes’ D
A matched cohort study. Patients for the ORH control
group matched in gender, age, Dukes’ staging, tumour site,
previous abdominal operation and extent of resection were
randomly selected from 87 patients who underwent ORH
during the same period. The mean duration of follow-up
time was 27.15 months (range 12–40 months) for the LRH
group and 26.19 months (range 13–40 months) for the ORH
group. No patients were lost to follow-up. No blinding
methods were reported 
The analysis of effectiveness data was based on intention-to-
treat. The following parameters were measured
prospectively: operation time, blood loss, analgesic
requirements, time to flatus passage, time to resume normal
diet and duration of hospitalisation, morbidity and mortality,
specimen length and lymph node yield, pathological staging
(Dukes’ staging), local recurrence rate and metachronous
metastasis rate and cumulative survival probability. Major
complications included massive haemorrhage, anastomotic
leak, pulmonary infection, urinary tract infection, wound
infection and ileus. There was no significant difference in
age, gender, Dukes’ staging, previous abdominal operation
and tumour site between the LRH and ORH groups
Statistically significant differences were found in blood loss
112.94 ml (SD 96.36 ml) for the LRH group and 274.5 ml
(SD 235.43 ml) for the ORH group (p = 0.009), analgesia
required postoperatively by 14 patients in the LRH group
and 26 in the ORH group. Time to flatus passage, hospital
stay and time to resume early activity in the LRH group
were 2.24 days (SD 0.56 days), 13.94 days (SD 6.5 days) and
3.94 days (SD 1.64 days), respectively, which were
significantly shorter than those in the ORH group (3.25 days,
SD 1.29 days; 18.25 days, SD 5.96 days; and 5.45 days, SD
1.82 days, respectively), p < 0.05 for all differences. Five
patients in the LRH group experienced postoperative
complications (2 pulmonary infection, 2 wound infection, 
1 ileus) and 10 patients in the ORH group (1 massive
haemorrhage, 1 anastomotic leak, 3 pulmonary infection, 
1 urinary tract infection, 4 wound infection) (16.7 vs 29.4%,
respectively, p = 0.23)Health Technology Assessment 2006; Vol. 10: No. 45
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HDU, high-dependency unit; HRQoL, health-related quality of life; ICU, intensive care unit; LCR, laparoscopic colonic
resection; LRH, laparoscopic right hemicolectomy; NA, not applicable; OCR, open colonic resection; ORH, open right
haemicolectomy.
Clinical conclusions LRH in patients with colon cancer has statistically significant
advantages over ORH. Hence LRH can be regarded as a safe
and effective procedure
Economic analysis Measure of health benefits
used in the economic analysis
Direct costs
Indirect costs
Currency
Statistical analysis of quantities/
costs
Sensitivity analysis
No summary of health benefit is used in the economic
analysis and clinical outcomes are left disaggregated; a
cost–consequences analysis was performed
Total cost for operation, cost for drugs and total cost (sum
of these two) were presented. No details of how these
figures were calculated were reported
No indirect costs were reported
Chinese renminbi (yuan, Y)
t-Tests were used to test the significance of cost differences
between groups
No sensitivity analysis was reported
Results Estimated benefits used in the
economic evaluation
Costs results
Synthesis of costs and benefits
Authors’ conclusions
A cost–consequences analysis was developed, then the
reader is referred to the effectiveness results reported
previously
The cost of operation in the LRH group was Y7810.7 (SD
Y1719.07), which was significantly higher than that in the
ORH group, Y5018.92 (SD Y845.62), p < 0.01. The cost of
drugs in the LRH group (Y3687.85, SD Y1977.42) was
significantly less than that in the ORH group (Y5209.42, SD
Y2212.37), p < 0.05. No significant difference was observed
in the total cost of operation and drugs between the two
groups: Y11,498.54, SD Y2618.86 vs Y10,228.34, SD
Y2372.57, p = 0.131
Not combined
LRH for right-sided colon cancer has the same oncological
clearance, surgical safety, cost-effectiveness and patient
survival as ORH. In addition, patients can benefit from the
quicker postoperative recovery of laparoscopic surgeryDerivation of the risk of hernia per cycle
The table below outlines the data available on the risk of hernia in the open arms of the identified
studies.
Ideally, data on the time to event would have been used to estimate the risk of hernia. However, owing to
the limited data available, it has been assumed that the risk per cycle is constant. The number of events
per cycle (i.e. per 6-month period) is the observed number of events divided by the follow-up in months.
The product of this is multiplied by the cycle length in months. The risk per cycle is the product of the
number of events per cycle divided by the sample size. The value used in the model is the median of the
values provided by the included studies. From these data, the 25 and 75 percentiles were calculated using
the percentiles command in Microsoft Excel and a triangular distribution assumed using these and the
median rates.
Derivation of the risk of emergency reoperation
The table below reports the data on risk of anastomic leakages reported in the open arms of the RCTs
included in the systematic review of effectiveness. As described in the section ‘Estimation of model
parameters’ (p. 40), the risk of an anastomic leakage has been assumed to be the same as the risk of an
emergency reoperation to treat a postoperative complication. 
Health Technology Assessment 2006; Vol. 10: No. 45
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Appendix 12
Estimation of parameter estimates used in the 
economic model
Studies providing data to enable the risk of hernia per cycle to be estimated
Study ID Events Sample Cumulative  Follow-up  Events  Risk 
rate (%) (months) per cycle per cycle
Winslow (COST), 200283 9 46 19.6 30.1 1.8 0.039
Leung, 200453 4 200 2.0 43 0.6 0.003
Patankar, 2003127 (NR) 2 172 1.2 59 0.2 0.001
Champault, 2002128 (NR) 3 83 3.6 60 0.3 0.004
Median  0.003a
NR, non-randomised study.
a Estimated 25 and 75 percentile observations 0.002 and 0.012. 
Studies providing data to enable the risk of emergency operation to be estimateda
Study ID Events Sample %
COLOR, 20054 10 545 0.018
King, 200640 1 19 0.053
Leung, 200453 4 200 0.020
Zhou, 200460 3 89 0.034
Hasegawa, 200349 0 26 0.000
Lacy, 200222 2 108 0.019
Tang, 200158 1 118 0.008
Median 0.019
a Estimated IQR, 0.008–0.034.The value used in the model is the median of the values provided by the included studies (1.9%). From
these data, the IQR was estimated and a triangular distribution assumed using these and the median
rates. 
Estimation of the costs of non-operable management
The table below describes the drugs used for the management of non-operable recurrent disease. The
description of resource use was provided by a Macmillan Nurse (O’Dea F, Hospital Specialist Palliative
Care Team, Grampian University Hospital NHS Trust: personal communication, 2005). The cost of these
drugs was obtained from the BNF.129
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Drug costs used for model for typical patients being treated for non-operable disease
Drug Dose per day Cost per cycle (£)
Paracetamol 1 g, 4 × day 10.95
Diclofenac 50 mg, 3 × day 21.05
Oxycodone (oxycontin) 40 mg, 2 × day 633.67
Oxynorms 20 mg, 2 × day 289.07
Co-danthramer 10 mg, 2 × day 31.29
Docusate (dioctyl) 200 mg, 2 × day 58.40
Metaclopramide 10 mg, 4 × day 22.68
Omeprazole 10 mg, 2 × day 148.61
Total 1215.72Health Technology Assessment 2006; Vol. 10: No. 45
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Appendix 13
Markov model for the management of colorectal 
cancer
The diagram below displays the unpopulated model for the laparoscopic arm. The tree structures for the
open and laparoscopic arms are identical.
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